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Advances in DNA sequencing technology have allowed detailed characterisation of cancer 
genomes and has highlighted the contribution of somatic structural variations to the mutational 
landscape of epithelial tumours. However, our understanding of the functional consequences of 
such genome rearrangements remains rudimentary. By surveying the METABRIC dataset, 
consisting of segmented array-CGH copy number data, and paired-end whole-genome DNA and 
RNA sequencing data from primary breast tumours, we found that the F-box protein encoded by 
FBXL17 is frequently rearranged in breast cancer. 
F-box proteins are the substrate-recognition components of Skp1-cullin 1-F-box protein (SCF) E3 
ligases. As essential components of the ubiquitin proteasome system (UPS) they are responsible 
for directing target proteins for ubiquitination. Fbxl17 is a relatively understudied member of the 
FBXL family of F-box proteins and, in breast cancers, is disrupted in the region of the gene that 
encodes its substrate-binding leucine rich repeat (LRR) domain. Truncating Fbxl17 LRRs impaired 
its association with the other SCF holoenzyme subunits Skp1, Cul1 and Rbx1, and decreased its 
ubiquitination activity. Loss of the LRRs also affected Fbxl17 binding to its targets. Thus, genomic 
rearrangements in FBXL17 are likely to disrupt SCFFbxl17-regulated networks in cancer cells. 
To investigate the functional effect of these rearrangements, we performed a yeast two-hybrid 
screen to identify Fbxl17-interacting proteins. Among the 37 binding partners Uap1, an enzyme 
involved in O-GlcNAcylation of proteins was identified most frequently. We demonstrate that 
Fbxl17 binds to UAP1 directly and inhibits its phosphorylation, which we propose regulates UAP1 
activity. Knockdown of Fbxl17 expression elevated O-GlcNAcylation in breast cancer cells, 
arguing for a functional role for Fbxl17 in this metabolic pathway. 
To identify further interacting partners of Fbxl17, we performed a mass spectrometry analysis of 
purified Fbxl17 SCF E3 ubiquitin ligases. Co-immunoprecipitates were enriched for DNA damage/ 
DNA repair proteins suggesting a novel role for Fbxl17 in the DNA damage response (DDR). We 
have demonstrated that Fbxl17 is recruited to DNA damage sites rapidly upon double-stand 
break (DSB) induction and knockdown of Fbxl17 protein expression sensitises cells to the DNA 
damaging agent Camptothecin. Furthermore, Fbxl17 can ubiquitinate the tandem BRCT domain 
of the well-known DDR protein 53BP1, which we propose targets 53BP1 for proteasomal 
degradation. 
In conclusion, we have identified two regulatory networks of Fbxl17 which provide an insight 
into the role of Fbxl17 in breast cancer pathogenesis. These pathways may be amenable to 
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CHAPTER 1 - Introduction 
1.1 Breast Cancer 
Cancer is by definition a group of over 100 genetic diseases, characterised by uncontrolled 
proliferation of cells [1]. Cancer cells accumulate genetic changes over time through a 
multistep process. Hanahan and Weinberg initially described six key processes that cells 
must possess to become malignant: resisting cell death, sustaining proliferative signalling, 
evading growth suppressors, activating invasion and metastasis, enabling replicative 
immortality and inducing angiogenesis [2]. The hallmarks were updated in 2011 to include 
deregulating cellular energetics and avoiding immune destruction, which are involved in the 
pathogenesis of some if not all cancers. Aside from these hallmarks, Hanahan and Weinberg 
also described two enabling characteristics that underpin neoplasia: tumour-promoting 
inflammation and genomic instability and mutation [3].  
Epithelial cancers represent 80-90% of all cancers diagnosed and of these breast cancers are 
among the most prevalent. In 2018 breast cancer was the second most common cancer 
diagnosed worldwide with an estimated 2.1 million new cases [4]. It remains the most 
common cancer in women and in the UK alone accounted for 31% of all female cancer cases 
in 2016 [5] and 7% of all cancer deaths from 2015-2017, despite significant improvements in 
survival over the last 25 years [6].  Breast cancer as with most other cancers is complex and 
its aetiology is still relatively unknown. The complexity of the disease is largely due to the 
heterogeneity exhibited by breast tumours [7]. Subpopulations of cells exist in tumours that 
can differ dramatically in both genotype and phenotype from their surrounding cells [8]. 
Breast cancers can therefore exhibit very distinct histopathological and biological features, 
which also differ in their response to therapeutic strategies. This makes diagnosis, 
classification and ultimately treatment of breast cancer very complicated and is one of the 
greatest challenges facing clinicians and researchers in this field.  
1.1.1 Stratification of breast cancers 
Classification of invasive breast cancer subtypes involves the assessment of 
immunohistochemical markers, namely the expression of hormone receptors (oestrogen 
(ER) and progesterone (PR)) and the overexpression and/or amplification of the human 
epidermal growth factor receptor 2 (HER2). This initial sub-classification alone has led to 
improved patient outcomes with the introduction of targeted therapies e.g. Tamoxifen for 
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hormone-receptor-positive cancers [9] and the HER2 targeted therapy Trastuzumab [10]. 
Increasingly, genomically-guided approaches are being used to stratify breast cancers even 
further [11]. In 2000, Perou et al. systematically investigated the gene expression patterns of 
human breast tumours and identified five subgroups into which breast cancers could be 
separated: luminal A, luminal B, HER2 overexpressing, basal-like and normal breast tissue-
like, based on 496 genes [12]. This intrinsic classification was refined to just 50 genes and 
used to generate the PAM50 assay (Prosigna), which maps a tumour sample to one of the 
five groups through microarray and quantitative reverse transcriptase PCR techniques [13].  
However, the true scale of genomic changes in breast cancers is not fully captured by 
histopathological or transcriptomic approaches. Previous technical limitations meant that 
genome-sequencing of cancers favoured the discovery of point mutations over genome 
rearrangement events, mainly due to the ease of analysis by PCR and array comparative 
genomic hybridisation (aCGH) [14]. Advances in sequencing technology however, have 
enabled analysis of tumour genomes at a much greater depth than was previously possible 
[15-17]. Whilst once believed to be confined largely to leukaemias and sarcomas, somatic 
rearrangements are now being shown to be prevalent in breast cancer and other epithelial 
cancers [18-21].  
1.1.2 Genomic rearrangements in breast cancer 
Genomic rearrangements are described as gross changes to DNA that can result in 
duplications, inversions, deletions or translocations (Figure 1. 1) [14]. These rearrangements 
affect whole chromosomes or parts of chromosomes and are often found recurring across 
tumour types [22]. This suggests they may have a significant role in tumour biology and 
cancer progression.  
Breast cancers are well known for acquiring multiple genomic rearrangements during their 
development [23] as shown by karyotyping [24, 25]. Studying the spectrum of copy number 
alterations in breast cancer using aCGH has already proven to be useful for characterising 
breast cancers and identifying new subtypes [26]. To further understand the complex 
landscapes of rearrangements in breast cancer, Stephens et al. analysed 24 breast cancer 
genomes by paired-end sequencing [19]. Intrachromosomal rearrangements were much 
more prevalent than interchromosomal rearrangements and of these, tandem duplications 
were most commonly observed. Most striking perhaps was the large variation in 
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rearrangement frequency between genomes, with some harbouring almost no duplications 
and others containing hundreds. This could in part be attributed to breast cancer subtype, as 
cancers that were ER negative had comparatively more tandem duplications than ER positive 
subtypes. It was also shown that 50% of rearrangements fell within protein coding regions, 
compared to the 40% that would be predicted by chance. This apparent enrichment may be 
due to selection of rearrangements that are advantageous to the breast cancer cells.  
Further analyses have also utilised next-generation sequencing to identify novel cancer 
genes that are recurrently mutated in breast cancer [27, 28].The limitation of most of these 
early studies was the relatively modest numbers of samples analysed, making it difficult to 
Figure 1. 1 - Types of genomic arrangements that can occur in DNA.  
(A) Genomic rearrangements can include tandem duplications, inversions and deletions, shown here 
for two exons (red and yellow boxes) in a single gene. Brackets indicate the region of rearrangement. 
(B) Larger scale rearrangements can result in the fusion of two different genes (Gene A: blue, Gene B: 
red). This results in a fusion gene that can have different activity and function within the cell. Figure 
adapted from [21]. 
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integrate this data with the histopathological and expression-based classifiers. To overcome 
this the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) dataset 
characterised the genomic and transcriptomic profiles of a discovery set of 997 primary 
breast tumours and a validation set of 995 tumours [29]. Analysis of inherited genomic 
variants; single nucleotide polymorphisms (SNPs) and copy number variants (CNVs), along 
with somatic genomic changes; copy number aberrations (CNAs), were found to be 
associated with alterations in gene expression. Clustering of the copy number and gene 
expression data revealed ten novel molecular subgroups of breast cancer. Each integrative 
cluster (IntClust 1-10) presented with distinct CNAs and clinical features that shed light on 
the potential molecular drivers and pathways underlying certain breast cancer subgroups 
[30]. The five distinct groups classified by PAM50 fall into several integrative clusters, for 
example IntClust 1 is predominantly luminal B tumours whereas IntClust 2 includes both 
luminal A and luminal B tumours. The IntClusts are characterised by distinct mutational 
landscapes which can stratify the five PAM50 classes even further. 
The disruptive nature of genomic rearrangements, the frequency at which they occur and 
the variability between breast cancer subtypes has increased our understanding of how 
genomic rearrangements contribute to the aetiology of breast cancer and helped us better 
understand breast cancer heterogeneity. However, despite validating numerous novel 
rearrangements, determining if rearrangements are in fact true ‘driver’ mutations that are 
advantageous to cancer cells and are therefore positively selected, or simply passenger 
mutations acquired along the way, can be challenging [31-33]. A few common, large-scale 
rearrangements across cancer types have been known for some time, such as loss of the 
distal arm of 8p [34], 17p [35, 36] and 18q [37] and the amplification of ERBB2 in breast 
cancer [38], but many less frequently occurring aberrations remain to be characterised and 
may be diagnostically or therapeutically important. For example, the EML4-ALK fusion occurs 
in only approximately 5% of non-small cell lung cancer (NSCLC) but is a target for therapy 
[39, 40] and interest in therapeutically targeting Neuregulin-1 (NRG1) gene fusions is 
increasing, despite only occurring in 0.2% of a wide range of carcinomas [41]. Characterising 
genes that are recurrently disrupted in breast cancer is therefore biologically and 
therapeutically important.   
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1.2 The Hexosamine Biosynthetic Pathway 
As discussed previously, cancer genotypes were originally described as the manifestation of 
six essential biological capabilities or ‘hallmarks’ acquired and exhibited by cells [2]. After 
over a decade of research, reprogramming of energy metabolism was highlighted as an 
additional hallmark of cancer [3]. The uncontrolled cell proliferation characteristic of 
neoplastic disease cannot be achieved without a compensatory change in the cellular 
energetics of a cell. Under normal aerobic conditions, cells primarily produce energy via 
mitochondrial oxidative phosphorylation (OXPHOS). In anaerobic conditions, cells instead 
catabolise glucose via the less efficient and oxygen-independent pathway glycolysis [42]. 
Cancer cells and other highly proliferative cells can utilise glycolysis even in the presence of 
oxygen (aerobic glycolysis), a phenomenon known as the Warburg effect [43-46]. To 
overcome the lower efficiency of glycolysis, cancer cells upregulate glucose transporters 
such as GLUT1 to significantly increase the flux of glucose into the cytoplasm [47, 48]. 
However, it is not just glycolysis and OXPHOS that utilise glucose. Glycolytic intermediates 
feed into various biosynthetic pathways and as such any changes in glucose flux are also 
likely to impact these pathways [49]. The Hexosamine Biosynthetic pathway (HBP), which 
utilises the glycolysis intermediate Fructose-6-phosphate (F6P), represents one such 
pathway (Figure 1. 2).  
The HBP utilises glucose, glutamine, fatty acids and amino acids to produce the amino sugar 
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), which serves as the basis for 
glycosaminoglycans, proteoglycans and glycolipids. Of the glucose that enters a non-cancer 
cell, 2-5% is used by the HBP [50]. The HBP and glycolysis share the first two metabolic steps, 
whereby glucose is first phosphorylated by hexokinase (HK) to Glucose-6-phosphate and 
then converted to Fructose-6-phosphate (F6P) by phosphoglucose isomerase (GPI). It is here 
that the two pathways diverge, and glutamine fructose-6-phosphate amidotransferase 
(GFAT) converts F6P and glutamine, to glucosamine-6-phosphate and glutamate, to drive the 
HBP. GFAT activity is considered rate-limiting for the HBP [50, 51]. Glucosamine entering the 
cell can also be directly converted to glucosamine-6-phosphate by GNK (GlcNAc kinase) and 
feed into the HBP without the need for glycolysis or the rate-limiting GFAT. Glucosamine-6-
phosphate and acetyl-coenzyme A (Ac-CoA); derived from free fatty acid oxidation, are then 
catalysed    by    glucosamine-phosphate   N-acetyltransferase   (GNPNAT)    to    generate   N- 
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Figure 1. 2 - Hexosamine Biosynthetic Pathway.  
Glucose enters the cells and is converted to Fructose-6-phosphate, after which 2-5% is directed to the 
Hexosamine Biosynthetic Pathway (HBP). The enzyme GFAT (glutamine fructose-6-phosphate 
amidotransferase) catalyses the first and rate-limiting step in the HBP, converting Fructose-6-
phosphate and glutamine to Glucosamine-6-phosphate. Glucosamine entering the cell can also be 
directly converted to glucosamine-6-phosphate by GNK (GlcNAc kinase) and feed into the HBP. 
Glucosamine-6-phosphate and acetyl-coenzyme A (Ac-CoA) are then catalysed by glucosamine-
phosphate N-acetyltransferase (GNPNAT) to generate N-acetylglucosamine-6-phosphate (GlcNAc-6-
P). GlcNAc phosphomutase (PGM3)-mediated isomerisation produces GlcNAc-1-phosphate (GlcNAc-1-
P) which along with uridine (UTP) is then rapidly converted to UDP-GlcNAc by the enzyme UDP-N-
acetylglucosamine pyrophosphorylase 1 (Uap1). UDP-GlcNAc can then be used for N- and O-linked 
glycosylation in the ER and Golgi or for the O-GlcNAcylation of nuclear and cytoplasmic proteins. OGT 
(O-GlcNAc transferase) and OGA (O-GlcNAcase) catalyse the addition and removal of O-GlcNAc 
respectively. Figure adapted from [76]. 
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acetylglucosamine-6-phosphate (GlcNAc-6-P). GlcNAc phosphomutase (PGM3)-mediated 
isomerisation produces GlcNAc-1-phosphate (GlcNAc-1-P), which along with uridine (UTP); 
produced during nucleotide metabolism, is then rapidly converted to UDP-GlcNAc by the 
enzyme UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) [52-58] (Figure 1. 2). Since 
the HBP utilises nutrient-derived precursors e.g. carbohydrates, lipids and amino acids to 
produce UDP-GlcNAc, it is considered a nutrient sensor pathway [53, 59]. Levels of UDP-
GlcNAc are therefore sensitive to the nutritional state of the cell. UDP-GlcNAc produced by 
the HBP has two fates, (1) O- and N-linked glycosylation of proteins in the endoplasmic 
reticulum (ER) and Golgi apparatus or (2) O-GlcNAcylation that takes place in the cytoplasm, 
nucleus and mitochondria. 
N-linked glycosylation is the attachment of complex oligosaccharides or ‘glycans’ to an 
asparagine residue of target proteins and takes place in the ER. This type of glycosylation 
requires the synthesis of a precursor oligosaccharide which can be found attached to the 
membrane of the ER. Once formed, the precursor oligosaccharide is transferred to a nascent 
polypeptide in the lumen of the ER [60]. Once proteins have been folded, they can also be 
modified in the Golgi apparatus by the addition of O-linked N-acetylgalactosamine (O-
GalNAc) to a serine or threonine residue. O-GalNAc sugars are common on membrane 
glycoproteins such as low-density lipoprotein receptor (LDL) and as such usually occur on 
proteins that will be secreted [61]. 
O-GlcNAcylation is the attachment of O-linked N-acetylglucosamine (O-GlcNAc) moieties to 
serine and threonine residues of nuclear and cytoplasmic proteins. O-GlcNAcylation of 
proteins is important in several cellular processes including cell signalling, gene regulation 
and metabolism [62-65] and in many respects is analogous to phosphorylation. It has  been 
shown that O-GlcNAcylation and phosphorylation can compete for the same residues on 
proteins highlighting a complex cross-talk between these two modifications [66]. O-
GlcNAcylation is a dynamic post-translational modification, which unlike O-glycosylation in 
the Golgi, can be added or removed from a protein several times. The addition and removal 
of O-GlcNAc is catalysed solely by O-GlcNAc-transferase (OGT) and O-GlcNAcase (OGA) 
respectively [55]. It has been proposed that there is an optimal level of global O-
GlcNAcylation levels for cells to function and this is maintained by mutual regulation and 
balance of OGT and OGA expression and activity [59, 67]. Knockout of OGT expression 
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results in a rapid decrease in OGA protein expression in murine embryonic fibroblasts [68]. 
In hepatocytes, OGA overexpression triggers an increase in OGT mRNA levels [69] further 
highlighting the mutual regulation of these proteins.  
O-GlcNAcylation is an important post translational modification on many intracellular 
proteins—including p53, RNA polymerase II, the polycomb complex and 
Phosphofructokinase 1 (Pfk1), the main regulator of glycolysis- and is essential for viability of 
several mammalian cell types [64, 70]. It is therefore unsurprising that disruption of O-
GlcNAc homeostasis has been implicated in many human diseases including diabetes, 
neurodegeneration and cancer [71-75]. 
1.2.1 O-GlcNAcylation in cancer 
There is already considerable evidence that GlcNAcylation is altered in cancer [76]. Increased 
protein O-GlcNAcylation and changes in OGT and/or OGA expression have been reported in 
different cancer types. Caldwell et al. found that breast cancer cells had increased O-
GlcNAcylation and elevated OGT [77].  Knocking down OGT inhibited tumour growth, 
decreased cell cycle progression, increased expression of the cell cycle inhibitor p27Kip1, and 
decreased invasiveness [77]. High nuclear and cytoplasmic O-GlcNAc was also observed in 
breast cancer patients with increased relapse rates, increased sites of distant metastases 
and poor outcome [78]. Dahl et al. found that MGEA5 expression, the gene encoding for 
OGA, was reduced by 56% in breast tumours [79]. In agreement with this, it was found that 
breast tumour tissues exhibit increased global O-GlcNAcylation and low OGA levels are 
linked to higher grade tumours and metastasis [80]. Treatment of breast cancer cells with 
PI3K or mTOR inhibitors reduced OGT expression and O-GlcNAcylation highlighting a role for 
the PI3K/mTOR/MYC signalling pathway in OGT elevation [81]. O-GlcNAcylation has also 
been shown to regulate cancer cell metabolic reprogramming by stabilising the transcription 
factor HIF-1α, which upregulates GLUT1 therefore protecting cancer cells from metabolic 
stress [82].  
In liver cancer, hepatocellular carcinoma (HCC) cells exhibit increased global O-GlcNAcylation 
levels, which is important for migration, invasion and viability [83]. Low OGA expression in 
HCC correlated with tumour recurrence suggesting it may a be a useful marker to predict 
patient risk of recurrence [83]. Similarly, in prostate cancer, OGT is overexpressed and both 
OGT and O-GlcNAcylation are elevated in prostate carcinoma cell lines [84]. OGT can 
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regulate the stability of c-Myc, which modulates prostate cancer growth [85, 86]. Mi et al. 
have shown that human lung and colon cancer tissues show significantly elevated O-
GlcNAcylation and OGT expression compared to adjacent tissues and this enhances growth 
and invasion [87].  
1.2.2 Uap1 
In contrast to OGT and OGA, upstream enzymes of the HBP, in particular Uap1, have 
received less attention with regards to their role in cancer pathogenesis. UDP-N-
acetylglucosamine pyrophosphorylase 1 (Uap1) is the enzyme responsible for converting 
GlcNAc-1-P and UTP into UDP-GlcNAc.  UDP-GlcNAc is an essential metabolite, which acts as 
the major cytoplasmic precursor of cell wall peptidoglycan in both Gram-positive and Gram-
negative bacteria and is a precursor for the synthesis of lipid A required for 
lipopolysaccharide (LPS), the major component of the Gram-negative bacteria outer 
membrane [88]. UDP-GlcNAc is also a substrate of chitin synthase, whose product is 
essential for fungal cell wall formation [88]. Extensive studies of UDP-GlcNAc in bacteria 
identified the bifunctional GlcNAc-1-P uridyltransferase (also called UDP-GlcNAc 
pyrophosphorylase) GlmU as the enzyme responsible for UDP-GlcNAc production [89].  
Discovery of the eukaryotic gene for UDP-GlcNAc pyrophosphorylase came from 
comparisons between the amino acid sequences of E. coli GlmU and S. cerevisiae UDP-Glc 
pyrophosphorylase (one of three enzymes in S. cerevisiae with UDP-sugar 
pyrophosphorylase activity but not responsible for UDP-GlcNAc formation). An amino acid 
motif, L(X)2GXGTXM(X)4PK where X represents any amino acid, was identified and used to 
search the yeast database for genes that could encode proteins with a sequence similar to 
the motif. YDL103C was one of two candidates that came out of the screen and thus was 
tested for UDP-GlcNAc pyrophosphorylase activity. Recombinant YDL103C fused to GST was 
expressed in E. coli and incubated with GlcNAc-1-P and UTP. YDL103C was able to produce 
UDP-GlcNAc in vitro in a dose-dependent manner and as such the gene was designated 
ScUAP1 (S. cerevisiae UDP-GlcNAc pyrophosphorylase gene 1) [90].  
ScUAP1 DNA was then used as a probe to identify the human homolog of ScUAP1 by 
screening a human testis cDNA library. The resulting HsUAP1 was cloned and sequenced and 
was shown to possess UDP-GlcNAc pyrophosphorylase activity in vitro. A null mutation in 
ScUAP1 is lethal but can be rescued by overexpression of the human Uap1 enzyme, further 
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highlighting its evolutionary conservation [90]. Interestingly the cloned HsUAP1 was identical 
to the previously reported AGX1, an antigen implicated in antibody-mediated human 
infertility [91]. Szumilo et al. successfully purified UDP-GlcNAc pyrophosphorylase from the 
soluble fraction of pig liver extracts and showed that the enzyme could synthesise UDP-
GlcNAc [56]. They isolated three peptides of 64, 57 and 49kDa by SDS-PAGE, which all 
showed strong cross-reactivity with an antibody prepared against the 64kDa protein.  It was 
therefore proposed that UDP-GlcNAc pyrophosphorylase functions as a homodimer of two 
64kDa subunits [56]. Concurrent with Mio et al. the isolated peptides were later shown to be 
100% identical to AGX1 [57].  
A second isoform of AGX1 exists, AGX2, that is identical in sequence to AGX1 except for an 
additional 17-amino acid insert near the carboxyl terminus. Wang-Gillam et al. therefore 
investigated whether AGX2 also has pyrophosphorylase activity and showed that AGX1 and 
AGX2 differ in their preference for substrates. AGX2 activity was around 8 times higher with 
GlcNAc-1-P than GalNAc-1-P highlighting a preference for UDP-GlcNAc pyrophosphorylase 
activity, whereas AGX1 exhibited higher activity with GalNAc-1-P [57, 92]. AGX1 and AGX2 
result from alternative splicing of HsUAP1 and their expression varies across tissue types. 
AGX1 is highly expressed in the testis and hence HsUap1 is also alternatively named sperm-
associated antigen 2 (SPAG2) [93] whereas AGX2 is more abundant in somatic tissues [91].  
The crystal structures of human Uap1 isoforms AGX1 and AGX2 have been solved and 
revealed a dimeric arrangement for both proteins as predicted by Szumilo et al., however 
AGX2 dimers were not observed in solution [94]. The 17 amino acid insert in AGX2 appears 
to dictate oligomeric assembly, which can modify the active site of the protein and influence 
enzymatic activity. However, both isoforms could bind to UDP-GlcNAc and UDP-GalNAc and 
showed no significant change in substrate specificity contrary to previous studies in AGX 
proteins isolated from pigs [57, 94]. 
In summary, Uap1 is the human UDP-GlcNAc pyrophosphorylase responsible for the 
production of the HBP end-product UDP-GlcNAc. Two isoforms of Uap1, AGX1 and AGX2 
have been identified, which show variable expression in tissues and may differ in their 
preference for GlcNAc-1-P or GalNAc-1-P. AGX2 seems to be the likely isoform driving UDP-
GlcNAc production in mammalian cells.  
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1.2.2.1 Uap1 in cancer 
There is increasing evidence that Uap1 is also implicated in the pathogenesis of cancer, 
namely prostate cancer [58, 95]. Itkonen et al. showed that Uap1 and the HBP rate-limiting 
enzyme GFAT are upregulated in localised prostate cancer and this upregulation is androgen 
receptor (AR) driven. Uap1 mRNA and protein levels were upregulated in AR-overexpressing 
prostate cancer cell lines LNCaP and VCaP whereas normal prostate epithelial cells RWPE-1, 
expressing wild-type AR, showed no changes in Uap1 expression after treatment with 
synthetic androgen [85].  
Further research by Itkonen et al. went on to show that cell lines with high UAP1 expression 
have 10-fold higher UDP-GlcNAc and UDP-GalNAc levels. Inhibition of Uap1 by siRNA 
resulted in a significant decrease in UDP-GlcNAc levels but did not affect total O-
GlcNAcylation levels. Uap1 overexpression was shown to protect cells against inhibitors of N-
linked glycosylation. Knockdown of Uap1 in LNCaP cells sensitised cells to inhibitors of N-
linked glycosylation and decreased their colony-forming ability. However, overexpression of 
Uap1 in RWPE-1 cells alone, was not sufficient to protect cells from inhibitors of N-linked 
glycosylation suggesting the combined overexpression of GFAT is also required [58].  
Changes in Uap1 expression associated with prostate cancer have the potential to be used as 
predictive biomarkers for prostate cancer diagnosis. Gene expression levels of Uap1 in 
plasma and urine samples from 319 patients recommended for prostrate biopsies were 
measured by qRT-PCR. Uap1 mRNA levels in plasma were significantly different in prostate 
cancer patients than post-prostatectomy control patients and urine Uap1 mRNA levels were 
statistically significant between cancer and non-cancer patient samples after normalisation 
to GAPDH [96]. 
One potential explanation for the overexpression of Uap1 in prostate cancer is the 
downregulation of microRNA (miR)-224-5p. In silico analysis revealed that miR-224-5p is 
downregulated in prostate adenocarcinoma and the prospective targets of miR-224-5p, 
which include Uap1, are highly expressed as a result. However further in vivo or in vitro 
experiments are required to confirm these findings [97].  
Aside from prostate cancer, GISTIC (Genomic Identification of Significant Targets in Cancer) 
analysis [98] of Liposarcoma patient samples, identified a statistically significant 
CHAPTER 1                                                                                                                         Introduction 
27 
 
amplification of chromosome 1 in the region encoding Uap1 [99]. This suggests that Uap1 
overexpression may also be involved in Liposarcoma pathogenesis. 
In breast cancer, reduction of UDP-GlcNAc production through inhibition of PGM3, the 
enzyme acting just upstream of Uap1 causes breast cancer growth arrest and apoptosis 
[100]. Uap1 may therefore also represent a viable biological target for the treatment of 
breast cancer given it acts in the same pathway as PGM3. Whilst no such data implicating 
Uap1 directly in breast cancer pathogenesis currently exists, Kaplan Meier analysis of Uap1 
using the KM Plotter (http://www.kmplot.com)[101] revealed that breast tumours with high 
Uap1 expression were associated with poorer survival in patients (Figure 1. 3). 
 
Figure 1. 3 - High Uap1 expression levels correlate with reduced breast cancer survival 
Kaplan Meier curves for Uap1 mRNA (left panel) and protein (right panel) expression were generated 
using the KM Plotter analysis platform (http://kmplot.com) resource. Publicly available breast cancer 
tumour datasets were mined for Uap1 expression data in correlation with survival probabilities, JetSet 
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1.3 DNA double-strand break repair 
The DNA in our cells continually suffers damage from environmental and endogenous 
stimuli, including reactive oxygen species (ROS) and ionising radiation (IR) [102-104]. Such 
insults generate a variety of DNA lesions including DNA double-stand breaks (DSBs), whereby 
the sugar-phosphate backbones of both DNA strands are broken [105]. DSBs are among the 
most harmful lesions and failure to accurately repair just one of these breaks can trigger 
permanent growth arrest and cell death and induce gross chromosomal rearrangements 
[106]. DNA damage events have the potential to be highly mutagenic and can promote 
tumorigenesis [106]. Indeed, genomic instability is considered an enabling characteristic of 
cancer cells [3]. To cope with the continuous threat to genome integrity posed by DSBs, 
eukaryotic cells have evolved a complex DNA damage response (DDR), which coordinates 
several DNA repair pathways with cell-cycle checkpoint activation. The two major and most 
studied DNA damage repair pathways, homologous recombination (HR) and non-
homologous end-joining (NHEJ), are largely distinct from one another [107]. HR uses an 
identical sister chromatid as a template ensuring accurate repair. The requirement of a sister 
chromatid restricts HR to phases S and G2 of the cell cycle [108]. Both HR and NHEJ are 
highly conserved pathways but the relative contribution to DNA repair differs from organism 
to organism [109]. Simple eukaryotes such as the yeasts S. cerevisiae and S. pombe rely 
mainly on HR to repair radiation-induced DSBs [110, 111]. In contrast, NHEJ is the favoured 
pathway for DSB repair in mammals [112, 113] with HR preferred for the repair of DSBs that 
arise during replication. NHEJ does not require a template but instead directly ligates broken 
DNA ends together. It is faster but potentially more mutagenic than HR and its activity is 
controlled throughout the cell cycle [114-119].  
Choosing which repair pathway to adopt is vitally important to maintain genetic stability 
[120-122]. A number of factors are believed to influence the selection of repair pathway 
including direct competition for DSB ends. HR is the pathway of choice during S and G2 
phases of the cell cycle. However, the canonical NHEJ factor DNA-dependent protein kinase 
(DNA-PK) consisting of the Ku70/80 (XRCC6/XRCC5) heterodimer (Ku) and the DNA-PK 
catalytic subunit (DNA-PKcs) can localise quickly and independently to DSBs during S phase 
and bind with high affinity to prevent HR and promote NHEJ. In this regard competition for 
binding to DSB ends is unlikely to dictate repair pathway choice, especially during S phase. 
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More sophisticated mechanisms must exist to drive DNA repair pathway choice. Indeed, 
CYREN (cell cycle regulator of NHEJ) has been shown to bind ku heterodimers to prevent 
NHEJ during S and G2 [119]. However, initial processing of the DNA ends at a DSB is 
considered the key process that stands at the crossroads between HR and NHEJ [107, 123].  
1.3.1 DNA end resection 
End resection is essential for HR-driven DSB repair and is considered the point at which cells 
are committed to repair by HR or not at all [123, 124]. DNA end resection only happens in 
phases S and G2 of the cell cycle where it can inhibit NHEJ and promote HR [125]. This is 
consistent with the fact that HR requires sister chromatids for accurate repair, which are also 
only present in S and G2 phase. During other cell cycle phases DNA end resection is actively 
inhibited or blocked by Ku heterodimers therefore only NHEJ can be initiated [126]. End 
resection catalyses the nucleolytic degradation of broken DNA ends in the 5’ to 3’ direction. 
This results in 3’ single-stranded DNA (ssDNA) which provides a platform for the recruitment 
of proteins required for HR repair (Figure 1. 4).  
Figure 1. 4 - Bidirectional DNA end resection 
Upon DSB induction the MRN complex (Mre11, Rad50 and 
Nbs1) localises to the damage site. Mre11 creates a nick in 
the 5’-terminated strand via its endonuclease activity and 
degrades DNA 3’ to 5’ back towards the DSB via its 
exonuclease activity. The resulting ssDNA is immediately 
coated with RPA to protect from degradation and inhibit 
Ku binding/NHEJ. The 5’ to 3’ exonuclease Exo1 can then 
bind to extend the resection. Rad51 eventually replaces the 
RPA loaded on the ssDNA to initiate strand invasion. Figure 
adapted from [139]. 
CHAPTER 1                                                                                                                         Introduction 
30 
 
End resection is initiated by the nuclease Mre11, the core component of the MRN complex 
[128]. The MRN complex, which comprises Mre11, Rad50 and nibrin (Nbs1), senses DSBs and 
binds DNA through its globular domain [127]. Mre11 exhibits a 3’ to 5’ exonuclease activity 
on dsDNA but 5’ to 3’ exonuclease activity is required for the generation of 3’ overhangs. 
This necessitates the recruitment of an additional protein with 5’ to 3’ exonuclease activity, 
Exo1. Experiments in yeast and later in human fibroblasts identified a two-step bidirectional 
model for end resection, whereby the MRN complex rapidly localises to DSBs during S and 
G2 phases of the cell cycle (Figure 1. 4). Mre11, which possesses ssDNA endonuclease 
activity, generates a ssDNA nick in the 5’-terminated strand upstream from the DSB and 
degrades DNA in a 3’ to 5’ direction back towards the DSB via its exonuclease activity [129-
131]. The resulting ssDNA is immediately coated by RPA to prevent degradation and 
becomes the preferred binding site for the 5’ to 3’ exonuclease Exo1, which can extend the 
resection to generate long 3’ ssDNA tails [132, 133] (Figure 1. 4). The MRN complex can bind 
to DSBs even in the presence of Ku heterodimers but Ku removal is essential for Exo1 
exonuclease activity to proceed [134]. Various potential Ku removal mechanisms have been 
proposed including ubiquitination of Ku by the E3 ubiquitin ligase RNF138 [135], 
phosphorylation of Ku70 [136] and CtIP (C-terminal binding protein (CtBP) interacting 
protein) endonuclease activity [137]. 
CtIP was first identified as a cofactor for the transcriptional repressor CtBP, but is now better 
known as an interacting partner of the MRN complex [138]. CtIP stimulates the 
endonuclease activity of Mre11 and is recruited to the MRN complex following cyclin-
dependent kinase (CDK) dependent phosphorylation after which it binds to the MRN subunit 
Nbs1 via its FHA/BRCT domains [139]. CtIP itself possesses 5’ flap endonuclease activity, 
which is required for the repair of more complex DNA lesions created by topoisomerase 
poisons or IR [140, 141]. The endonuclease activity of CtIP requires further phosphorylation 
of CtIP by ataxia telangiectasia mutated (ATM) protein kinase and is considered the crucial 
step for end resection initiation. Chanut et al. showed that the endonuclease activity of CtIP 
is also important for Ku removal at DSBs. CtIP depletion from human U2OS cells strongly 
impaired DNA resection and resulted in an accumulation of Ku foci following DNA damage. 
ATM-mediated phosphorylation of CtIP was required to inhibit Ku accumulation [137]. CtIP 
depletion can also impair cell survival when DSBs are generated in S phase but causes only 
weak hypersensitivity at other cell cycle stages highlighting its role in HR [142].  
CHAPTER 1                                                                                                                         Introduction 
31 
 
The final steps of HR sees breast cancer susceptibility gene 2 (BRCA2) mediate assembly of a 
Rad51 filament, which replaces RPA on ssDNA to initiate homology search and strand 
invasion (Figure 1. 5) [143, 144]. Rad51 binds to ssDNA in a ternary complex with ATP, 
binding to ATP but not ATP hydrolysis is required for stable Rad51-DNA binding. The 
transient interaction or ‘invasion’ of the Rad51 nucleoprotein filament with the template 
dsDNA leads to displacement of one of the template strands, and the presynaptic Rad51 
Figure 1. 5 - Non-homologous end joining and homologous recombination 
NHEJ starts with recognition of DSB ends by the Ku70/80 heterodimer which recruits DNA-
PKcs. If the ends are incompatible nucleases such as Artemis trim the ends and the XRCC4-
DNA Ligase IV-XLF ligation complex seals the break. HR repair involves DNA end resection by 
the MRN-CtIP complex to generate single stranded DNA (ssDNA). At this point the break can 
only be repaired by HR. The ssDNA is coated by RPA and subsequently replaced by Rad51 
aided by BRCA2. Rad51 nucleoprotein filaments mediate strand invasion of the homologous 
template forming a displacement loop (D-loop) for repair. Figure taken from [122]. 
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filament binds its complementary sequence to form a displacement loop (D-loop).  Rad51 is 
removed from the ssDNA strands by Rad54 to allow DNA synthesis by DNA polymerases δ 
(Polδ) or DNA polymerase ε (Polε) [145, 146]. As a result, the initial DSB is repaired 
accurately ensuring no loss of genetic instability (Figure 1. 5).  
1.3.2 Non-homologous end-joining 
Outside S and G2 phases of the cell cycle, homology-directed repair is simply not feasible in a 
eukaryotic cell. DNA is condensed into highly-ordered chromatin structures, and thus 
homology searching, and strand invasion are extremely difficult. NHEJ becomes the 
markedly preferred DNA repair pathway of choice in this instance. DNA ends at break points 
are bound by Ku heterodimers in a sequence-independent manner. Ku has a toroidal, ring-
shaped structure, and broken DNA ends can thread through the hole at the centre of Ku as 
though the eye of a needle [147]. Ku is considered the first protein to bind DSB breaks due to 
its high abundance in cells and strong binding affinity for duplex DNA ends. It does so at all 
cell cycle stages [114], where it acts as a scaffold to recruit the NHEJ machinery (Figure 1. 5). 
Recruitment is not in a step-wise manner but rather a dynamic assembly that can occur in 
any order. The phosphatidylinositol-3 kinase-like kinase family member DNA-PKcs is 
recruited rapidly to DSBs and results in translocation of Ku inwards on the dsDNA to allow 
DNA-PKcs direct access to the DSB end which activates DNA-PKcs kinase activity. If the DSB 
ends are incompatible, the NHEJ machinery can trim or fill in the DNA ends, as required. 
Artemis is the best established NHEJ nuclease and is regulated by DNA-PKcs. The 
Artemis/DNA-PKcs complex has a diverse range of nuclease activities and can 
endonucleolytically cut a variety of damaged DNA overhangs [117]. The DNA polymerases 
mu (Polμ) and lambda (Polλ) are both able to bind to Ku:DNA complexes to conduct 
template-independent synthesis of DNA at DSB ends [114]. These polymerases have no 
proofreading capability and so are error-prone. Once the required DNA end processing is 
complete the final step of NHEJ is the ligation of the broken DNA ends (Figure 1. 5). The DNA 
ligation complex consists of DNA Ligase IV and its co-factor, X-ray repair cross-
complementing protein 4 (XRCC4). XRCC4 stimulates DNA Ligase IV activity by stabilising it 
and promoting its adenylation [117]. XLF also forms part of the ligation complex and 
facilitates the ligation of mismatched or non-cohesive ends by DNA Ligase IV. XRCC4 appears 
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to have functions independent of the terminal ligation step highlighting the versatility of the 
NHEJ pathway [114].  
1.3.3 53BP1 
Ku removal from DSB ends is essential for HR to progress, and CtIP-mediated DNA end 
resection is considered the key step after which cells are committed to DNA repair by HR. 
However, the post-translational regulation of CtIP is not the only control mechanism 
dictating repair pathway choice. During the non-replicative phases of the cell cycle i.e. M and 
G1, DNA end resectioning is actively inhibited, suppressing HR and promoting DNA repair by 
NHEJ.  The tumour suppressor p53-binding protein 1 (53BP1) was identified as a key protein 
involved in the inhibition of end resectioning and therefore a key promotor of NHEJ in G1. 
53BP1, as the name suggests, was first identified as a binding partner of the well-known 
tumour suppressor protein p53 [148] and can stimulate p53-mediated transcriptional 
activation [149, 150]. It is however, the p53-independent roles of 53BP1 that have received 
most attention, in particular the role of 53BP1 in the DDR. Schultz et al. showed that 53BP1 
localised to distinct nuclear foci following treatment of cells with agents that specifically 
induce DSBs, suggesting a role for 53BP1 in DNA repair [151]. Further fluorescence 
microscopy experiments showed 53BP1 is recruited to DSBs at all stages of the cell cycle 
[152, 153]. The recruitment of 53BP1 to DSBs is well understood and requires the 
ubiquitination of histone 2A (H2A). ATM is recruited to the DSB by the MRN complex, and a 
signalling cascade is initiated by ATM-mediated phosphorylation of H2A variant H2AX 
(γH2AX). Mediator of DNA damage checkpoint protein 1 (MDC1) binds to the modified 
histone (γH2AX) and is subsequently phosphorylated by ATM. Phosphorylated MDC1 recruits 
the E3 ubiquitin ligase RNF8, which adds K63-linked ubiquitin chains to histone H1 (Ub-H1). 
This recruits a second E3 ligase, RNF168, that binds Ub-H1 with high affinity. RNF168 
ubiquitinates H2A at lysine 13 or 15 (H2AK13Ub or H2AK15Ub), which leads to the stable 
recruitment of 53BP1 via its ubiquitylation-dependent recruitment (UDR) motif (Figure 1. 6). 
RNF168 can also recognise its own histone mark leading to an amplification of the Ub signal 
and therefore increased 53BP1 recruitment.  
The ability of 53BP1 to recognise mono-methylated and di-methylated histone H4 
(H4K20me2) is also vital, but not sufficient for 53BP1 recruitment to DSB sites. The tandem 
Tudor motif of 53BP1 binds to H4K20me1 and H4K20me2 (Figure 1. 6), but H3K20me2 is an 
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abundant histone mark, present in 80% of all nucleosomes and so the modification must be 
regulated to be selective for DNA damage sites [154]. In the absence of damage, H4K20me2 
is masked by the binding of chromatin compaction factor L3MBTL1 and lysine demethylase 
JMJD2A to the modified histone mark. After DSB initiation, the E3 ubiquitin ligases RNF8 and 
RNF168 ubiquitinate L3MBTL1 and JMJD2A, which are evicted by the ATPase VCP or targeted 
for proteasomal degradation, respectively [155]. 53BP1 will only bind to nucleosomes that 
are both ubiquitinated at H2AK13/15 and methylated at H4K20.  
Figure 1. 6 - Schematic of wild-type 53BP1 
p53 binding protein 1 (53BP1) contains 28 N-terminal Ser/Thr-Gln sites at which it can be 
phosphorylated by ataxia-telangiectasia mutase (ATM) kinase. ATM-mediated phosphorylation 
promotes the binding of Rif1 (Rap1-interacting factor 1) and PTIP (PAX transactivation activation 
domain-interacting protein).  53BP1 also contains an oligomerisation domain (OD), a tandem Tudor 
motif (TD) that binds to demethylated Lys20 of Histone 4 (H4K20me2) and a ubiquitylation-dependent 
recruitment (UDR) motif that interacts with H2AK15Ub. The C-terminus of 53BP1 contains tandem 
BRCT domains that bind most notably to p53. 
53BP1 has no intrinsic enzymatic activity but rather acts to recruit other effector proteins, 
namely Rif1 and PTIP, which mediate inhibition of DNA end resection during the G1 stage of 
the cell cycle. Rif1 was first identified in yeast as an interacting partner of Rap1 and 
promotes telomere length homoeostasis [156]. In vertebrates however, Rif1 does not 
accumulate at functional telomeres but instead shows a pattern of telomere association 
typical of DNA-damage response factors. Rif1 accumulates at damaged chromatin in a 
53BP1- and ATM-dependent manner with depletion of either protein leading to loss of Rif1 
foci in cells after DSB induction [157]. Rif1 is recruited to damaged chromatin by the N-
terminal domain of 53BP1 which contains multiple ATM-phosphorylated Ser/Thr-Gln sites 
(Figure 1. 6) [158]. Mutation of all 28 of these phosphorylation sites (53BP128A), or inhibition 
of ATM, abolishes the 53BP1-Rif1 interaction and prevents recruitment of Rif1 to damaged 
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chromatin [159]. Furthermore, the 53BP1 mutant 53BP115AQ, which has the five most N-
terminal S/TQ motifs intact and the following 15 motifs substituted for alanine, failed to 
recruit Rif1 into IR-induced foci (IRIF) [159]. Phospho-mutant 53BP1 can still accumulate at 
DSBs supporting the fact that 53BP1, but not Rif1, recognises DSBs. However, cells lacking 
Rif1 show a delayed resolution of DSB-induced 53BP1 foci, arguing that whilst Rif1 may be 
dispensable for recruitment of 53BP1 to damaged chromatin, it appears to be required for 
the repair function of 53BP1 [159]. The exact mechanism by which Rif1 and 53BP1 cooperate 
to inhibit resection is unclear, but Drané, et al. have shown Rif1 may also act prior to 
resection inhibition to dissociate a protein that binds to the tandem Tudor motif of 53BP1, 
thereby promoting binding to methylated H4K20. An uncharacterised protein, TIRR (Tudor 
Interacting DNA Repair Regulator) was identified that interacts directly with the Tudor 
domain of 53BP1 and prevents binding to chromatin at H4K20. Dissociation of the 53BP1-
TIRR complex was impaired by the depletion of Rif1. Co-depletion of TIRR restored 53BP1 
foci formation, suggesting the impact of Rif1 loss on 53BP1 is due to the sustained complex 
with TIRR [160]. 
PTIP appears to be a context-specific effector of 53BP1 which executes only a subset of 
53BP1 functions. In contrast to 53BP1 and Rif1, PTIP depletion has no effect on class switch-
recombination, a specialised form of NHEJ that occurs at DSBs generated by cytosine 
deamination in developing B cells [159, 161, 162]. PTIP contains BRCT repeats which also 
interact with 53BP1 (Ser25) in an ATM-dependent manner, but it is not clear whether 53BP1 
is required for the focal accumulation of PTIP. In human cells, binding to 53BP1 was shown 
to be dispensable for PTIP recruitment at DSB sites [163]. However, Callen, et al. showed 
PTIP accumulation at DNA damage foci was diminished in the absence of 53BP1 [164].  
Given that 53BP1 can be recruited to DSBs at all stages of the cell cycle [152, 153], it appears 
to be the default cellular response to DSBs. This suggests NHEJ is the repair pathway of 
choice in the cell. Indeed, it has been shown that NHEJ predominates even in G2 and occurs 
faster than HR [165]. How then do cells overcome this clear preference for 53BP1-driven 
NHEJ? The answer lies with Breast Cancer susceptibility protein 1 (BRCA1), a known 
antagonist to 53BP1 and a central effector of pathway choice.  




BRCA1 is a known tumour suppressor protein with important checkpoint and DNA damage 
repair functions [166]. Mutations in BRCA1 predispose carriers to an elevated risk of breast 
and ovarian cancer, and BRCA1-mutated tumours present with genomic instability as a 
consequence of impaired DNA repair [167]. The first indication that 53BP1 and BRCA1 were 
functionally interrelated came from the finding that loss of 53BP1 rescues the embryonic 
lethal phenotype of BRCA1 exon 11 deletion (BRCA1Δ11/Δ11) by preventing premature 
senescence and apoptosis [168]. Unlike rescue by concomitant deletion of ATM, Chk1 or 
p53, the loss of 53BP1 in a BRCA1Δ11/Δ11 background did not lead to increased tumorigenesis 
and premature aging [168]. Bunting et al. explored this further and found that radial 
chromosome formation, characteristic of HR-defective cells, was present in BRCA1Δ11/Δ11 cells 
and was dependent on 53BP1. Loss of 53BP1 was therefore proposed to positively affect the 
residual capacity of cells to carry out HR. Indeed, this was found to be the case and the 
rescue was specific to 53BP1, as deletion of DNA Ligase IV and inhibition of DNA-PKcs, both 
of which are required for NHEJ, did not rescue the HR defect of BRCA1-deficient cells [169]. 
These data demonstrate that BRCA1 is not required for the promotion of resection but 
instead is critical to overcome the resection block imposed by 53BP1. DNA repair pathway 
choice is therefore controlled by the balance or mutual antagonism between 53BP1 and 
BRCA1 in the cell. Loss of BRCA1 promotes NHEJ as shown by the accumulation of Rif1 and 
53BP1 at DSBs in S/G2 phases of the cell cycle, when repair by HR usually predominates 
[153, 159, 170]. Similarly, knockdown of 53BP1 induces ectopic BRCA1-containing nuclear 
foci in G1, indicating that the potential for BRCA1 recruitment exists in G1 but is blocked in a 
53BP1-dependent manner [170]. The overexpression of BRCA1 can overcome the inhibition 
of DNA end resection enforced by 53BP1 and leads to increased resection at IR-induced DNA 
breaks [171].  
1.3.5 BRCA1 antagonises 53BP1 
The exact mechanism by which BRCA1 can overcome the end resection block imposed by 
53BP1 is still somewhat unclear. It was shown by super-resolution microscopy that 53BP1 
localised to IRIF, subnuclear aggregates containing numerous DNA-damage-responsive 
genes, most prominently in G0/G1 cell cycle stages, consistent with its role in NHEJ. BRCA1, 
on the other hand, accumulated as cells transitioned through S phase and was associated 
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with an exclusion of 53BP1 to the foci periphery in a BRCA1-dependent manner, and an IRIF 
core primed for DNA repair by HR [172]. RPA foci also form following 53BP1 repositioning 
suggesting end resectioning progresses following the removal of 53BP1 from DSB sites [173]. 
BRCA1 interacts with its N-terminal binding partner BRCA1-associated RING domain protein 
1 (BARD1) to form an active E3 ubiquitin ligase. Several targets of the BRCA1-BARD1 E3 
ligase have been identified including Histone H2A. H2A modification by ubiquitin has been 
implicated in the recruitment of the chromatin remodeller SMARCAD1 to DSBs, the ATPase 
activity of which is required for positioning of 53BP1 away from break sites and promotion of 
end resectioning [174]. Consistent with this model, it was found that the deubiquitinase 
(DUB) ubiquitin specific protease-48 (USP48) can remove ubiquitin from H2A at the specific 
BRCA1-BARD1 ubiquitination site and in doing so restricts resection. USP48 depletion results 
in a hyper-resection phenotype and positioning of 53BP1 further from the break site [175].  
Feng et al. showed that BRCA1 can restrain the phosphorylation of 53BP1 by ATM in S/G2 
with increased phosphorylation of 53BP1 observed following BRCA1 depletion. The 
phosphorylation of other ATM substrates was not affected, with the exception of Nbs1, but 
the mechanism for this was unclear. Feng, at al. went on to show that the C-terminus of 
53BP1 can be ubiquitinated by BRCA1-BARD1 but not by the BRCA1 mutant C61G which 
contains a mutation in the RING domain; however, this could not be directly linked to the 
suppression of 53BP1 phosphorylation. They did, however, show that unlike WT BRCA1, re-
introduction of BRCA1 C61G to BRCA1-depleted cells was unable to suppress PTIP foci 
formation in S/G2 cells, suggesting that the E3 ligase activity of BRCA1 is important for 
inhibiting 53BP1 phosphorylation, either directly or indirectly [153]. 
A cell-cycle dependent interaction between BRCA1 and CtIP may also be important for 
antagonising 53BP1. As cells enter S phase, CDK-mediated phosphorylation of CtIP at Ser327 
mediates binding to BRCA1 which is reported to be required for end resectioning [142, 170, 
176].  The inhibition of Rif1 at DSB break sites in chicken DT40 cells was impaired following 
CtIP depletion or re-introduction of the BRCA1 S1655A mutant, which disrupts CtIP binding, 
implicating the binding of BRCA1 to CtIP in Rif1 antagonism [170].  Whether this also holds 
true in mammalian cells is still debated with research suggesting the BRCA1-CtIP interaction 
is dispensable for end resection and proficient HR [177-179]. The BRCA1-CtIP interaction 
may instead be controlling the speed of resection. The CtIP S237A mutant, which cannot 
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bind BRCA1, exhibited slower resection than WT CtIP, potentially due to the role of BRCA1 in 
removing 53BP1-Rif1 complexes [180]. Alternatively, BRCA1-CtIP interactions may only be 
required for the repair of a subset of DNA breaks. Aparicio, et al. showed that whilst 
dispensable for resection of endonuclease-generated DSB ends, the interaction between 
BRCA1 and CtIP is required for resection of topoisomerase II (Top2)-adducted DSBs, and 
therefore resistance to the chemotherapeutic agent etoposide [181].  
Figure 1. 7 - Antagonistic relationship between 53BP1 and BRCA1 
a) During G1, oligomerised 53BP1 binds to H2AK13/15Ub and H4K20me2 and recruits its effector 
proteins Rif1 and PTIP following ATM-mediated phosphorylation at the amino terminus of 53BP1. 
Chromatin-bound 53BP1-Rif1 prevents association of BRCA1 with the MRN complex subunit CtIP 
through an unknown mechanism. The net outcome of this inhibition is to limit DNA end resection and 
thus enable NHEJ-mediated DSB repair. b) As cells enter S phase, CtIP is phosphorylated in a CDK-
dependent manner which promotes its binding to BRCA1. This prevents the chromatin association of 
53BP1-Rif1 and 53BP1-PTIP through unknown mechanisms. Acetylation of H4K16 further reduces 
53BP1 binding to the K4K20me2 mark. Deacetylation of CtIP by Sirtuin 6 (SIRT6) upregulates the end 
resection activity of CtIP which enables 3’ to 5’ resection of the DNA end and commits cells to HR. 
Figure taken from [155], reprinted with permission. 
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In summary, 53BP1 is a key regulator of NHEJ that recruits its effector proteins Rif1 and PTIP 
following ATM-mediated phosphorylation of N-terminal Ser/Thr-Gln sites. Rif1 and PTIP 
promote DNA end resection during G1 and thus inhibit HR. During S/G2 stages of the cell 
cycle, BRCA1 can counteract the block imposed by 53BP1 by an as yet indeterminate 
mechanism (Figure 1. 7). BRCA1 may inhibit the phosphorylation of 53BP1 by ATM or 
interact with CtIP to promote DNA end resection. What is clear, is that the relationship 
between 53BP1 and BRCA1 is vital for repair pathway choice and is highly regulated to 
ensure DSBs are repaired efficiently to maintain genomic stability. 
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1.4 The Ubiquitin Proteasome System (UPS) 
A number of cellular processes including cell cycle progression, cell division and apoptosis 
require the rapid degradation of proteins. This rapid degradation is essential to allow protein 
levels to change quickly in response to external stimuli. In eukaryotic cells there are two 
major pathways controlling this degradation, lysosomal degradation/autophagy and the 
ubiquitin proteasome system (UPS). Lysosomal degradation involves the uptake of proteins 
by lysosomes, membrane-enclosed vesicles that contain proteases and other digestive 
enzymes [182]. This process can be non-selective and is primarily adopted during apoptosis 
or as a response to cellular stress such as infection or cell starvation. In contrast, the UPS is a 
highly regulated and selective pathway, whereby proteins are targeted for degradation upon 
covalent conjugation of a 76 amino acid ubiquitin peptide.  
Addition of ubiquitin requires the combined action of E1 (ubiquitin activating), E2 (ubiquitin 
conjugating) and E3 (ubiquitin ligating) enzymes in an ATP-dependant cascade [182, 183]. 
First, the E1 enzyme forms a thio-ester bond with ubiquitin which activates the carboxyl-
terminal glycine residue of ubiquitin. This allows the transfer of activated ubiquitin to a 
cysteine residue of an E2 enzyme. The E3 ubiquitin ligase is responsible for bringing 
substrates into close proximity with the E2 enzyme and for catalysing the transfer of 
ubiquitin to the amino group of a lysine residue on target proteins [184]. Proteins with 
multiple lysine residues can be mono-ubiquitinated (addition of a single ubiquitin moiety), 
on more than one lysine at once to become multi-mono-ubiquitinated. Ubiquitin itself can 
also be ubiquitinated on any of its seven internal lysines resulting in a polyubiquitin chain. 
These chains can be linear, homologous; consisting of one linkage type, heterogenous; 
consisting of multiple ubiquitin linkages in a single polymer or branched [185, 186]. The 
functions of some linkage types are well characterised but by no means exclusive, for 
example, K48 linkages are known to target proteins for proteasomal degradation at the 26S 
proteasome and are the most abundant linkage type identified in organisms, while K63-
linked chains have non-proteolytic functions such as NF-κB activation and re-localisation of 
proteins. The physiological consequences of the remaining atypical ubiquitin chain linkages 
(K6, K11, K27, K29 or K33) remain relatively uncharacterised despite their high abundance, 
but may all mediate protein degradation [187]. K11-linked ubiquitin chains are utilised by 
the anaphase  promoting complex (APC/C) to target proteins for degradation [188], and K6 
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chains may regulate DNA repair [189]. 
1.4.1 SCF-type E3 ubiquitin ligases 
The functional complexity of ubiquitination signalling is as a result of the large and diverse 
range of enzymes that catalyse ubiquitination reactions. The human genome encodes for 
two E1 enzymes, 38 E2 enzymes and approximately 600-1000 E3 ligases [190-192]. The 
combination of these enzymes enables a high degree of substrate specificity. The selectivity 
of the UPS is determined by the E3 ligases and the E2 enzymes they interact with. E3 ligases 
bind, and therefore select, the substrate to be ubiquitinated, but it is the E2 enzyme that 
determines the ubiquitin linkage specificity. For example, the E3 ligase BRCA1-BARD1 
assembles K63-linked chains with the E2 UBE2N but K48-linked chains with UBE2K [193]. E3 
enzymes can be subdivided into three different classes: the HECT (Homologous to E6-
associated protein C-terminus)-domain type, RING (Really Interesting New Gene)-finger type 
and RBR (RING-in-between-RING) family [194]. HECT and RBR E3 ligases catalyse the transfer 
of ubiquitin to a substrate in two steps: first ubiquitin is transferred from the E2 to the E3, 
and then from the E3 to the substrate. In contrast, RING-finger type E3s catalyse the transfer 
of ubiquitin directly from the E2 enzyme to the substrate [195]. RING-finger type E3 enzymes 
can function as monomers, dimers or multi-subunit complexes. The largest family of this 
type is the Cullin-RING E3 ligase (CRL) complex family, with over 200 members [196]. 
The central scaffold of the CRL comprises one of seven cullin proteins which binds a RING-
box protein (Rbx1 or Rbx2) at its C-terminus. CRL1 or SCF (S-phase kinase-associated protein 
1 (Skp1)-Cullin 1-F-box protein) E3 ligases are the best characterised of the CRL ligases. In 
these ligases, the CRL scaffold Cullin 1 (Cul1) binds the adaptor Skp1 at its N-terminus and 
Rbx1 at its C-terminus, thereby bringing together two essential components required for E3 
ligase activity. Skp1 binds to an F-box-domain containing protein (FBP); which acts as the 
substrate recognition component of the SCF  ligase and Rbx1 binds the E2 enzyme 
conjugated to activated ubiquitin, thus enabling the direct transfer of ubiquitin to the 
substrate (Figure 1. 8). Skp1 binds to FBPs via their characteristic F-box domain, an 
approximately 50aa protein-protein interaction motif first identified in cyclin-F (Fbxo1) and 
conserved in FBPs. The FBP:Skp1 dimer is a switchable unit that docks the cullin scaffold and 
is actively dissociated by the protein Cand1 (Cullin-associated NEDD8-dissociated protein 1) 
to regulate levels of active E3 ligases in the cell [197].  
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It is worth noting that FBPs not engaged as part of active E3 ligases also have functions 
outside of the UPS [198]. FBPs compete for binding to cullin scaffolds and so it is 
unsurprising that many have functions that do not require the assembly of ligase complexes. 
In yeast FBP:Skp1 dimers have been identified with roles in centromere complex assembly 
and recycling of endosome components independent of an SCF complex [199]. It is not just 
yeast that utilise FBPs outside of the UPS, Emi1 (Fbxo5), a mammalian example of an FBP 
with SCF-independent roles, can stably bind and inhibit the APC/C complex to coordinate 
DNA replication and mitosis [200, 201].  Furthermore, some FBPs, despite being able to bind 
Skp1, utilise their F-box domains to bind proteins other than Skp1. For example, Fbxo38 uses 
its F-box domain to interact with the transcription factor Klf7 to act as a transcriptional 
cofactor [202]. 
Figure 1. 8 - Schematic showing the SCF complex and ubiquitination of target proteins. 
 Ubiquitination of target substrates requires the combined action of E1 (red), E2 (orange) and E3 
(blue) enzymes. The SCF E3 ubiquitin ligase is shown here in its characteristic horseshoe 
conformation. The scaffold protein Cul1 binds Rbx1 and Skp1. Skp1 binds the substrate determining 
component F-box protein which can recruit substrates. Sequential ATP-dependent reactions transfer 
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1.4.2 F-box proteins 
F-box proteins recruit target substrates to the SCF ligase complex via a variable protein-
protein domain. The protein-binding domain present determines the nomenclature of FBP 
subfamilies, Fbxws contain WD40 repeats, 10 family members, Fbxls have leucine rich 
repeats, 21 family members and Fbxos have other known binding domains such as proline 
rich regions, 38 family members [198]. There are 69 known FBPs in human, at least 42 of 
which have been shown to interact with Cul1 to form SCF-type E3 ubiquitin ligases 
complexes [203]. This allows for recognition of a diverse range of substrates and far-reaching 
roles within the cell. Most substrates require post-translational modification before they can 
be recognised and bound by FBPs. The canonical model of FBP substrate recruitment 
requires binding to short degradation motifs (known as degrons) which are often primed by 
phosphorylation on specific serine or threonine residues prior to FBP binding (known as 
phosphodegrons) [204]. In the absence of phosphorylation, a protein is stable, but upon 
phosphorylation at sites within the degron the protein can be ubiquitinated and degraded 
[205-207]. To increase stringency some degrons contain multiple phosphorylation sites or 
can require the combined activity of multiple kinases before recognition by an FBP [208]. 
Phosphorylation is not the only modification that facilitates FBP binding, Fbxo2 and Fbxo6 
bind glycosylated proteins [209, 210] and the binding of Fbxl17 and Fbxo24 to target 
proteins is determined by the acetylation status of binding motifs (acetyl-degrons) within 
their substrates [211, 212]. Not all FBPs require modified degrons to bind substrates [213, 
214], and in some cases post-translational-modification actually prevents binding [215, 216].  
On the other hand, some FBPs require more than just post-translational modifications to 
recognise substrates and therefore utilise co-factors. For example, Skp2 (Fbxl1)-mediated 
degradation of p27 requires the accessory protein Cks1 (CDK regulatory subunit 1). It is in 
fact Cks1 that binds to the phosphodegron (Thr187) on p27, not Skp2, to recruit p27 to the 
SCF ligase complex as a substrate for ubiquitination [217-219]. Skp2 can still interact with 
p27 directly, but via an alternative interface [218].  
1.4.3 F-box proteins in cancer 
Many FBPs have already been implicated as tumour suppressors or oncogenes due to their 
ability to regulate the expression and activity of other oncogenic or tumour suppressive 
proteins. Dysregulation of F-box protein mediated proteolysis leads to human malignancies 
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and inhibition of FBPs has been shown to have potential as a therapeutic strategy [220]. 
Skp2 (Fbxl1) is perhaps the best characterised FBP and a known oncoprotein. First identified 
as a cell cycle regulator, Skp2 has been reported to be overexpressed in various human 
tumour samples including breast, lymphoma, non-small cell lung cancer and glioblastoma 
[221-223]. Transgenic mice overexpressing Skp2 show low-grade carcinoma but knock-out 
mice are resistant to sarcoma and lymphoma [221]. Skp2 exerts its oncogenic effect by 
ubiquitinating its substrates, many of which are tumour suppressors, most notably the 
cyclin-dependent kinase inhibitor, p27 [224-228]. Therefore understanding the target 
repertoire of F-box proteins is important for determining their mechanistic roles in cancer 
progression [229]. 
In contrast Fbxw7 is a well-established tumour suppressor that targets oncogenic proteins 
including cyclin E and c-myc for degradation [230]. Fbxw7 also targets mTOR (mammalian 
target of rapamycin) for degradation, and tumour cell lines containing Fbxw7 mutations are 
particularly sensitive to rapamycin treatment [231].  Approximately 6% of all primary human 
cancers have a mutation in FBXW7 with the most frequent mutations identified in T cell 
acute lymphoblastic leukaemia (T-ALL: 30%) and cholangiocarcinomas (35%) [232]. Mouse 
models have been used to confirm its tumour suppressive role with bone-marrow specific 
Fbxw7-knockout mice developing T-ALL within 16 weeks, due in part to an accumulation of 
the Fbxw7 substrates c-myc and Notch1 [233].  
β-TRCP1 and β-TRCP2 (Fbxw1 and Fbxw11) differ from Skp2 and Fbxw7 in that they show 
context-dependent roles in governing tumorigenesis and have been shown to possess both 
tumour suppressive and oncogenic properties dependent on the specific tumour type. β-
TRCP1 is overexpressed in pancreatic [234] and colorectal cancer [235] with the latter 
associated with poor patient outcome, and β-TRCP2 is overexpressed in breast, prostate and 
gastric cancers [236, 237]. Targeted expression of β-TRCP1 in the mammary gland led to 
tumour formation, which supports the idea that β-TRCP1 is an oncogene [238]. However, β-
TRCP1 and β-TRCP2 mutations have been identified in gastric cancer that result in loss of the 
E3 ligase activity of β-TRCP. The resulting stabilisation of the β-TRCP substrate β-catenin was 
associated with development of tumours in this setting, suggesting a tumour suppressive 
role for β-TRCP1 and β-TRCP2 [239].  
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F-box proteins and the dysregulation thereof have been implicated in almost all the 
hallmarks of cancer described by Hanahan and Weinberg [2, 3, 240]. For example, Fbxo31 is 
downregulated in gastric cancer and inhibits gastric cancer progression by suppressing the 
epithelial-mesenchymal transition (EMT) [241, 242]. Fbxo31 is also known to target Cyclin-
D1 for degradation in response to DNA damage to activate the cell cycle arrest checkpoint. 
Loss of Fbxo31 is therefore also likely to sustain cell proliferation and promote uncontrolled 
cell cycle progression. Fbxo5 (Emi1) is overexpressed in ovarian tumours and is associated 
with poor outcome in in hepatocellular carcinoma [243, 244]. Emi1 stabilisation inhibits the 
APC/C complex which blocks APC/C-mediated degradation of Skp2 and promotes cell 
proliferation in chronic myeloid leukaemia cells [245]. Fbxo8 negatively regulates the small 
GTPase Arf6, a regulator of membrane trafficking and remodelling. Fbxo8 expression was 
lost in several breast tumour cell lines that require Arf6 for invasion, but this invasiveness 
could be suppressed with the forced expression of Fbxo8 [246]. There are undoubtedly 
further roles for FBPs in cancer and other diseases. Wang et al. identified Fbxo11, Fbxw8, 
Fbxl3, Fbxo1, Fbxo4 and Fbxo18 as emerging tumour suppressors further highlighting the 
role of F-box proteins in cancer pathogenesis [224].  
1.4.4 Fbxl17 
Fbxl17 is a relatively understudied member of the FBXL family of FBPs which binds to Skp1 
via its F-box domain to assemble an SCF-type E3 ligase complex. The protein structure of 
Fbxl17 is characterised by its 11 C-terminal leucine rich repeats through which it can interact 
with target substrates (Figure 1. 9). LRRs are a repeating motif, 20-29 residues long that 
contain a conserved 11-residue consensus sequence (LxxLxLxxN/cxL, where x can be any 
amino acid and L can be occupied by leucine, valine, isoleucine or phenylalanine; amino 
acids with hydrophobic side chains) [247]. Proteins may also bind at the N-terminus of 
Fbxl17, but it is unclear whether these would also be targeted for ubiquitination. As Fbxl17 
assembles into an SCF complex, its role is to bring substrates into close proximity with an E2 
enzyme for the direct transfer of ubiquitin from the E2 to the target protein.   
Whilst some substrates of Fbxl17 have been identified most remain widely unknown. Fbxl17 
was first reported to stabilise ribonucleotide reductase subunit M2 (RRM2), promoting its 
overexpression in the breast cancer cell line MCF-7. RRM2 expression and activity has been 
associated with resistance to multiple drugs in human cancer and together with RRM1 
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makes up the two subunits of human ribonucleotide reductase (RR). RR is an S-phase specific 
rate-limiting enzyme that mediates the synthesis of deoxyribonucleotides, DNA precursors. 
Patients less sensitive to the RR antisense oligonucleotide inhibitor GTI-2040 were shown by 
Xiao et al. to have high levels of Fbxl17. However, the mechanism of this apparent 
stabilisation is unclear. They suggest that Fbxl17 may therefore be a useful biomarker for 
breast cancer therapy [248].  
In 2013, Tan, et al. identified the transcriptional repressor BACH1 as a substrate of Fbxl17. 
Parallel adaptor capture (PAC) proteomics was used to systematically identify FBXL FBP 
substrates for 19 FBXL family members (all except Fbxl6 and Fbxl21). Fbxl17 was found to 
associate with several BTB-domain containing proteins including BACH1 [249]. Further 
analysis showed that Fbxl17 is important for turnover of BACH1 which promotes 
transcription of the NRF2 target HMOXI. HMOXI encodes Heme oxygenase 1 which is 
important for the breakdown of free Heme. This has a cytoprotective role as an excess of 
free Heme sensitises cells to undergo apoptosis. The ubiquitination of BACH1 by Fbxl17 
provides one mechanism for controlling HMOXI activation in response to oxidative stress. 
Figure 1. 9 - Schematic of an E3 SCF ligase complex with wild-type Fbxl17.  
Fbxl17 binds to Skp1 via its Fbox domain (purple) to form the SCF complex. The leucine rich repeats 
(LRRs, red) of Fbxl17 then interact with target substrates and bring them into close proximity with 
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Fbxl17 has also been shown to mediate the ubiquitination and degradation of Sufu 
(Suppressor of fused), a central regulator of Hedgehog (Hh) signalling. Sufu was identified as 
a candidate substrate by Tan, et al. [249], and further research by Raducu, et al. showed that 
Fbxl17 targets Sufu for proteolysis. Sufu sequesters Gli (Glioma-associated oncogene 
homolog) transcription factors to negatively regulate Hh signalling thus acting as a tumour 
suppressor (Figure 1. 10A). Polyubiquitination of Sufu by Fbxl17 is favoured by the presence 
of Gli1, bound to Sufu, and dephosphorylation of Sufu residues S342 and S346. Degradation 
of Sufu following ubiquitination by Fbxl17 releases Gli1 which can then activate the Hh 
pathway (Figure 1. 10B). This regulation by Fbxl17 is exploited in medulloblastoma cells to 
aberrantly amplify Hh signalling.  
In human medulloblastoma DAOY cells Fbxl17 depletion impaired proliferation suggesting 
that Fbxl17 mediates cancer cell proliferation. A naturally occurring mutation (S352F) found 
in medulloblastoma patients affected by Gorlin syndrome abolishes phosphorylation of Sufu 
at S352. This substitution increases Fbxl17 binding allowing for faster proteolysis of Sufu, 
amplified pathway activation and increased cell proliferation (Figure 1. 10C). Fbxl17 
inhibition was able to rescue this sustained activation and prevent medulloblastoma tumour 
growth by blocking Sufu degradation (Figure 1. 10D). Therefore, the control of Sufu levels by 
Figure 1. 10 - SCFFbxl17-ubiquitination of Sufu regulates Hedgehog signalling and medulloblastoma 
(A) Phosphorylation of Sufu at S342 and S346 prevents Fbxl17 binding. Gli1 is sequestered by Sufu 
and so cannot activate the Hh pathway. (B) Dephosphorylation of Sufu initiates Fbxl17 
polyubiquitination of Sufu at Lys257. Sufu is degraded which releases Gli1 to activate the Hh 
pathway. (C) In medulloblastoma, the Sufu substitution S352F abolishes Sufu phosphorylation and 
promotes Fbxl17 binding, resulting in sustained Hh pathway activation. (D) Inhibition of Fbxl17 blocks 
Sufu degradation and prevents medulloblastoma tumour growth. Figure adapted from [250]. 
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Fbxl17 in medulloblastoma is important for regulating Hh activation. This evidence suggests 
that targeting Fbxl17 and the UPS may be a useful therapy in the treatment of cancer [250].  
In the case of Sufu, Fbxl17 binding could be inhibited by phosphorylation of Sufu highlighting 
the importance of post-translational modifications in substrate binding. There is now 
evidence that Fbxl17 can recognise and bind a tandem IK (Isoleucine, lysine) motif (IKxxxIK) 
within the histone modifying protein PRMT1 [212]. The lysine acetylation status of this motif 
or so called ‘acetyldegron’ determines Fbxl17 binding. The co-ordinately ordered activity of 
the deacetylase Sirt1 and the acetylase p300 prime this acetyldegron within PRMT1 for 
Fbxl17 binding. Fbxl17 can then dock and target PRMT1 for proteasomal degradation. 
Bronchial epithelial cells treated with pathogen-derived lipopolysaccharide (LPS) 
downregulated p300 and Sirt1 which protected PRMT1 from Fbxl17-mediated degradation 
and increased cell proliferation. This perhaps explains how bronchial epithelial overgrowth 
occurs in asthma. Identifying other proteins that contain the tandem IK motif identified in 
PRMT1 may be a means of identifying further Fbxl17 substrates. 
Most recently, Fbxl17 has been shown to interact with BTB-domain containing proteins in a 
quality-control capacity [251]. In concurrence with Tan, et al. it was found that Fbxl17 can 
bind many BTB-domain-containing proteins and can recognise inactive BTB heterodimers 
which are consequently targeted for proteasomal degradation. This ensures only functional 
BTB dimers are present in cells. Interestingly these data demonstrate that Fbxl17 recognises 
domains shared by many proteins rather than simply targeting a specific substrate. Mena et 
al. showed that Fbxl17 preferentially recognises BTB heterodimers by recognising a degron 
within the dimer interface. These residues are only exposed and therefore accessible to 
Fbxl17 in nascent or mutant BTB proteins or aberrant heterodimers. Binding is dependent on 
a conserved cysteine residue (C627) of Fbxl17 and the somatic mutation C627R identified in 
breast cancer ablated the interaction of Fbxl17 with BTB proteins. The dimerization quality 
control (DQC) function of Fbxl17 was shown to be required for neural differentiation and 
function in Xenopus laevis embryos, highlighting the importance of DQC for specific BTB 
proteins [251].  
1.4.5 Fbxl17 is recurrently rearranged in breast cancer 
Data-mining of the METABRIC (Molecular Taxonomy of Breast Cancer International 
Consortium) dataset [29], consisting of segmented array-CGH copy number data from 1,992 
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primary breast tumours, was carried out by Dr Susanne Flach, a previous PhD student in the 
lab, to identify genes that are recurrently disrupted in cancers [252]. Many of the genes in 
the top 1000 most frequently broken genes, as derived by copy number changes, resided in 
common fragile sites (CFS). These are loci prone to breaks when cells are under replicative 
stress. Given the increased rate of breaks at these sites, it can be difficult to determine 
whether these rearrangements confer any advantage and are true driver mutations. After 
excluding genes in CFS, and cancer genes already described in the literature, we found that 
multiple family members of the F-box protein (FBP) family appeared in the top half of the 
frequently broken genes list. These identified proteins were both novel with regards to 
cancer involvement at the time of discovery and did not fall within CFS. By surveying the 
METABRIC dataset in more detail it was found that 135 (7%) tumours had at least one 
genomic break within the FBP FBXL17, often clustered around the LRR-encoding regions. 
These genomic alterations suggest the ability of Fbxl17 to recruit substrates for 
ubiquitination or to form part of an SCF complex may be compromised in breast cancers. 
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1.5 Aims of this thesis 
1.5.1 Investigating the functional consequences of FBXL17 rearrangements 
As a result of the identified rearrangements of FBXL17 in breast cancer, described above, the 
initial aim of this thesis was to determine the functional consequences of these mutations 
for Fbxl17. Many of the rearrangements observed previously, truncated Fbxl17, resulting in 
loss of LRRs. We therefore investigated the effect of loss of LRRs on SCF ligase assembly and 
function. By surveying paired-end whole-genome sequencing data from primary breast 
tumours, we also set out to identify further breast cancer-associated rearrangements in 
FBXL17. 
1.5.2 Identifying and verifying new target substrates of Fbxl17 
Only a few substrates of Fbxl17 are currently known, and so the second aim of this thesis 
was to identify and verify new potential binding partners of Fbxl17. Identifying the 
regulatory network of Fbxl17 will provide an insight into its role in breast cancer 
pathogenesis, which may then reveal pathways amenable to therapeutic targeting. To 
address this aim, we identified potential interacting partners of Fbxl17 by yeast two-hybrid 
and mass spectrometry approaches. The resulting aims were then to validate Fbxl17 binding 
partners, and to investigate the downstream effects of FBXL17 mutations on its regulatory 
networks.  
 
In summary, this thesis investigates the functional downstream effects of novel FBXL17 
rearrangements identified in breast cancer and identifies two distinct pathways that appear 





2 MATERIALS AND METHODS 
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CHAPTER 2- Materials and methods 
2.1 CELL CULTURE AND ANALYSIS 
2.1.1 Cell line maintenance 
Frozen ampoules of cells were thawed at room temperature from -80°C and diluted in 
complete growth medium, centrifuged at 300G for 3 mins, washed once in PBS to remove 
traces of dimethyl sulfoxide (DMSO, Sigma D8418), centrifuged again and resuspended in 
10ml complete growth medium. Complete medium for the cell lines grown are shown in 
Table 1. Cells were grown in 90mm tissue culture dishes, unless otherwise stated, at 37°C, 
5% CO2 humidified atmosphere. Confluent cells were washed with 5ml PBS after removal of 
growth medium and 2ml of trypsin was added. Cells were incubated at 37°C until no longer 
adhered to the dish and passaged as required. Fresh complete medium was then added to a 
total volume of 10ml. 
Cells were frozen by trypsinising as above and pelleting the cells by centrifugation 300G 3 
mins. Pellets were resuspended in freezing media (90% (v,v) FBS, 10% (v,v) DMSO), 1ml per 
90mm dish and frozen slowly at -80°C  before transfer to liquid nitrogen. 
2.1.2 Transfection of adherent cells 
24 hours prior to transfection cells were seeded in order to reach 50-80% confluency 
overnight, ~2 x 106 cells for 90mm dishes and ~2 x 105 cells for flat bottomed 6 well plates. 
For 90mm dishes a minimum of 5μg of DNA was added to 300μl OptiMEM® (Thermo Fisher 
Scientific, 51985026) and 15μl PEI (3μl/μg DNA) vortexed 10s and incubated room 
temperature (RT) for 15 minutes. For 6 well plates 1ug DNA was added to 50μl OptiMEM® 
and 3μl PEI. The entire volume was then added drop-wise to cells whilst gently rocking the 
plate to ensure an even distribution. Unless otherwise stated, cells were incubated for 48 h 
before assaying.  
2.1.3 Retroviral infection of adherent cells 
Viral packaging cell line Phoenix-ECO [253] were transfected as above (PEI mediated) with 
3μg DNA of interest and 2μg viral envelope VSVG. Eight hours after transfection the media 
was changed to that of the target cells. 24h prior to infection 2 x 105 target cells were seeded 
in complete growth medium to flat bottomed 6 well plates and grown overnight to 50-80% 
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confluency. 24h after the initial transfection the conditioned media from the Phoenix-ECO 
cells containing virus was sterile filtered through a 0.45μm filter and collected in a Falcon 
tube. The cationic polymer Polybrene was added (1:1000) to increase the efficiency of 
infection as well as ~1ml of complete growth medium to replenish serum. Medium was 
removed from the target cells and 2ml of viral conditioned media was added per well, cells 
were then centrifuged at 2000rpm for 30-45 minutes and returned to incubate at 37°C, 5% 
CO2. Fresh target cell complete growth medium was added to the Phoenix-ECO cells and 
they were returned to incubate. This process was repeated the following day or every other 
day depending on the cell line. After the final infection the Phoenix-ECO cells were 
disinfected with Virkon and discarded. Infected cells were trypsinised and a small sample 
was run through a flow cytometer to check infection efficiency.   
2.1.4 Cell fractionation 
3 x 106 cells were resuspended in 75µl Buffer A (10mM Hepes pH7.9, 10mM KCl, 1.5mM 
MgCl2, 0.34M Sucrose, 10% Glycerol, 1mM DTT, 0.1mM PMSF, protease inhibitors). Triton X-
100 was added to a final concentration of 0.1%, lysates were then incubated on ice 5 min 
and centrifuged 4 min 3,500 rpm at 4°C. Supernatant was removed (cytoplasmic fraction) 
and clarified by centrifugation, 15 min, 13,000 rpm, 4°C. The remaining nuclear pellet was 
washed in Buffer A + Triton X-100 and lysed in Diehl Buffer with protease inhibitors, 
incubated on ice 5 min and centrifuged 13,000 rpm 15 min, 4°C (nuclear fraction). 
2.1.5 siRNA transfection 
U2OS cells were seeded at 5x105 per 60mm dish in 2ml DMEM media containing 5% FBS 
without antibiotics (no P/S).  Once cells were adhered (~6 hours), 250µl OptiMEM® was 
added to 10µl siRNA and 10µl Lipofectamine™ RNAiMAX (Thermo Fisher Scientific, 
13778075) in separate Eppendorf tubes. After 5 mins at RT the two tubes were mixed and 
incubated at RT for a further 15 mins. siRNA mixes were then added dropwise to cells. A 
minimum of 12 hours later, media was replaced to DMEM + 10% FBS no antibiotics. 72 hours 
after siRNA transfection cells were harvested for analysis. siRNAs were purchased from 
Eurofins genomics and transfected at a final concentration of ~60nM. Sequences for the 
siRNAs were as follows: siRNA1: GGAUAUACAUGCAGGAAAA (targets exon 4) 
siRNA2: GCAGAGAACUCAAAGAUAU (targets exon 4) 
siRNA3: GGACAAACUCACUGAUGAA (targets exon 3) 
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2.1.6 shRNA knockdown of Fbxl17 expression 
Short hairpin RNA sequences targeting FBXL17 were taken from the RNAi Codex database 
(http://codex.cshl.org) [254]. shRNA vectors were generated by PCR amplification of a single 
mir30 template oligonucleotide containing restriction enzyme sites either side of the 
complete shRNA sequence, for subsequent cloning into the LMP vector (MSCV-LTRmir30-
IRES-GFP). The 22-mer shRNA sequences chosen, and the region of FBXL17 they target, are 
listed in Table 2. Vectors were sequenced to ensure correct amplification of the shRNA 
sequence. shRNA vectors were then used to retrovirally infect cells for Fbxl17 knockdown. 
 





For cell cycle analysis 2x105 cells were seeded to 6 well plates and irradiated (2Gy). Non-
irradiated cells were used as a control. Cells were harvested at the indicated time points, 
washed in PBS, centrifuged and the pellet slowly resuspended in ice-cold 70% ethanol with 
vortexing to prevent clumping. Cells were fixed for at least 24h before propidium iodide (PI) 
staining. Prior to analysis by flow cytometry, cells were pelleted by centrifugation 2000rpm 5 
mins, washed in PBS and resuspended in PI staining solution. Cells were incubated at 37°C 
for 30 mins and then analysed on a Cytek DxP8 Flow Cytometer with a minimum of 20,000 
events collected per sample.  
2.1.8 Annexin V staining 
To assay apoptosis, supernatant was collected from cells, remaining adhered cells were 
trypsinised and added to the supernatant. Cells were spun down 300G, 3 min, washed in PBS 
and counted. Cells were spun down again, 300G 3min, and resuspended in 100µl/ 100,000 
cells Annexin V buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH7.4). Annexin V- Alexa 
Fluor 647 (Invitrogen, A23204) (1µl/100µl) and propidium iodide (PI) (5µg/ml) were added to 
each sample. PI was used to discriminate live cells from dead cells. Cells were incubated at 
RT for 15 mins and then analysed on a Cytek DxP8 Flow Cytometer with a minimum of 
15,000 events collected per sample. 
Table 2 - shRNA design – 21-mer shRNA sequences targeting FBXL17 
 Sequence Target region 
shRNA 1 CGGATAGTAACTGGTCAGGATA 3’ UTR of FBXL17 
shRNA 2 CGCTTTCTGACACCTCTATTAT exon 3 of FBXL17 
shRNA 3 CCCTGTAATCTTTAGATGGTTA 3’ UTR of FBXL17 
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2.2 MOLECULAR BIOLOGY METHODS 
2.2.1 Polymerase chain reaction 
All standard PCRs were carried out using Vent DNA polymerase (New England Biolabs, 
M0254S); primers were purchased from Sigma Aldrich and resuspended in nuclease free H2O 
to give 100μM stock solutions. A typical PCR reaction was prepared as per  Table 3 to a total 
of 50μl. PCR reactions were run on an MJ Research Tetrad PTC-225 Thermal Cycler; standard 
PCR cycling conditions are shown in Table 2.  















10x Thermo Pol Buffer 1x 
Template 30ng (plasmid DNA)  
Forward primer 1μM 
Reverse primer 1μM 
dNTPs 0.4mM 
Vent Polymerase 1U 
DMSO (if required) 10% 
DEPC Water up to 50μl 
Table 4 - Standard PCR Cycling conditions 
Standard PCR 
Step Temperature Time 
1 Denature 95°C 5min  
2 Denature 95°C 30s 
3 Anneal 60°C 30s 
4 Elongate 72°C 1min per Kb of template 
Repeat steps 2-4 (35-40 times) 
5 Elongate 72°C 5min 
6 Reaction end/hold 4°C ∞ 
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2.2.2 Two-step mutagenesis PCR 
Site-directed mutagenesis for the deletion of the FBD of Fbx;17 was achieved using the two-
step PCR method. Two-step PCR mutagenesis required two rounds of amplification (Figure 
2.1). The first round produced the 5’ and 3’ products using primers A/B and C/D respectively. 
Primers B and C spanned the FBD region to be deleted (Δ324-358aa). Reactions were carried 
out as described previously. Fragments were resolved by gel electrophoresis and the DNA 
fragments purified from the gel. The second round of amplification allowed hybridisation of 
the 5’ and 3’ products before addition of primers A and D for extension of the mutated 
fragment (Figure 2. 1). Cycling conditions for the 2nd step are shown in Table 5.  
  
Table 5 - Two-step PCR cycling conditions 
Two-step PCR 
Step Temperature Time 
1 Denature 95°C 5min  
2 Denature 95°C 30s 
3 Anneal 60°C 30s 
4 Elongate 72°C 1min per Kb of template 
Repeat steps 2-4 (10 times) without primers 
Add primers (A and B) 
5 Denature 95°C 30s 
6 Anneal 60°C 30s 
7 Elongate 72°C 1min per Kb of template 
Repeat steps 5-7 (30 times) 
8 Elongate 72°C 5min 
9 Reaction end/hold 4°C ∞ 
Figure 2. 1 - Two-step mutagenesis 
PCR strategy 
The first round of PCR produces a 5’ 
and a 3’ product. Primers B and C 
contain the mutation or span the 
region to be deleted. The 2nd PCR 
step requires hybridisation of the two 
products followed by extension with 
primers A and D. 
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2.2.3 Agarose gel electrophoresis 
DNA fragments and PCR products were resolved on 0.8% (w,v) agarose gels. Agarose 
(Bioline, BIO41025) was dissolved in 1x Tris-Acetic acid-EDTA (TAE) buffer by heating in a 
microwave to boiling point. Once cooled but prior to setting ethidium bromide or SYBR™ 
Safe (Thermo Fisher Scientific, S33102) was added (1:1000) to a final concentration of 
0.5μg/ml and mixed in gently to avoid bubbles before being poured into a gel casting tray. 
Samples were loaded after addition of 6x DNA loading buffer (Thermo Fisher Scientific) and 
run alongside 10-15μl of molecular weight marker (GeneRuler 1kb Plus DNA Ladder, Thermo 
Fisher Scientific, SM1331) at 120V with 1x TAE as the running buffer. DNA was visualised 
under UV light using a ChemiDoc™ XRS+ imaging system or Syngene G:Box Chemi XRQ gel 
imaging system.  
2.2.4 Cloning 
2.2.4.1 Plasmids 
Plasmids used are shown in Table 7 along with the restriction enzymes used to insert the 
fragments into the associated vector. Where the source states ‘constructed’ these plasmids 
were either subcloned or made by PCR for this project.  
2.2.4.2 Gel purification of DNA fragments 
DNA fragments were resolved by agarose gel electrophoresis (see 2.2.3) and the desired 
band excised from the gel using a sterile scalpel under UV visualisation. DNA was then 
extracted from the gel using the QIAquick gel extraction kit (Qiagen, 28706) to 
manufacturer’s instructions. DNA was eluted in 30μl elution buffer (EB buffer) and stored at 
-20°C. 
2.2.4.3 Restriction enzyme digests of DNA 
For digestion reactions 1μg of the backbone vector DNA was digested in a 20μl reaction and 
the entire 30μl elution for the inserts was digested in a 50μl reaction. Glycerol 
concentrations of the final reactions were no more than 10%. Digests were carried out in a 
37°C water bath for 1h. Double digests were performed sequentially; both enzymes were 
incubated for 1h at 37°C with a 20 min incubation using a heat block at 65°C to inactivate the 
first restriction enzyme before the second enzyme was added. Digestion of a vector 
backbone with a single restriction enzyme was followed by alkaline phosphatase, calf 
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intestinal (CIP, New England Biolabs, M0290S) treatment to prevent relegation of the vector 
to itself. Following digestion 0.2μl CIP was added and the reaction was incubated for a 
further 30min at 37°C. Digested (and treated) DNA fragments were then resolved by agarose 
gel electrophoresis and gel purified. 
Table 6 - PCR primers for cloning and sequencing 
Restriction endonuclease sites are underlined. Bases in italics and underlined constitute 
Fbxl17 specific shRNA segment. 
PRIMERS Sequence 5’-3’ 
Fbxl17 sequencing primers 
Fbxl17 seq F1 GAA GTC TCT TCC TGG CCA GCT TG  
Fbxl17 seq F2 ACT GAT GAA GGA CTC AAG CAG CTG  
Fbxl17 seq R1 TTC CGC TTG CAC ACC ATT TCG  
Fbxl17 654 R TGA CGA TCA TGC CTT CAT CT 
Deletion of F-box domain 
ΔF box R1 CCA AAA CTG GAA CTG GTT GAT GTC TGG GGT TTC GGG  
ΔF box F1 GAC ATC AAC CAG TTC CAG TTT TGG AAG CAG CTG GAT  
XhoI kozak Flag F CGTT CTCGAG CACC ATGGACTACAAGGACGACGAC 
HpaI Fbxl17 
aa701 Rev 
CG GTTAAC CTA GGA GGA GGC GGC AGA CAT 
Fbxl17 shRNA construction 
mir30 forward CAG AAG GCT CGA GAA GGT ATA TTG CTG TTG AC AGT GAG CG 
mir30 reverse CTA AAG TAG CCC CTT GAA TTC CGA GGC AGT AGG CA 
mir30 
sequencing 
CCA GGT TAA GAT CAA GGT CTT TTC ACC 
Fbxl17 GFP fusion construction 
XhoI Fbxl17 F CGTT CTCGAG CCA TGG GCC ACC TTC TCT CG 
Fbxl17 EcoRI R GGAC GAATTC GGG AGGA GGC GGC AGA CAT G 
GST Fbxl17 from aa321 
EcoRI Fbxl17 
Fbox F 
CGG AAT TCA AAT GAT CAA CCA GCT GCC 
Removing tag from Uap1 
BamHI Uap1 F CGTT GGATCC ATG AAC ATT AAT GAC CTC AAA CTC ACG TTG TCC 
UAP1 NotI R CTTA GCGGCCGC TCA AAT ACC ATT TTT CAC CAG CTC ATG 
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Table 7 - Plasmids used in this dissertation 




pcDNA3 FLAG FLAG 
From Dr W. 
Breitwieser 
pcDNA3 HA HA 
From Dr S. Flach 
Fbxl17 WT FLAG-Fbxl17 (1-701aa) 
Fbxl17 (ΔFbox) FLAG-Fbxl17 ΔF box (Δ324-358) See section 2.2.2 
Fbxl17 (Δ3LRR) FLAG-Fbxl17-Δ3LRR (1-586aa) 
From Dr S. Flach 
Fbxl17 (Δ10LRR) FLAG-Fbxl17-Δ10LRR (1-384aa) 
Fbxl17 WT HA-Fbxl17 (1-701aa) 
Cloned from pcDNA3 
FLAG Fbxl17 vector 
Uap1 Uap1 
PCR cloned from 
pcDNA3 HA Uap1 into 
pcDNA3 
Uap1 HA-Uap1  From Dr S. Flach 
Skp1 Skp1 Laman lab 
Rbx1 Myc-Rbx1 Laman lab 
Cullin 1 Cullin1 Laman lab 
Sufu HA-Sufu 
From Dr V. 
D’Angiolella 
DDB1 FLAG-DDB1 





- From Dr S. Lowe 
Fbxl17 shRNA1 Fbxl17 shRNA1 
See section 2.1.6 Fbxl17 shRNA2 Fbxl17 shRNA2 




From Dr Y. Galanty 
[249] 
53BP1 ΔBRCT 53BP1 ΔBRCT (1-1710bp) 
53BP1 N term. NLS 53BP1-N terminus (1-1052bp) 
53BP1 C term. 53BP1 C-terminus (1052-1972bp) 
53BP1 BRCT 53BP1 BRCT only (1483-1972bp) 
53BP1 C term. 
ΔBRCT 
53BP1 C-terminus ΔBRCT (1052-1710bp) 
Ubiquitin pCMV 6xHis-Myc-Ubiquitin Laman lab 
Venus EV 
pVenus-N1 
- Laman lab 
Fbxl17 WT Fbxl17 (1-701aa) From Dr S. FLach 
GFP EV 
pEGFP-C1 
- From Dr. P D’Avino 
Fbxl17 WT GFP-FBXL17 (1-701aa) Subcloned 
Ku70 (XRCC6) GFP-Ku70 (XRCC6) 
From Dr Y. Galanty 
Ku80 (XRCC5) GFP-Ku80 (XRCC5) 
Fbxl17_Skp1 pGEX (KG) 





GST-Fbxl17 (321-701aa) F-box to end 
PCR cloned from 
pcDNA3 WT 
Fbxl17 (Δ10LRR) GST-Fbxl17 (321-384aa) F-box to Δ10 
PCR cloned from 
pcDNA3 WT 
Skp2 GST-Skp2 full-length Laman lab 
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2.2.4.4 Ligation  
Ligation reactions were carried out in a total of 20μl using 0.5μl T4 DNA ligase (New England 
Biolabs, M0202L) per reaction and 2μl T4 DNA ligase buffer (10x). Ligation reactions were 
incubated at room temperature (RT) for a minimum of 20 mins with a vector to insert ratio 
of 1:3 most commonly used as well as a no insert, vector only control to determine ligation 
efficiency.  
2.2.4.5 Transformation of bacteria with plasmid DNA 
To transform bacteria with plasmid DNA 50μl aliquots of chemically competent E.coli cells 
(Subcloning Efficiency™ DH5α™ Competent Cells, Thermo Fisher Scientific, 18265017) were 
thawed on ice from -80°C, one aliquot per ligation reaction. The entire 50μl of cells was 
added to the ligation reaction and mixed gently with the end of the pipette. The cells plus 
ligation mix were incubated on ice for at least 20 min, heat-shocked in a water bath at 42°C 
for 45 seconds then returned to ice for at least 2 min prior to plating on LB-Agar plates with 
added Ampicillin antibiotic (1μl/ml of stock: 100mg/ml) under sterile conditions. Plates were 
incubated at 37°C overnight (O/N). The following day colonies were isolated for preparation 
of plasmid DNA. 
2.2.4.6 Preparation of plasmid DNA 
Isolated bacteria colonies from a transformation plate were used to inoculate 3ml of 2xTY 
liquid culture media with added Ampicillin (1μl/ml of stock: 100mg/ml) and incubated O/N 
at 37°C with shaking. Around 16 hours later plasmid DNA was extracted using the QIAprep 
Spin Plasmid Kit (Qiagen, 27104) according to manufacturer’s instructions. DNA was eluted 
in 50μl of EB buffer and 1μl was then taken for a test restriction enzyme digest and run on 
an agarose gel to check for the presence of the desired insert. Plasmids verified by the test 
digests were then sent for Sanger sequencing. 0.2μl of this plasmid DNA was used to 
transform bacteria (see 2.2.4.5), colonies were then used to inoculate 100ml of 2xTY (+ 
ampicillin, 100µl/ml) cultured O/N at 37°C with shaking. Plasmid DNA was then prepared 
using the QIAGEN Plasmid Midi Kit (Qiagen, 12143) according to manufacturer’s instructions. 
DNA was eluted in 400μl EB buffer and DNA concentration was determined using a 
NanoDrop™ Lite Spectrophotometer (Thermo Fisher Scientific) before storing at -20°C. 
  




2.3.1 Protein extraction and quantification 
For western blots, cells were washed once in PBS after media had been removed and 
trypsinised as described previously. Cells were collected in 15ml Falcon tubes and spun down 
at 300G for 3min. Cells were washed once more in PBS and spun again and pellets 
resuspended in 50μl RIPA lysis buffer (25mM Tris-HCl pH7.6, 150mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS) plus additional protease inhibitors (Protease inhibitor 
cocktail (Sigma, P8340) 1:100, 1mM Na3VO4, 10mM NaF, 1mM PMSF). Samples were 
vortexed briefly and then incubated on ice for 30min. Lysates spun again at 13000rpm for 15 
mins to pellet cell debris, supernatant removed to fresh tube and protein concentration 
determined by BCA assay (Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific, 23227). 
Samples diluted in Laemmli buffer (125mM Tris pH 6.8, 4% SDS, 20% Glycerol, 10% β-
mercaptoethanol, 0.02% Bromophenol Blue) and boiled 95°C 10min prior to loading. 
2.3.2 Western blotting 
Proteins were separated on the basis of molecular weight by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) using a 30% (w,v) acrylamide/methylene 
bisacrylamide solution (37.5:1 ratio) (National diagnostics, EC890). Different percentage gels 
were run depending on the molecular weight of the proteins to be resolved. Gels were run in 
a 1x Tris-Glycine-SDS PAGE running buffer (National Diagnostics, B9-0032) at 60V until the 
protein had migrated through the stacking gel, and then at 120V until good separation was 
achieved. Proteins were then transferred onto polyvinylidene fluoride (PVDF) membrane 
using a Trans-Blot® SD Semi-Dry Transfer Cell system (BioRad). Blots were blocked for 1 hour 
in 5% dried skimmed milk powder in 1x PBS-T (1x PBS, 0.05% TWEEN® 20) or 3% BSA before 
probing overnight with primary antibody (Ab) diluted in 5% milk or 1% BSA, 4°C with rocking. 
The following day blots were washed 3 x 5min in 1x PBS-T on gyro rocker, incubated at RT 
with secondary Ab diluted in 5% milk for 1h and then washed a further 3 times in 1xPBS-T. 
Amersham enhanced chemiluminescence (ECL) Western Blotting Detection Reagent (GE 
Healthcare Life Sciences) and X-ray film (Konica) were used for signal detection. 
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2.3.2.1 Gradient gels 
For the separation of 53BP1 constructs, samples were loaded on Novex™ 4-20% Tris-Glycine 
Mini Gels (ThermoFisher, XP04200BOX) and run in 1x Tris-Glycine-SDS as described above 
(2.3.2) using an XCell SureLock Mini-cell electrophoresis system (ThermoFisher). For 
optimum protein transfer, proteins were transferred to PVDF membrane using a wet/tank 
transfer method (BioRad), 250mA with stirring, 4°C, overnight. The following day 
membranes were blocked for 1 hour in 5% milk and incubated for a minimum of 3 hours in 
primary antibody before detection of proteins with secondary antibody conjugated to HRP.  
2.3.3 GST protein purification 
Chemically competent E.coli strain FB810 cells were transformed with GST DNA constructs 
by heat shock (42°C for 45s). Transformed cells were grown in 200ml cultures of 2xTY media 
containing ampicillin (100µg/ml) to log phase (~OD600 0.3-0.6) at 37°C. Once at the required 
density cultures were cooled on ice for 10 minutes. Recombinant protein expression was 
induced by addition of 1mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) for 3 hours at 
30°C. Bacteria were harvested by centrifugation (4500 rpm, 10 min) and resuspended in 5ml 
Tris buffered saline (TBS) plus protease inhibitors (cOmplete™ EDTA free protease inhibitor 
cocktail, Roche, 118733580001), lysozyme (from chicken egg white, Sigma, L6876) and 1mM 
PMSF. Cells were incubated on ice for 20 minutes followed by sonication (3 cycles of 15 
seconds at 10 microns). 250µl Triton X-100 (VWR, 28817.295) was added and tubes inverted 
4 times to mix. Cell debris was removed by centrifugation (18000 xg, 4°C, 30min) and the 
supernatant incubated with rotation, overnight at 4°C with 100µl of TBS/1% Triton X-100 
and Glutathione-Sepharose 4B beads (GE Healthcare, 17075601) at a 50% slurry. Purified 
proteins, bound to beads, were harvested by centrifugation (1200 rpm, 4°C, 5min) and 
washed twice in TBS/1% Triton X-100 and twice in PBS, and resuspended in PBS as a 50% 
slurry. Ten microlitre samples were added to equal volumes of 2x Laemmli buffer and 
denatured at 95°C for 5mins. Proteins were resolved by SDS-PAGE and the gel stained with 
Quick Coomassie stain (Generon, GEN-QC-STAIN) to visualise proteins. Equal protein loads 
were estimated, and equivalent input volumes used in a GST pull-down assay.  
2.3.4 GST pull-down assay 
One microgram of pcDNA3 Uap1 (or empty pcDNA3 control) were used to express proteins 
in vitro using the TnT Quick Couple Transcription/Translation System (Promega, L1170) 
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according to manufacturer’s instructions. The reticulocyte lysates were diluted in Alternative 
binding buffer (20mM Hepes-KOH pH7.6, 50mM KCl, 2.5mM MgCl2, 10% glycerol, 0.02% NP-
40, 1mM PMSF, 1mM DTT) to a final volume of 260µL. Diluted lysate was centrifuged 
(13,000 rpm, 15-30min, 4°C) and 50µL of diluted lysate was added to equal amounts of GST 
proteins bound to beads. Samples were rotated for 2h at 4°C. Beads were then washed five 
times with 10x volume of wash buffer, NET-N (50mM Tris pH7.5, 1mM EDTA, 1% NP-40, 
150mM NaCl) and resuspended in 40µL 2x Laemmli buffer. Equal volumes of samples were 
then analysed by immunoblotting.   
2.3.5 Co-Immunoprecipitation 
 2.3.5.1 FLAG Co-IP 
Cells were transfected or infected as described previously and lysed in 500μl/90mm plate 
modified RIPA buffer (25mM Tris HCl pH 7.6, 150mM NaCl, 1% NP-40, 0.1% SDS) with 
additional protease inhibitors (see 2.3.2). Samples incubated on ice for 10mins with 
occasional vortexing. NaCl added to 150mM and incubated for a further 5min on ice. Lysates 
spun at 13,000rpm 15mins at 4°C. 50μl supernatant kept for total lysate sample, remainder 
added to 20μl/90mm plate ANTI-FLAG® M2 Affinity gel (Sigma, A2220) beads washed 3x 
with lysis buffer. Beads and lysates were incubated rotating at 4°C for 4hrs. Beads then 
washed 3x in lysis buffer, spinning down at low speed (2000rpm 1min) in between washes. 
50μl Laemmli (1:1 ratio) added to total lysate sample and 40μl added to beads to elute 
proteins. Samples boiled 95°C for 3min prior to loading of equal volumes for western blot 
analysis. 
 2.3.5.2 Normal Co-IP 
Lysates prepared as described above in modified RIPA buffer. After spinning at 13,000rpm 
15min at 4°C 50μl supernatant kept for total lysate sample, remainder added to 20μl/90mm 
plate. Protein A/G PLUS agarose beads (Santa Cruz) washed 3x with lysis buffer. Beads and 
lysates incubated rotating at 4°C for 1hr to preclear lysates. Beads then spun down at low 
speed (2000rpm 1min) and lysate added to fresh Eppendorfs containing 2μg primary 
antibody (or species IgG control) for 2hrs rotating at 4°C. 20μl/90mm plate of washed  
Protein A/G PLUS agarose beads added to each tube and incubated for a further 2hrs 4° with 
rotation. Beads then washed 3x in lysis buffer spinning down at low speed (2000rpm 1min) 
in between washes 50μl Laemmli added to total lysate sample and 40μl added to beads to 
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elute proteins. Samples boiled 95°C for 3min prior to loading equal volumes for western blot 
analysis. 
2.3.6 E3 ligase production 
HEK293Ts were transfected (PEI mediated) with 5μg pcDNA3 Fbxl17 constructs and 1.7μg of 
each ligase component (Rbx1, Skp1, Cul1). 48h after transfection cells lysed and FLAG Co-IP 
performed as described previously. After 4h incubation beads washed 3x with lysis buffer 
and 2x with FLAG elution buffer (10mM Hepes, 225mM KCl, 1.5mM MgCl2, 0.1% NP-40, 
protease inhibitors, phosphatase inhibitors). FLAG peptide (Sigma) diluted to 500μg/ml in 
FLAG elution buffer, 100μl added to beads and incubated 2h 4°C with rotation after 
removing buffer from washes. Beads pelleted and eluate recovered. Samples frozen in a final 
15% Glycerol solution at -20°C.  
2.3.7 In vitro ubiquitination assay 
A screen of 10 different E2 enzymes determined that E2 UbcH5a enabled the most specific 
SCFFbxl17 activity and was used in subsequent experiments. Purified SCF complexes at 12.5, 
25, 50 and 100 nM were tested in the presence of a ubiquitin-mix (ubiquitin buffer, ubiquitin 
(20µM) E1 (UBE1,100nM), E2 (UbcH5a, 500nM) and Mg-ATP (2mM) (Boston Biochem) 
incubated at 30°C for 90min to determine ligase activity by auto ubiquitination. 50nM of the 
SCF was sufficient for ligase activity and used in subsequent experiments.  To test substrate 
ubiquitination substrates were transfected into HEK293T cells and immunoprecipitated using 
their indicated epitope tags conjugated to agarose beads. The purified substrate was then 
eluted from the beads and added as a component of the ubiquitin-mix. HA-Sufu was kindly 
provided by Vincenzo D'Angiolella (CRUK/MRC Oxford Institute for Radiation Oncology, 
Oxford, UK). Ubiquitination was detected by probing for the substrate or HA tag (for Sufu). 
2.3.8 In vivo ubiquitination assay 
HEK293T cells were transfected with expression constructs of interest, including myc-
ubiquitin, and treated with 10 µM MG132 (Sigma-Aldrich) 4 hr prior to lysis. UAP1 was 
then immunoprecipitated with Monoclonal Anti-HA-Agarose antibody (Sigma-Aldrich). 
Modified UAP1 was detected with an endogenous UAP1 antibody. To test for 
phosphorylation 10mM β-glycerophosphate was added to the LB or washed Anti-HA-
Agarose beads were CIP treated, 15 min, 37°C. 
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2.3.9 Metabolites extraction and LC-MS analysis 
Cells were washed three times with PBS prior to the extraction and 1 ml of extraction buffer 
(50% LC-MS grade methanol and 30% acetonitrile, 20% ultrapure water) was added per 
1x106 cells. Cell were then incubated on dry ice for 15 min, collected, kept under vigorous 
shaking for 15 min at 4°C, and left for 1-hour incubation at 20°C. Samples were centrifuged 
at 13,000 rpm and supernatants were transferred to autosampler vials for LC-MS analysis. To 
avoid bias due to machine drift and processed blindly, samples were randomized. Q Exactive 
mass spectrometer (Thermo Fisher Scientific) coupled to a Dionex U3000 UHPLC (Thermo 
Fisher Scientific) system was used to perform the LC-MS analysis. Sequant ZIC-pHILIC column 
(150mm x 2.1 mm) and guard column (20mm x 2.1 mm) (Merck Millipore) were utilized for 
the chromatographic separation and the column oven temperature was maintained at 40°C. 
The mobile phase was composed of 20mM ammonium carbonate and 0.1% ammonium 
hydroxide in water (solvent A), and acetonitrile (solvent B). The flow rate was set at 200 
ml/min and the gradient was programmed as follows: initially stayed at 20% of A and 80% of 
B for 2 min, then subjected to a linear increase to 80% of A and decrease to 20% of B in 15 
min. Both solvents were then brought back to initial condition and staid for 8 min. The mass 
spectrometer was operated in full MS and tSIM (targeted Single Ion Monitoring), in positive 
and negative mode. XCalibur Qual Browser and XCalibur Quan Browser software (Thermo 
Fisher Scientific) were used to acquire the spectra and analyse the data.  
 
  




2.4 1 Immunofluorescence 
U2OS cells were seeded onto glass coverslips and transfected 24h later with FLAG-Fbxl17 
constructs. 48h post-transfection cells were washed in ice cold PBS, fixed in 4% PFA (in PBS) 
RT for 10min, permeabilised in 0.1% Triton X-100 (in PBS) RT for 10min and blocked in 0.2% 
fish skin gelatine (in PBS) for 30min. Endogenous Fbxl17 was immunostained with anti-
Fbxl17 antibody and exogenous constructs with anti-FLAG antibody, both diluted in 0.2% fish 
skin gelatine. After 1h cells were stained with Alexa Fluor 488 conjugated secondary 
antibodies. Coverslips were then washed in PBS-T and ddH2O and mounted using 50% 
glycerol (in PBS) containing 1µg/ml DAPI counterstain. Images were collected using a Zeiss 
Confocal LSM700 Laser Scanning Microscope and ZEN imaging software. 
2.4.2 Laser micro-irradiation 
U2OS cells stably expressing RFP-53BP1 were seeded onto glass bottomed plates (Mattek) 
and pre-sensitised with 10µM BrdU. 24h later, the cells were transfected with GFP-Fbxl17 or 
GFP empty vector. 48h post transfection, fresh prewarmed, CO2 adjusted media 
supplemented with 10% FBS and 1% pen/strep was added to the U2OS cells. Localised lines 
of DNA-damage were induced by laser micro-irradiation using a Zeiss Confocal LSM700 Laser 
Scanning Microscope equipped with a Solent heated environmental chamber. To induce 
localised DNA damage a stripe of 5-pixel width was irradiated with a 405nm laser diode 
(laser set to 100%, 50 iterations, pixel dwell time 12.61 µsec) on regions of interest in the 










Table 8 - Primary antibodies used for immunoblotting 
Antibody Species Company (ID) Dilution 
53BP1 Rabbit polyclonal   Novus (MB100-304) 1:5000 
Actin Rabbit polyclonal   Sigma (A2066) 1:5000 
Cul1 Rabbit polyclonal Santa Cruz (sc-11384) 1:1000 
Fbxl17 Rabbit polyclonal Genetex (GTX119211) 1:2000 
Flag tag Mouse monoclonal Sigma (F3165) 1:5000 
GAPDH Rabbit polyclonal Sigma (g9545) 1:5000 
GFP Mouse monoclonal Santa Cruz (sc-9996) 1:1000 
HA tag Rabbit monoclonal Cell Signaling (3724S)  1:1000 
Histone H1 Mouse monoclonal Santa Cruz (sc-8030) 1:1000 
myc tag Rabbit polyclonal Cell Signaling (2272)  1:1000 
OGA/MGEA5 Rabbit monoclonal Abcam (ab124807) 1:5000 
O-GlcNAc Mouse Monoclonal Covance (MMS-248R) 1:1000 
OGT Rabbit monoclonal (Abcam) ab177941 1:1000 
Skp1 Mouse monoclonal  BD (610530) 1:1000 
Uap1 Rabbit polyclonal Abcam (ab95949) 1:1000 
Uap1 Rabbit polyclonal Bethyl Laboratories (A305-643A-M) 1:1000 
Ubiquitin  Mouse monoclonal Santa Cruz (P4D1, sc8017) 1:1000 
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Table 9 - Secondary antibodies and normal IgG used for immunoblotting/ IP 
Antibody Species   Company (ID)  Dilution 
Anti-mouse IgG HRP donkey Jackson ImmunoResearch (711-035-150) 1:5000 
Anti-mouse IgG HRP goat Santa Cruz (sc-2055) 1:10,000 
Anti-rabbit IgG HRP donkey Jackson ImmunoResearch (711-035-152) 1:5000 
Anti-rabbit IgG HRP donkey Santa Cruz (sc-2313) 1:10,000 
- Mouse IgG Santa Cruz (sc-2025) N/A 





Table 10 - Antibodies used for immunohistochemistry  
Antibody Species   Company (ID)  Dilution 
Anti-mouse IgG AlexaFluor488 donkey Invitrogen (A21206) 1:500 
Anti-rabbit IgG AlexaFluor488 donkey Invitrogen (A-21206) 1:500 
Fbxl17 Rabbit polyclonal Genetex (GTX119211) 1:100 
Flag tag Mouse monoclonal Sigma (F3165) 1:100 
  







1x PBS, 0.05% Tween-20 
 
TAE 
40mM Tris pH8, 20mM glacial acetic acid, 1mM EDTA 
 
TBS 
50mM Tris pH7.6, 150mM NaCl 
 
TBS-T 
1x TBS, 0.1% Tween-20 
 
NET-N (for GST pull-down washes) 
50mM Tris pH7.5, 1mM EDTA, 1% NP-40, 150mM NaCl 
 
2x Laemmli buffer 
125mM Tris pH 6.8, 4% SDS, 20% Glycerol, 0.02% Bromophenol Blue, 10%, β-
Mercaptoethanol 
 
RIPA buffer (lysis) 
25mM Tris-HCl pH7.6, 150mM NaCl, 1% NP-40, 1% Sodium deoxycholate, 0.1% SDS 
 
Diehl buffer (lysis) 
50mM Tris-HCl pH7.6, 150mM NaCl, 1% NP-40, 0.1% SDS 
 
KCl buffer 
50mM Tris HCl pH7.5, 225mM KCl, 1% NP-40 
 
Elution buffer (elution of immunoprecipitates from FLAG/HA beads) 
10mM Hepes, 225mM KCl, 1.5mM MgCl2, 0.1% NP-40 
 
Buffer A (cell fractionation) 
10mM Hepes pH7.9, 10mM KCl, 1.5mM MgCl2, 0.34M Sucrose, 10% Glycerol, 1mM DTT, 
0.1mM PMSF 
 
Annexin V binding buffer 
10mM Hepes, 140mM NaCl, 2.5mM CaCl2 
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Alternative binding buffer (for GST pull-down) 
20mM Hepes pH7.6, 50mM KCl, 2.5mM MgCl2, 10% Glycerol, 0.02% NP-40, 1mM DTT, 1mM 
PMSF 
 
PI staining solution 
1x PBS, 100 μg/ml RNase A, 50 μg/ml propidium iodide 
 
Fixing/Staining solution (For Clonogenic assay) 













CHAPTER 3 - Characterising breast cancer-associated rearrangements of 
FBXL17 
3. INTRODUCTION 
A vast amount of data regarding mutations in cancer genomes has been published. 
However, analysis of such data is laborious and in many cases much of the data remains 
uncharacterised. Massively-parallel paired-end sequencing has overcome this problem 
somewhat and whilst once believed to be confined largely to leukaemias and sarcomas, 
somatic rearrangements are now being shown to be prevalent in breast cancer and other 
epithelial cancers [18-21]. Genome-sequencing of cancers previously favoured point 
mutations over structural rearrangements due to ease of analysis by PCR and array CGH [14], 
but genomic rearrangements can now be resolved to much better resolution thanks to 
advances in sequencing techniques. A few common large-scale rearrangements have been 
known for some time, but many more aberrations found in 5-10% cases remain to be 
described and may be diagnostically or therapeutically important. 
Previous work in the lab surveying the METABRIC (Molecular Taxonomy of Breast Cancer 
International Consortium) dataset, which contains array-CGH copy number data for 1,992 
primary breast tumours, identified FBXL17 as being highly rearranged in breast cancer [29]. 
135 (7%) tumours had at least one genomic break within FBXL17, detected as a copy number 
step, distributed in various ways. The majority of copy number losses or gains identified in 
FBXL17 occurred at the 3’ end, with small deletions clustered around exon 4 and potential 
tandem duplications observed [255]. FBXL17 encodes the 701 amino acid (aa) F-box protein, 
Fbxl17, which can function as a substrate-determining component of an SCF-type E3 
ubiquitin ligase. It binds Skp1 via its characteristic F-box domain and recruits substrates for 
ubiquitination via its C-terminal leucine rich repeat domains (LRRs) (Figure 1. 9, Page 46). 
Given the LRRs of Fbxl17 are encoded from exon 3 onwards it is likely these protein-protein 
interacting domains are disrupted by such rearrangements.  
In addition to breaks in tumours, array-CGH data showed breaks in FBXL17 in four cancer cell 
lines, the breast carcinoma cell lines, BT-474, HCC38, and HCC1395, and the 
oesophageal/gastric cardia adenocarcinoma line OE-19 [32]. The breaks were verified by 
FISH, RT-PCR and paired-end sequencing and included an FBXL17-PJA2 fusion transcript 
reported in [256] and an internal homozygous deletion in FBXL17 between exons 6 and 9 




[19, 32]. The FBXL17-PJA2 fusion in HCC38 cells, which joins exon 1 of FBXL17 to exon 2 of 
PJA2, is not in frame at the PJA2 portion, and so would encode an Fbxl17 that retains most of 
the N-terminal domain (1-331aa) but only a partial F-box domain and no LRRs. Deletion of 
exons 7 and 8 in HCC1395 cells would truncate Fbxl17 at its C-terminus after LRR8, resulting 
in loss of 3 LRRs (Δ583-655aa). 
As demonstrated, at least some of these detected breaks truncate Fbxl17 at its C-terminus, 
removing some or all of the LRRs and sometimes also the F-box domain. I have identified 
further examples of FBXL17 rearrangements in breast cancer, in paired-end whole-genome 
DNA and RNA sequencing data from primary breast tumours, which also seem to target the 
LRR domain. These genomic alterations suggest the ability of Fbxl17 to recruit substrates for 
ubiquitination or to form part of an SCF complex may be compromised. To study this further 
I have investigated the effect of loss of LRRs on Fbxl17 expression, localisation and ligase 
activity in order to characterise the functional consequences of these novel genomic 
rearrangements recurring in breast tumours and determine the role that they play in breast 
cancer. Some of the data in this chapter is included in a manuscript published in Cellular and 










3.1 Fbxl17 is rearranged in primary breast tumours 
The array-CGH data for FBXL17 from the METABRIC dataset clearly demonstrated that 
FBXL17 is highly rearranged in breast cancer. However, the exact consequences of the 
rearrangements could not be concluded due to the absence of paired-end next generation 
sequencing (NGS) data. Equally the cell line examples, despite mirroring the tumour data, 
may not accurately reflect the mutations that occur in primary tumours. We therefore 
looked for examples of FBXL17 rearrangements in breast cancers, in paired-end whole-
genome DNA sequencing data from 250 primary breast tumours of the Cambridge 
Personalised Breast Cancer Programme. Rearrangements (‘Structural variants’) in FBXL17 
were identified by collaborators in 5 of the tumours (Appendix A). Manual inspection of RNA 
sequences from these 5 tumours confirmed that 2 of the rearrangements were transcribed 
as predicted: a translocation joining exon 6 to an undocumented exon on chromosome 7 
and a duplication of exon 6, respectively (Figure 3. 1A; Appendix A).  A third case with a 
breakpoint in intron 6 showed unspliced transcription from exon 6 into intron 6, however, 
we cannot rule out that this was normal unspliced RNA. Serendipitously, a further RNA 
sample, inspected because it had a rearrangement which did not pass filtering, showed 
splicing from exon 6 into exon 4. This suggested the presence of a rearrangement, which was 
not detected by DNA sequencing in an additional tumour. The partial agreement we find 
between RNA and DNA sequencing is expected as both methods lack sensitivity to identify 
all rearrangements [257]. Thus, consistent with the cell line rearrangements, the breakpoints 
in the tumours fell within introns that would disrupt the expression of LRRs, with the 
majority (4/6) occurring in intron 6 (Figure 3. 1B).  
There was no clear relationship between FBXL17 rearrangement and any molecular 
classification [30] of the tumours and cell lines, although 5/6 tumours and the breast cell 
lines were TP53 mutant (Figure 3. 2A, Appendix A). Of the tumours, three were oestrogen 
receptor (ER) positive, and three were ER-negative. One tumour and one cell line were 
ERBB2/HER2 positive (Figure 3. 2A, Appendix A). We also classified these tumours into the 
11 IntClust sets [30], and they fell into three sets: clusters 4, 7 and 10. In addition, classifying 
these six cases using PAM50 breast cancer subtyping, gave four basal and two luminal A 
cases (Appendix A).  Although the number of cases is small, these data suggest Fbxl17 is not 
rearranged in a particular cancer subtype. 





Figure 3. 1 - FBXL17 is rearranged in primary breast tumours.  
(A) Schematic of structural variant found in case FBXL17_1 shows a breakpoint sequence between 
intron 6 of FBXL17 and an undocumented region on chromosome 7. The corresponding spliced mRNA 
transcript sequence identified from paired RNAseq data shown below, indicates splicing from exon 6 
of FBXL17 to an undocumented exon on chromosome 7 resulting in a fusion protein of unknown 
length. (B) FBXL17 exons from Ensembl transcript ENST00000542267.5 (Refseq NM_001163315.2, 
NP_001156787.2), chr5:107,859,045-108,382,098 in GRCh38/hg38. Triangles indicate breakpoints in 
FBXL17 identified in cell lines (as labelled) or primary breast tumours (unlabelled), * indicates known 
fusion. Bottom, protein domains of Fbxl17 scaled to protein sequence. L, leucine-rich repeat. 







Figure 3. 2 - FBXL17 is rearranged in primary breast tumours and mutations cluster in the LRRs of 
Fbxl17.  
(A) Molecular classification of the primary breast tumours containing FBXL17 rearrangements with 
regards to Oestrogen receptor (ER), HER2/ERBB2 expression and TP53 status (WT=wild-type), n=6. (B) 
Non-synonymous somatic mutations mapped to Fbxl17 as reported by The Cancer Genome Atlas 
(TCGA), arrows indicate breast cancer associated mutations. Schematic underneath represents Fbxl17 
domains, green, N-terminus, purple, F-box domain, red, leucine-rich repeats. 
 
  




Rearrangements of FBXL17 have also been detected in other epithelial cancers including 
prostate [258] and oesophageal adenocarcinoma [259]. Many of these rearrangements are 
also predicted to truncate Fbxl17, resulting in loss of LRRs. TCGA (Cancer Genome Atlas 
project) data was mined for genomic alterations affecting FBXL17 using the National Cancer 
Institute GDC Data portal (https://portal.gdc.cancer.gov/) [260, 261].  Perhaps most striking 
was the TCGA mapping of non-synonymous somatic FBXL17 mutations. Mutations in FBXL17 
almost exclusively (68/70) target its C-terminus containing the FBD and LRRs; with five 
resulting in premature stop codons that would truncate the LRR domains of Fbxl17 (Figure 3. 
2B). 
In summary, FBXL17 was identified as being frequently rearranged in primary breast 
tumours and cancer cell lines by array-CGH and FISH analysis. I have identified further 
rearrangements in six primary breast tumours, which have been validated by paired DNA 
and/or RNA sequencing data.  I have shown that at least some of the breaks truncate Fbxl17, 
resulting in loss of the LRRs and sometimes also the FBD. These genomic alterations suggest 
the ability of Fbxl17 to recruit substrates for ubiquitination may be altered or lost and the 
SCF activity of Fbxl17 may be compromised.    
  




3.2 WT and mutant Fbxl17 expression and localisation 
3.2.1 Truncation of Fbxl17 LRRs enhances protein expression 
Full-length Fbxl17 (1-701aa) and two LRR-truncation constructs, Fbxl17Δ3LRR (1-586aa) and 
Fbxl17Δ10LRR (1-384aa), were cloned into pcDNA3 expression vectors with an N-terminal 
FLAG-tag by a previous graduate student S. Flach (Figure 3. 3). The Δ3LRR mutant is 
representative of the FBXL17 rearrangements observed in the breast cell line HCC1395 and 
primary breast tumours, i.e. deletion of exons 7 and 8 or breaks in intron 6, both of which 
would truncate Fbxl17 by 3LRRs. Fbxl17 Δ10LRR is representative of the Fbxl17-PJA2 fusion 
observed in HCC38 cells. The fusion is not in frame and so would encode an Fbxl17 that 
retains most of the N-terminal domain but only a partial F-box domain and no LRRs. The first 
LRR of Fbxl17 overlaps slightly with the FBD and so, unlike in HCC38 cells, this was not 
removed in Fbxl17Δ10LRR to ensure the FBD remained intact. To be able to test the 
ubiquitin ligase activity of SCFFbxl17 I also generated an Fbxl17 construct containing an 
internal F-box domain deletion (Δ324-358aa) by two-step PCR to act as a negative control. 
The F-box domain binds to Skp1 to enable SCF holoenzyme assembly and so deletion should 
render Fbxl17 incapable of recruiting other components of the SCF complex. This construct 
was also cloned into pcDNA3 with an N-terminal FLAG-tag (Figure 3. 3).  
Figure 3. 3 - Schematic of wild-type Fbxl17 domains and mutant constructs. 
Wild-type (WT) Fbxl17 contains an N-terminus (green) of mostly unknown function. The characteristic 
F-box domain (purple) binds Skp1 to enable the SCF holoenzyme formation. At its C-terminus, Fbxl17 
contains 11 leucine rich repeats (LRRs, L, red) through which it binds target substrates. Fbxl17 Δ3LRR 
contains the first eight LRRs and Fbxl17 Δ10LRR just a single LRR. The ΔF-box mutant removes the F-
box domain preventing SCF assembly. All constructs contain a FLAG tag at their N-terminus. 




To test whether the Fbxl17 constructs could be expressed in mammalian cells, I transfected 
HEK293T cells with Fbxl17 WT, ΔFbox, Δ3LRR and Δ10LRR. All constructs were expressed, 
and I noted truncation of LRRs resulted in increased expression of Fbxl17 (Figure 3. 4A). This 
increased expression appears to correlate with the number of LRRs lost. The higher 
molecular weight bands present in the Δ10LRR lane are indicative of ubiquitination. This 
suggests the cells are targeting Fbxl17Δ10LRR for degradation. 
 
Figure 3. 4 - Expression of Fbxl17 constructs and ΔFbox Co-IP with Skp1.  
(A) Protein lysates from HEK293T cells transfected with the indicated Fbxl17 constructs resolved by 
SDS-PAGE and immunoblotted with the indicated antibodies. (B) Immunoprecipitates using anti-FLAG 
beads from HEK293T cells expressing FLAG-Fbxl17 or FLAG-Fbxl17ΔFbox, probed for Skp1 and FLAG. 
 
3.2.2 Deletion of the F-box domain of Fbxl17 abolishes Skp1 binding 
 To test whether the Fbxl17ΔFbox construct binds Skp1, I performed a co-
immunoprecipitation assay. HEK293T cells were transfected with Fbxl17WT, Fbxl17ΔFbox or 
an empty vector. Forty-eight hours post-transfection cells were lysed, immunoprecipitated 
with FLAG antibodies and blotted for endogenous Skp1. Whilst WT Fbxl17 




immunoprecipitated endogenous Skp1, deletion of amino acids 324-358 of Fbxl17 abolished 
binding to Skp1 (Figure 3. 4B). Failure to bind Skp1 will prevent SCF complex assembly 
rendering Fbxl17ΔFbox enzymatically inactive. 
3.2.3 Fbxl17 mutant constructs show wild-type localisation 
Cellular fractionation and immunofluorescence assays were conducted in parallel to 
determine the distribution of WT and mutant Fbxl17 proteins in cells. Endogenous Fbxl17 
was present in both cytoplasmic and nuclear fractions with greater expression observed in 
the nuclear fraction (Figure 3. 5). However, in the absence of a cytoplasmic marker we 
cannot be certain the fractionation is clean. Immunofluorescence showed all transfected 
Fbxl17 constructs showed a predominantly nuclear localisation as observed with 
endogenous Fbxl17 immunostaining and concurrent with the fractionation data (Figure 3. 6).  
  
Figure 3. 5 - Cellular fractionation of endogenous Fbxl17 and Fbxl17 constructs. 
Cellular fractionation of MCF7 cells immunoblotted for indicated proteins, n=2. Arrow represents 
bands corresponding to Fbxl17. Histone H1 used as a nuclear fraction marker, β-actin used a loading 
control.  
 





Figure 3. 6 - Subcellular localisation of Fbxl17 and Fbxl17 constructs. 
Confocal microscopy images of endogenous Fbxl17 and indicated FLAG-Fbxl17 constructs using 
immunostaining with Fbxl17/FLAG antibodies and Alexa Fluor 488. DNA visualized with DAPI, scale 
bar is 15μm. 




3.3 WT and mutant SCFFbxl17 purification and characterisation 
3.3.1 Deletion of LRRs impairs SCF subunit recruitment 
To check the incorporation of Fbxl17, WT and mutant, into an SCF E3 ligase I used co-
immunoprecipitation assays. HEK293T cells were transfected with N-terminally FLAG-tagged 
Fbxl17 constructs (WT, ΔFbox, Δ3LRR or Δ10LRR) and also co-transfected with the SCF 
subunits, Skp1, Cullin1 and Rbx1. Forty-eight hours post transfection, cells were lysed, 
immunoprecipitated with FLAG antibodies, and blotted for the associated SCF subunits 
(Figure 3. 7).   While Skp1, Rbx1 and Cullin1 co-immunoprecipitated efficiently with WT 
Fbxl17, these components were reduced in the immunoprecipitates of the truncation 
mutants when normalised to Fbxl17 expression. This was somewhat surprising given that 
Figure 3. 7 - Co-immunoprecipitation of Fbxl17 wild-type and mutant constructs with SCF ligase 
components.  
Immunoprecipitates using anti-FLAG beads from HEK293T cells expressing FLAG-Fbxl17, FLAG-
Fbxl17ΔFbox, FLAG-Fbxl17Δ3LRR or FLAG-Fbxl17Δ10LRR, probed for Cul1, Skp1 and myc-tag (Rbx1). 
 




Fbxl17Δ3LRR and Fbxl17Δ10LRR contained intact F-box domains. As expected, when the FBD 
was deleted in Fbxl17ΔFbox, Cul1 and Skp1 were not co-immunoprecipitated and binding to 
Rbx1 was significantly reduced. The faint myc-tag band present in the ΔFbox lane could be 
an artefact as Cullin1 is responsible for recruiting Rbx1 to the SCF complex and was not co-
immunoprecipitated with Fbxl17ΔFbox in this assay. It could also represent a direct 
interaction between the FBP and Rbx1. My data suggests the presence of unknown 
stabilising interactions between the LRRs and Cullin 1 and so Rbx1 may also have a cryptic 
binding site on Fbxl17. 
Since these interaction data indicated differential capabilities of the Fbxl17 mutants to 
assemble the SCF enzyme, I next tested the Fbxl17 ligase activity in vitro by purifying SCFFbxl17 
ligase complexes from cells. As described above, I transfected HEK293T with the subunits of 
SCF ligases, Skp1, Cullin1, Rbx1, and the FLAG-tagged Fbxl17 constructs (WT, ΔFbox, Δ3LRR 
or Δ10LRR). Forty-eight hours post-transfection, cells were lysed, immunoprecipitated with 
FLAG antibodies and then eluted from the FLAG agarose beads with FLAG peptide. Purified 
SCF E3 ubiquitin ligases were resolved by SDS-PAGE, stained with Coomassie and quantified 
by densitometry in relation to BSA standards (Figure 3. 8A). Purified ligases were also 
resolved by SDS-PAGE and immunoblotted for SCF holoenzyme components (Figure 3. 8B). 
Following purification of equal amounts of Fbxl17 we observed the recruitment of SCF 
subunits by mutant Fbxl17 proteins was again significantly reduced. For example, Cullin1 
binding to Fbxl17Δ3LRR was reduced by 81% (p=4.12E-04; n=4) and Fbxl17Δ10LRR by 82% 
(p=1.28E-06; n=4) relative to WT Fbxl17, while Skp1 binding to Fbxl17Δ3LRR was reduced by 
77% (p=5.52E-05; n=5) and Fbxl17Δ10LRR by 67% (p=2.74E-05; n=4) relative to WT Fbxl17 
(Figure 3. 8C). These data indicate that in addition to the FBD, the LRRs of Fbxl17 facilitate or 
stabilise the assembly of the SCFFbxl17 ligase. Since the Cullin1 and Rbx1 subunit allow E2 
recruitment, these data suggest that the mutant SCFFbxl17 ligases will have reduced activity. 
  





Figure 3. 8 - Loss of Fbxl17 LRRs impairs SCF subunit recruitment.  
(A) Coomassie gel of purified SCF ligases and BSA standards used for quantification by densitometry. 
(B) Representative immunoblot for SCF holoenzyme components that co-immunoprecipitate with 
purified FLAG-Fbxl17 and mutant Fbxl17 constructs; FLAG-Fbxl17 ΔFbox, FLAG-Fbxl17 Δ3LRR and 
Fbxl17 Δ10LRR. (C) Expression of SCF components Cul1, Skp1 and Rbx1 that co-immunoprecipitate 
with WT and mutant Fbxl17 constructs. Normalised to WT expression. Mean ± SEM, n≥3, ***p<0.001 
compared to WT. 
 




3.3.2 Auto-ubiquitination assays 
To test the activity of SCFFbxl17 ligases I performed in vitro ubiquitination assays of purified 
SCF complexes, assembled with either WT or LRR-truncated Fbxl17 proteins, in the presence 
of an E1 and E2 enzyme.  To begin with I screened six different E2 enzymes to determine 
which would have specific ubiquitination activity with SCFFbxl17. Purified SCFFbxl17 and 
SCFFbxl17ΔFbox were added to a ubiquitin mix (ubiquitin buffer, ubiquitin, E1 (UBE1), E2 
(various) and ATP) and incubated to allow auto-ubiquitination of Fbxl17. Samples were 
resolved by SDS-PAGE and immunoblotted for ubiquitin (Figure 3. 9). UbcH2 and UbcH3 
showed little to no activity with Fbxl17. UbcH6 showed non-specific ubiquitination activity 
and residual activity with the negative control SCFFbxl17ΔFbox (Figure 3. 9, UbcH6 panel, lanes 1 
and 5) so was not selected. UbcH5a, 5b and 5c all showed robust ubiquitination activity with 
SCFFbxl17 and no activity with SCFFbxl17ΔFbox (Figure 3. 9). UbcH5a was selected for use in all 
subsequent assays since it demonstrated the highest levels of activity of the three E2 
ubiquitin ligases. 
  
Figure 3. 9 - E2 ligase activity screen for Fbxl17.  
Screen of in vitro ubiquitination activity of purified SCFFbxl17 complexes with various E2 ligases. Probed 
with anti-Ub antibody to detect ubiquitinated proteins, n=2. 




I then tested the ability of the mutant Fbxl17 proteins to promote auto-ubiquitination as 
part of an SCF E3 ligase (Figure 3. 10). Purified SCF complexes at 12.5, 25, 50 and 100nM 
were tested in the presence of a ubiquitin-mix as above. We observed higher molecular 
weight bands using an antibody raised against FLAG-tag (Fbxl17) using 25nM of SCFFbxl17 in in 
vitro ubiquitination reactions, and the signal intensified with increasing concentrations of 
the WT ligase. In parallel assays, 50nM of mutant SCFFbxl17∆3LRR ligase showed residual 
activity, which increased at 100nM but was still considerably less than WT SCFFbxl17 ligase. 
SCFFbxl17Δ10LRR ligase showed the greatest reduction in activity (Figure 3. 10A), comparable to 
the inactive SCFFbxl17ΔFbox mutant when probing for FLAG. The difference in activity of the SCF 
complexes was even more apparent when the membranes were probed for ubiquitin (Figure 
3. 10B). SCFFbxl17ΔFbox had no ligase activity, while E3 ubiquitin ligases made with the LRR-
truncated Fbxl17 mutants had reduced ligase activity compared to WT Fbxl17.  
Figure 3. 10 - Loss of Fbxl17 LRRs impairs SCFFbxl17 auto-ubiquitination activity.  
(A) Titration of the auto-ubiquitination activity of purified SCFFbxl17 ligase complexes. A concentration 
gradient (12.5nM, 25nM, 50nM, 100nM) of purified SCFFbxl17 or mutant complexes SCFFbxl17ΔFbox, 
SCFFbxl17Δ3LRR or SCFFbxl17Δ10LRR was used in an in vitro ubiquitination assay in the presence of a ubiquitin 
mix (ubiquitin buffer, UBE1, UbcH5a and ATP). Following SDS-PAGE membranes were probed with anti-
FLAG antibody to detect SCFFbxl17 ligases, n=2. (B) As (A) but probed with anti-ubiquitin antibody, n=2. 




3.3.3 Ubiquitination of the Fbxl17 target substrate Sufu 
To test whether the ligases made by WT or mutant versions of Fbxl17 could ubiquitinate a 
heterologous substrate, I performed in vitro ubiquitination assays using the published Fbxl17 
substrate Sufu (Figure 3. 11) [250]. HA-Sufu was purified from HEK293T cells by 
immunoprecipitation. High molecular weight smears can be seen after the addition of 
SCFFbxl17 (Figure 3. 11, lane 4) and to a much lesser extent SCFFbxl17Δ3LRR (Figure 3. 11, lane 6). 
Both SCFFbxl17ΔFbox and SCFFbxl17Δ10LRR show greatly reduced ubiquitination activity.   Together 
these data indicate the LRRs in Fbxl17 facilitate or stabilise assembly of the SCF E3 ligase and 




Figure 3. 11 - Loss of Fbxl17 LRRs impairs ubiquitination of the Fbxl17 substrate Sufu.  
In vitro ubiquitination assay of SCFFbxl17 and mutant ligase complexes in combination with HA-tagged 
substrate Sufu in the presence of a ubiquitin mix (ubiquitin buffer, UBE1, UbcH5a and ATP). Proteins 
resolved by SDS-PAGE and membrane probed with anti-HA antibody, n=3. 
 




3.4 Fbxl17 protein structure prediction 
The 3D structure of Fbxl17 is yet to be determined. To better understand how the genomic 
rearrangements we identified may affect Fbxl17 structure, I used the Robetta protein 
structure prediction service (http://new.robetta.org/) to model the 3D structure of Fbxl17 
WT and mutant constructs.  
3.4.1 The N-terminus of Fbxl17 is highly disordered 
Within the Robetta interface, the DISOPRED3 disorder prediction server estimated that 31% 
of Fbxl17 is natively unfolded (disordered) (Figure 3. 12). The majority of this disorder 
occurred at the N-terminus of Fbxl17, which is characterised by low complexity sequence. 
Disordered regions are usually flexible and dynamic to allow molecular recognition of 
proteins and nucleic acids [262].  The function of the N-terminus of Fbxl17 is still unknown 
but it may be important for recruitment of other proteins such as those that regulate Fbxl17 
localisation, expression or activity. The nuclear localisation signal (NLS) motif of Fbxl17 is 
predicted to be at the N-terminus of the protein. 
3.4.2 The LRRs of Fbxl17 are highly structured helical repeats 
Robetta uses three protein prediction servers to generate secondary structures from protein 
sequences; Raptor X Property (DeepConcNF) [263], PSIPRED [264] and SPIDER3[265, 266]. All 
three approaches show that the LRRs of Fbxl17 are predicted to be a series of helices and β-
strands. They show no native disorder suggesting these are highly structured domains 
(Figure 3. 12). 
Comparative modelling by Robetta generated five 3D model predictions for full-length 
Fbxl17 (1-701aa) (Figure 3. 13A) with a confidence value of 0.50 (scale of 0.0-1.0 where 1.0 is 
the highest confidence, confidence corresponds to the agreement in structure between the 
partial threaded models from the top alignment of each independent alignment method). 
Comparative modelling works on the assumption that proteins with similar sequences that 
are related evolutionarily will have similar structures [267]. Given that LRRs are a widespread 
structural motif and the crystal structures for other LRR-family F-box proteins have been 
resolved [218, 268] it is unsurprising that the prediction error rate for the LRR domains is low 
compared to the N-terminus of Fbxl17 (Figure 3. 13B). The 3D models for Fbxl17 show a 
characteristic curved solenoid structure [269]. The concave side of this ‘horseshoe’ is a series 




of parallel β-strands and the convex side is comprised of α-helices. Across all five models, the 
LRR structure remains largely unchanged but the relative position of the N-terminus varies. 
This is expected as the N-terminus is natively disordered and therefore predicted to have 
greater flexibility. Model 5 has the lowest angstrom error estimates across the N-terminus 
and most of the LRR domains; the lower the angstrom error, the more accurate the 3D 
position of a particular residue has been predicted, whilst models 1,2 and 4 show a more 
compact and organised LRR structure with no projecting loops, reflected by low angstrom 
error estimates across the whole LRR region (Figure 3. 13B). In models 1, 2 and 5 the LRRs of 
Fbxl17 loop back to remain in close proximity to the N-terminus, which likely offers greater 
protein stability or may represent an auto-inhibited conformation of Fbxl17 (Figure 3. 13A).   
3.4.3 Loss of LRRs changes the predicted 3D structure of Fbxl17 
The genomic rearrangements we have observed in Fbxl17 often target the LRRs resulting in 
complete loss or truncation of this domain. To determine the potential effects of these 
rearrangements on the 3D structure of Fbxl17, I input the two mutant Fbxl17 sequences into 
the Robetta prediction server; Fbxl17Δ3LRR (1-586aa) and Fbxl17Δ10LRR (1-384aa). As with 
WT Fbxl17, Robetta generated five 3D structure model predictions for Fbxl17Δ3LRR and 
Δ10LRR with a confidence value of 0.36 and 0.06, respectively (Figure 3. 14 and Figure 3. 15).  
All five of the Fbxl17Δ3LRR models had similar angstrom error estimate plots, and as with 
WT Fbxl17 predicted structure, the error estimate was lowest across the F-box domain and 
LRRs. The eight remaining LRRs of Fbxl17Δ3LRR still form the characteristic solenoid shape, 
but in contrast to WT Fbxl17, the LRRs no longer loop back to remain close to the N-terminus 
of Fbxl17 (Figure 3. 14). This more open and linear structure may offer less protein stability 
and may explain the impaired SCF complex assembly observed previously. 
The 3D structure of Fbxl17Δ10LRR was difficult to model by comparative modelling methods, 
reflected by the low confidence score (0.06). This is due to a lack of homology of this region 
to known 3D protein structures. The N-terminus of Fbxl17 is highly disordered, and the five 
predicted 3D models suggest it contains a number of helices, with model 4 showing the 
lowest angstrom error estimates across all the models (Figure 3. 15). Ab initio modelling was 
also utilised within the Robetta interface as an alternative to comparative modelling. Ab 
initio or ‘from the beginning’ methods aim to build 3D models from scratch based on 
physical principles, such as ensuring hydrophobic residues are buried, rather than making 




predictions based on previously solved structures [270].  Ab initio modelling improved the 
confidence score of Fbxl17Δ10LRR to 0.12 but the predicted models (not shown) were very 
similar to those predicted by comparative modelling. It is clear that the structure of Fbxl17 
would be drastically altered following loss of 10LRRs. The changes in structure of Fbxl17 
caused by loss of LRRs may in part explain the compromised SCF assembly and activity we 
have observed for the Fbxl17 truncation mutants.  
 






































































































































































































Figure 3. 13 - 3D structure predictions for Fbxl17 using Robetta protein structure prediction service. 
(A) Fbxl17 3D structure models generated by comparative modelling. N-terminus, blue; C-terminus, 
red. (B) 3D modelling error in angstroms for each amino acid position of Fbxl17 for the five Robetta 
generated 3D models. Schematic underneath represents approximate locations of Fbxl17 domains 
(lower rectangle); green, N-terminus; purple, F-box domain; red, leucine rich repeats, mapped to 
spectrum colouring used in (A) (top rectangle). 
  




Figure 3. 14 - 3D structure predictions for Fbxl17Δ3LRR using Robetta protein structure prediction 
service.  
(A) Fbxl17Δ3LRR 3D structure models generated by comparative modelling. N-terminus, blue; C-
terminus, red. (B) 3D modelling error in angstroms for each amino acid position of Fbxl17 Δ3LRR for 
the five Robetta generated 3D models. Schematic underneath represents approximate locations of 
Fbxl17 domains (lower rectangle); green, N-terminus; purple, F-box domain; red, leucine rich repeats, 
mapped to spectrum colouring used in (A) (top rectangle). 




Figure 3. 15 - 3D structure predictions for Fbxl17Δ10LRR using Robetta protein structure prediction 
service.  
(A) Fbxl17Δ10LRR 3D structure models generated by comparative modelling. N-terminus, blue; C-
terminus, red. (B) 3D modelling error in angstroms for each amino acid position of Fbxl17Δ10LRR for 
the five Robetta generated 3D models. Schematic underneath represents approximate locations of 
Fbxl17 domains (lower rectangle); green, N-terminus; purple, F-box domain; red, leucine rich repeats, 
mapped to spectrum colouring used in (A) (top rectangle). 




3. DISCUSSION  
It was previously found that FBXL17 is rearranged in around 7% of breast cancers according 
to array-CGH data. Rearrangements of FBXL17 were also validated in breast and 
oesophageal cancer cell lines [255]. Independently, analysis of sequence-level mutation data 
suggested that FBXL17 behaves like a tumour suppressor gene [271]. My results further 
indicate that FBXL17 is frequently mutated in breast cancers and consistently in the genomic 
regions encoding its LRRs. The incidence of FBXL17 mutations in the primary breast tumours 
was 2%, which was lower than predicted from the array-CGH data. However, it has been 
shown in other cancer types that rare rearrangements can be important. Most notably, the 
EML4-ALK translocation is present in an estimated 5% of NSCLC cases [39]. Patients with the 
oncogenic fusion gene respond well to ALK inhibitors and as such discovery of the genomic 
rearrangement lead to an effective clinical therapy and improved patient outcome [272]. As 
such, Fbxl17 may also be a suitable therapeutic target in breast cancers rearranged for 
FBXL17. 
FBXL17 rearrangements did not cluster with a specific breast cancer subtype; however, the 
tumours with FBXL17 mutations may be enriched for TP53 mutations, given 83% of the 
FBXL17-rearranged tumours were TP53 mutant, compared to only 40% of the 250 tumours 
overall. Half of the tumours were assigned to IntClust 10, a high-risk subtype usually 
presenting clinically at a younger age, with high-grade and poorly differentiated tumours 
[30]. Furthermore, most (4/6) tumours with FBXL17 rearrangements were basal-like, which 
are often aggressive tumours with poor therapeutic responses. Most (but not all) basal-like 
tumours are characterised by the lack of hormone receptors (ER, PR and HER2, triple-
negative cancers) which limits therapeutic targets [273]. Modulating Fbxl17 expression in 
these tumours may therefore be a viable therapeutic option.  
Many point mutations and breaks in FBXL17 occurred in regions encoding its LRRs. Indeed, 
the TCGA data mapping somatic point mutations were striking, with only two mutations 
falling outside the F-box domain or LRR regions. The cancer cell lines and tumour-associated 
mutations cluster around intron 6. Breaks here would disrupt a short linker region in Fbxl17 
that exists between LRR8 and 9 and would truncate Fbxl17 by 3LRRs. The LRR motifs are 
proposed to be the substrate docking sites within FBXL proteins and are predicted to cause a 
failure to recruit substrates if lost or mutated. Indeed, Raducu, et al. showed that the LRRs of 




Fbxl17 are required for binding to Sufu [250] and the cysteine residue (C627) that is required 
for binding to BTB-domain containing proteins would be lost in both Fbxl17Δ3LRR and 
Fbxl17Δ10LRR [251]. We find that progressive deletion of the LRRs of Fbxl17 also caused 
decreased auto-ubiquitination and decreased ubiquitination of a substrate, Sufu, by SCFFbxl17. 
Auto-ubiquitination is a regulatory feedback mechanism adopted by Fbox proteins to control 
the pool of free FBPs in a cell in the absence of substrate [208]. As a result, the truncated 
Fbxl17 protein is likely to be unable to efficiently regulate its own abundance and may 
sequester Skp1 from other FBPs. This may also explain why we observed more abundant 
expression of the mutant Fbxl17 constructs in mammalian cells. The ability of SCFFbxl17 to 
auto-ubiquitinate with several E2 ligases highlights the promiscuity of E2 enzymes and the 
functional plasticity of the UPS system. It also highlights the potential for Fbxl17 to conjugate 
different ubiquitin chain linkage types onto substrates. It has already been shown that the 
E3 ligase BRCA1-BARD1 can assemble both K63-linked chains and K48-linked chains, 
depending on the E2 enzyme it recruits [193]. 
Deleting LRRs also impaired the assembly of the E3 ubiquitin-ligase complex, which likely 
explains the decreased ubiquitination activity we observed. I was able to purify SCF 
complexes from cells, which were found to be active to varying degrees in vitro. Surprisingly 
both Fbxl17 LRR truncation mutants, ∆3LRR and ∆10LRR, bound Skp1 less well compared to 
WT, despite the presence of a Skp1 binding motif. The C-terminus of an FBP has been shown 
in specific cases to contact Skp1 to stabilise the ligase [274]. Consistent with this, my data 
shows that truncating the LRRs of Fbxl17 destabilises the SCF ligase as demonstrated by a 
lack of SCF subunit recruitment. Reduced interactions with Cul1 and Rbx1 are likely due to 
less Skp1 binding, since FBPs do not interact directly with Cul1 or Rbx1 [274]. This contrasts 
BTB-Cul3-Rbx1 E3 ligases, where BTB proteins contact both Cul3 and their substrates 
directly. The destabilisation caused by loss of LRRs may be due to a change in the 3D 
structure of Fbxl17, as predicted by Robetta modelling. Robetta models for the Fbxl17 
mutants showed that the LRRs of Fbxl17 no longer loop back to remain in close proximity to 
the N-terminus/F-box domain of Fbxl17, which we propose is important to stabilise Skp1 
binding and SCF complex assembly.  
Given that the ubiquitination of Sufu was decreased by Fbxl17 LRR-truncated mutants I 
predict that the pool of substrates ubiquitinated bySCFFbxl17 would be diminished or indeed 




altered as a result of loss of LRRs. It is possible that the decreased ubiquitination we 
observed for Sufu with the truncation mutants is simply due to lack of binding to Fbxl17. 
However, even if a truncated Fbxl17 were able to recruit some of its substrates, I have 
shown that it would be less efficient in ubiquitinating them. Thus, in the context of breast 
cancer, the rearrangements that target the LRRs of FBXL17 would likely diminish 
ubiquitination of the network of SCFFbxl17 substrates. The resulting dysregulation of the 
SCFFbxl17 ubiquinome is likely to have effects on multiple cellular pathways. To fully 
understand the implications of Fbxl17 mutations in breast cancer, we need to identify its 
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CHAPTER 4 - Fbxl17 as a regulator of the Hexosamine Biosynthetic Pathway 
4. Introduction 
Ubiquitination controls key cellular processes, including cell cycle progression and 
inflammatory responses. It is likely that aberrant ubiquitination by mutant SCFFbxl17, as a 
consequence of rearrangement, will negatively impact the cellular pathways reliant on 
Fbxl17 for regulation. We predict that loss of Fbxl17 LRRs will also impede binding to other 
substrates or diminish substrate ubiquitination where binding to Fbxl17 is still possible. 
However, the substrates of Fbxl17 remain widely unknown. At the start of this PhD project 
only two papers reporting binding partners of Fbxl17 had been published. Fbxl17 was first 
shown to stabilise ribonucleotide reductase subunit M2 (RRM2) promoting its 
overexpression in breast cancer cells [248] and in 2013, a second substrate of Fbxl17, 
BACH1, was identified. Turnover of BACH1 by Fbxl17 was important for transcription of the 
NRF2 target HMOX1, which protects cells from oxidative stress [249]. More recently Fbxl17 
has been shown to target Sufu [250] and PRMT1 [212] for proteasomal degradation with 
implications in medulloblastoma and asthma respectively. In 2018, Mena et al. found that 
Fbxl17 acts in a quality control capacity to target aberrant BTB heterodimers for 
degradation, which is required for neural differentiation in Xenopus laevis embryos [251]. 
The range of substrates identified so far highlights the far-reaching effects of the SCFFbxl17 
regulatory network in cells.  
In order to find substrates of Fbxl17 and therefore identify the regulatory network of Fbxl17 
on a wide scale, a yeast two-hybrid (Y2H) screen was performed by Dr Susanne Flach. To 
focus the screen on LRR-binding partners and therefore potential ubiquitinated substrates of 
Fbxl17, the bait plasmid contained the F-box domain (FBD) and LRRs (321-701aa) of Fbxl17 
but omitted its N-terminus. A normalised human cDNA library fused to a Gal4 activation 
domain (GAD) was used as prey. Thirty-seven unique prey, cloned in-frame to the GAD, were 
identified as candidate partners for Fbxl17. More than a third (13/37) of the prey were 
isolated independently at least twice. The most frequently isolated cDNA encoded GAD 
fusions to UDP-N-acetylglucosamine pyrophosphorylase 1 (Uap1), which were isolated 26 
times [255].  
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Uap1 is an enzyme required for the synthesis of UDP-GlcNAc, an intermediate utilised in the 
Hexosamine biosynthetic pathway (HBP), to add O-GlcNAc modifications onto serine or 
threonine residues of target proteins (O-GlcNAcylation) (Figure 4. 1).  O-GlcNAcylation is an 
important post-translational modification on many intracellular proteins. In this chapter I set 
out to validate the Y2H results and test whether Uap1 is an interacting partner of Fbxl17. I 
then investigated the consequences of LRR rearrangements on this interaction and the 
downstream effects of Fbxl17 activity, or lack thereof, on the HBP and O-GlcNAcylation. A 
manuscript containing some of this work, published in September 2019 in Cellular and 
Molecular Life Sciences, can be found in Appendix B. 
  
Figure 4. 1 - Downstream steps of the Hexosamine Biosynthetic pathway 
When glucose enters the cell, 2-5% is directed to the Hexosamine biosynthetic pathway (HBP). At the 
downstream steps of the HBP, the enzyme UDP-N-acetylglucosamine pyrophosphorylase 1 (Uap1) 
converts N-acetylglucosamine-1-phosphate to UDP-GlcNAc. UDP-GlcNAc can then be utilised by OGT 
for the O-GlcNAcylation of nuclear and cytoplasmic proteins. OGT (O-GlcNAc transferase) and OGA 
(O-GlcNAcase) catalyse the addition and removal of O-GlcNAc respectively. 
 




4.1 Fbxl17 interacts with Uap1 in human cells in vivo. 
The Y2H results suggested that Uap1 interacts with Fbxl17. To validate this interaction in 
mammalian cells Dr Flach performed a co-immunoprecipitation assay (Figure 4. 2A). 
Immunoprecipitates from HEK293T cells expressing N-terminally FLAG-tagged Fbxl17 and 
HA-tagged Uap1 were isolated using anti-FLAG agarose beads. To test whether the 
interaction between Fbxl17 and Uap1 is dependent on the LRRs of Fbxl17, the experiment 
also included the truncated mutants Fbxl17Δ3LRR and Fbxl17Δ10LRR. Western blotting 
revealed that Uap1 is co-immunoprecipitated with WT Fbxl17 thus confirming the Y2H 
results. Uap1 also co-immunoprecipitated with Fbxl17Δ3LRR, but truncation of 10LRRs 
ablated the interaction, indicating that Uap1 binding is dependent on LRRs 2-8 (Figure 4. 2A). 
In addition to this, I performed a co-immunoprecipitation assay to test Uap1 binding to 
Fbxl17ΔFbox. The Y2H Fbxl17 bait contained the FBD and LRRs, and as such Uap1 may bind 
to either domain. FLAG-tagged Fbxl17 WT and ΔFbox were isolated from HEK293T cell 
lysates, and immunoprecipitates were probed for exogenous HA-tagged Uap1 (Figure 4. 2B). 
Uap1 can still bind to Fbxl17ΔFbox indicating the FBD is not required for the interaction of 
Fbxl17 with Uap1.  
Figure 4. 2 - Deletion of ten LRRs ablates binding of Fbxl17 to Uap1 
(A) Immunoprecipitates; using anti-FLAG beads, of HEK293T cells expressing FLAG-Fbxl17, FLAG-
Fbxl17∆3LRR or FLAG-Fbxl17∆10LRR, probed for exogenous HA-tagged Uap1. Experiment performed 
by Dr. Susanne Flach, reproduced here with permission. (B) As (A) but HEK293T cells expressing 
FLAG-Fbxl17 or FLAG-Fbxl17ΔFbox, and Uap1, probed for Uap1, n=2; EV, empty vector; WT, Fbxl17 
WT (1-701aa);  ΔFbox, Fbxl17ΔFbox (Δ324-356). 
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4.2 Fbxl17 binds Uap1 directly via its LRRs 
Interactions in the Y2H screen and in co-immunoprecipitation assays, could arise from 
proteins bridging the interaction between Fbxl17 and Uap1. Therefore, to test the directness 
of the interaction between Fbxl17 and Uap1, I performed an in vitro GST pull-down assay 
(Figure 4. 3). I first attempted to express GST-Fbxl17 (321-701aa) and GST-Fbxl17Δ10LRR 
(321-384aa) in bacteria. As with the Y2H, I omitted the N-terminus of Fbxl17 to focus the 
assay on binding that occurs via the LRRs. Fbxl17Δ10LRR was robustly expressed in bacteria 
as demonstrated by Coomassie staining of proteins immobilised on GST-beads, but we were 
unable to express GST-Fbxl17 (321-701aa) (data not shown). To try and overcome this issue, 
I cloned Fbxl17 into a bacterial expression vector that co-expressed Skp1 
(Fbxl17_IRES_Skp1), since this has previously been reported to stabilise FBP and their 
expression in bacteria [275]. Co-expression of GST-Fbxl17 with Skp1 facilitated the 
expression in bacteria (Figure 4. 3, right panel). The volume of sample loaded to the gel, and 
Figure 4. 3 - Fbxl17 binds Uap1 directly. 
In vitro GST pull-down assay using bacterially expressed and purified Fbxl17 constructs or Skp2/GST 
as controls, immobilised on a GST column incubated with rabbit reticulocyte lysate (left panel). 
Fbxl17 (321-701aa) and Skp2 constructs contained an IRES_Skp1 to aid expression. Input for rabbit 
reticulocyte lysate= 20%, arrow represents Uap1. Coomassie staining of GST proteins (right panel), 
volume of sample loaded indicated below lanes * indicates bands relating to expressed proteins, n=2. 
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subsequently used in the binding assay, was optimised to equalise protein expression (Figure 
4. 3, right panel). GST-Fbxl17_IRES_Skp1 and GST-Fbxl17Δ10LRR were immobilised on a GST 
column and incubated with in vitro transcribed and translated (IVT) Uap1. GST-
Skp2_IRES_Skp1, another LRR containing FBP, and GST alone were included as controls. 
Following the binding assays, samples were resolved by SDS-PAGE and membranes probed 
with antibody to Uap1. I observed binding specifically to GST-Fbxl17_IRES_Skp1 (321-701aa) 
but not to GST only or GST-Skp2_IRES_Skp1. This shows that binding of Uap1 to Fbxl17 is 
specific and not via an interaction with Skp1. Furthermore, in agreement with the co-
immunoprecipitation data, deletion of 10 LRRs abolished Uap1 binding to Fbxl17 (Figure 4. 3, 
left panel). The folding of GST-Fbxl17Δ10LRR is likely to be disrupted (see Chapter 3), which 
may explain the loss of binding to Uap1. These results indicate Fbxl17 interacts directly with 
Uap1, and this occurs via its LRRs. 
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4.3 Overexpression of Fbxl17 does not increase Uap1 turnover 
To test the functional significance of Fbxl17 interaction with Uap1, I over-expressed Fbxl17 
and monitored the steady state levels of Uap1 by immunoblotting (Figure 4. 4). Fbxl17ΔFbox 
was included as a negative control. Uap1 levels were unchanged in the presence of the 
proteasome inhibitor MG132 and with increased levels of Fbxl17, which suggests Fbxl17 
activity does not promote the proteasomal degradation of Uap1 (Figure 4. 4). However, not 
all modification of proteins by ubiquitination results in their degradation, and so this does 
not rule out Uap1 as a substrate of Fbxl17. We also cannot rule out that the cells have 
adopted a compensatory mechanism, within 48 hours, to counteract any changes to Uap1 










Figure 4. 4 - Fbxl17 does not target Uap1 for proteasomal degradation.  
HEK293T cells transfected with Fbxl17 WT, ΔFbox or empty vector (EV) for 48h, treated with 10µM 
MG132 or DMSO for 4h prior to lysis. Whole cell lysates immunoblotted with the indicated antibodies, 
n=3. 
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4.4 Fbxl17 does not ubiquitinate Uap1 in vitro 
To test whether Uap1 is a substrate of SCFFbxl17 ligase I conducted an in vitro ubiquitination 
assay. Initially, untagged Uap1 was transcribed and translated in vitro and added to a 
ubiquitin mix in the presence of purified SCFFbxl17 ligases. Samples were resolved by SDS-
PAGE and immunoblotted for Uap1. No higher molecular weight bands, indicative of 
modification with ubiquitin, were present in any of the samples suggesting Uap1 is not 
ubiquitinated by Fbxl17 (Figure 4. 5A). I hypothesised that the concentration of ligases may 
be too low for robust ligase activity towards Uap1. Alternatively, Uap1 may require 
additional post-translational modification before it can be recognised as a substrate by 
Fbxl17, which are not added during IVT preparation of Uap1. To address these concerns, I 
purified HA-UAP1 from HEK293T cells by immunoprecipitation. I then repeated the in vitro 
ubiquitination assay with 50nM (data not shown) and 100nM of purified SCF ligases. Once 
again, I did not detect any higher molecular weight bands representing modification of Uap1 
(Figure 4. 5B). The absence of a positive control for SCFFbxl17 activity makes it difficult to 
conclude this with certainty. However, the Fbxl17 SCF ligases samples used in this assay have 
already been shown to be active in vitro (Chapter 3, Figure 3. 11) which suggests the absence 
of modification of Uap1 is unlikely to be due to lack of SCFFbxl17 ligase activity. Together these 
data indicate that Fbxl17 cannot ubiquitinate Uap1 in vitro.   
Figure 4. 5 - Fbxl17 does not ubiquitinate Uap1 in vitro. 
In vitro ubiquitination assay of SCFFbxl17 and mutant ligase complexes in combination with Uap1 
(untagged) produced by IVT (A) or HA-Uap1 purified from HEK-293T cells (B), in the presence of a 
ubiquitin mix (ubiquitin buffer, UBE1, UbcH5a and ATP). In (B) the SCF concentration was increased to 
100nM. Proteins resolved by SDS-PAGE and membrane probed with anti-Uap1 or anti-HA antibody as 
indicated, n=2. 
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4.5 Fbxl17 inhibits the phosphorylation of Uap1. 
Some substrates require co-factors to bind substrates, which could explain why Fbxl17 was 
unable to ubiquitinate Uap1 in vitro. I therefore conducted an in vivo ubiquitination assay to 
see if Fbxl17 could ubiquitinate Uap1 in a cellular setting, where any potential co-factors 
would be present (Figure 4. 6A). HEK293T cells were co-transfected with HA-Uap1, Myc-
ubiquitin and FLAG-Fbxl17 (WT or ΔFbox) constructs. Following immunoprecipitation of 
Uap1 with HA antibody immobilised on agarose beads, samples were analysed by 
immunoblotting. I found no evidence of laddering or smearing of Uap1 indicative of its 
Figure 4. 6 - Fbxl17 does not target Uap1 for ubiquitination.  
(A) In vivo ubiquitination assay for UAP1.  HA-UAP1 immunoprecipitated from HEK293T cells 
transfected with ubiquitin and indicated Fbxl17 constructs. Membranes probed with anti-UAP1 
antibody, arrow indicates modified Uap1, n=3. (B) as (A) but including mutant Fbxl17 constructs 
Fbxl17Δ3LRR and Fbxl17 Δ10LRR. (C-D) as (A) but probed for ubiquitin (C) and myc-epitope tag (D). 
TL, total lysate. 
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polyubiquitination. Instead I detected a discrete, higher molecular weight species of Uap1 
upon transfection of Myc-ubiquitin (Figure 4. 6A, lane 2). Moreover, levels of this modified 
form of Uap1 were reduced when Fbxl17 was overexpressed (Figure 4. 6A, lane 5). 
Interestingly, this reduction of Uap1 modification was not observed when Fbxl17 ΔFbox was 
overexpressed, suggesting this effect was dependent on Skp1 binding and/or the ligase 
activity of Fbxl17 (Figure 4. 6A, lane 6). I next tested whether the Fbxl17 truncation mutants 
could also inhibit the modification of Uap1 and repeated the in vivo ubiquitination assay in 
the presence of Fbxl17Δ3LRR and Fbxl17Δ10LRR. Over-expression of Fbxl17Δ3LRR was also 
able to prevent the modification of Uap1 to a level comparable to WT Fbxl17 (Figure 4. 6B, 
lane 5) but this effect was lost following deletion of 10LRRs (Figure 4. 6B, lane 6). This 
suggests that the inhibition of this modification not only requires the F-box domain but also 
the first eight LRRs of Fbxl17.  
To determine the type of modification this higher molecular weight species of Uap1 
represented, I immunoblotted with antibodies to ubiquitin and to myc-epitope tag (Myc-
ubiquitin) (Figure 4. 6C and D). The modification of Uap1 was only present after 
overexpression of Myc-ubiquitin and the resulting gel shift, due to a change in molecular 
Figure 4. 7 - Fbxl17 inhibits the phosphorylation of Uap1.  
(A) In vivo ubiquitination assay for UAP1.  HA-UAP1 immunoprecipitated from HEK293T cells 
transfected with ubiquitin and indicated Fbxl17 constructs in the presence of β-Glycerophosphate 
(lane 3) and Alkaline phosphatase (CIP) (lane 4), Membranes probed with anti-UAP1 antibody, arrow 
indicates modified Uap1, n=2. 
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weight, could be accounted for by the addition of a single 8 kDa ubiquitin molecule. I 
therefore hypothesised that the higher molecular weight band may represent a mono-
ubiquitinated form of Uap1. Antibodies to ubiquitin and Myc-tag did not yield any signal in 
Uap1 immunoprecipitates, only IgG heavy chain, and therefore indicate that the 
modification present on Uap1 is not ubiquitination.  
Data-mining of the PhosphoSitePlus database highlighted multiple studies showing Uap1 is a 
phosphorylated protein. As such, I tested whether this modified version of Uap1 
represented a phosphorylated form of the protein. I repeated the in vivo ubiquitination 
assay in the presence of the phosphatase inhibitor β-glycerophosphate and the alkaline 
phosphatase (CIP) (Figure 4. 7), which should increase and decrease phosphorylation of 
proteins, respectively. Strikingly, the levels of modified Uap1 were almost completely 
ablated following CIP treatment (Figure 4. 7, lane 4), suggesting the higher molecular weight 
species represented a phosphorylated form of Uap1. There was also a slight increase in 
modified Uap1 following β-glycerophosphate treatment (Figure 4. 7, lane 3), further 
suggesting the observed modification of Uap1 is phosphorylation. Overexpression of Myc-
ubiquitin seems to promote the phosphorylation of Uap1. In summary, overexpression of 
ubiquitin increases Uap1 phosphorylation and overexpression of Fbxl17 prevents this 
modification in an FBD and LRR-dependent manner.  
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4.6 Fbxl17 knockdown inhibits UDP-GlcNAc production. 
Since Fbxl17 overexpression reduced the abundance of phosphorylated Uap1, but not its 
steady state levels, we reasoned Fbxl17 might regulate endogenous Uap1 activity. Uap1 
catalyses the formation of UDP-N-acetylglucosamine (UDP-GlcNAc), an intermediate used by 
the glycosyltransferase O-GlcNAc Transferase (OGT) to add N-acetylglucosamine in O-
glycosidic linkages to proteins, known as O-GlcNAcylation. We hypothesised that the 
phospho-Uap1 may be an activated form of the enzyme, and our results indicate Fbxl17 acts 
to suppress this modification. We therefore tested whether reducing Fbxl17 expression 
would increase endogenous Uap1 activity. Small interfering RNA (siRNA) targeting Fbxl17 
were initially tested in HEK293T, U2OS, MCF7 and HB4a cells, with siRNA3, targeting exon 3 
of Fbxl17, in U2OS cells found to provide the best knockdown and therefore used in 
subsequent experiments (Figure 4. 8A). The steady state levels of Uap1 in U2OS cells treated 
with siRNA3 were monitored by immunoblotting. As with Fbxl17 overexpression, Uap1 levels 
were unchanged following Fbxl17 knockdown (Figure 4. 8B).  
 
Figure 4. 8 - Uap1 steady state levels are not altered following Fbxl17 knockdown 
(A) Expression of Fbxl17 in U2OS cells treated with Fbxl17 targeting siRNA. Immunoblotted with anti-
Fbxl17. Arrow represents band corresponding to Fbxl17. (B) U2OS cells treated with Fbxl17 targeting 
siRNA3 or control non-targeting siRNA. Whole cell lysates immunoblotted for indicated proteins, n=2.  
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If Fbxl17 negatively regulates Uap1 activity, we hypothesised that loss of Fbxl17 should 
increase Uap1 activity, which should increase the total amount of UDP-GlcNAc, the product 
of this enzyme. To test if this was the case, U2OS cells were treated with siRNA targeting 
Fbxl17, metabolites were extracted from cells and UDP-GlcNAc levels were determined by 
liquid chromatography mass spectrometry (LC-MS) (Figure 4. 9). Surprisingly we observed a 
36% decrease (p=0.013; n=5) in total UDP-GlcNAc levels following Fbxl17 knockdown, which 
suggests Fbxl17 promotes Uap1 activity. 
  
Figure 4. 9 - Knockdown of Fbxl17 inhibits UDP-GlcNAc production.  
LC-MS analysis of total UDP-GlcNAc levels in U2OS cells treated with Fbxl17 siRNA3 or control siRNA 
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4.7 Fbxl17 knockdown results in increased levels of O-GlcNAcylation. 
To determine the downstream effects of Fbxl17 knockdown on the HBP, we next tested the 
effect of reduced Fbxl17 expression on global cellular O-GlcNAcylation. The activity of OGT is 
very sensitive to concentrations of UDP-GlcNAc in the cytosol and nucleus; therefore, we 
would expect the observed decrease in UDP-GlcNAc levels upon reduction of Fbxl17 levels, 
to affect OGT’s ability to add O-GlcNAc modifications to proteins. U2OS cells were treated 
with Fbxl17 siRNA as above and lysates immunoblotted for total O-GlcNAc. Although UDP-
GlcNAc levels were reduced in Fbxl17 knockdown cells, we observed total O-GlcNAc was 
increased when Fbxl17 was knocked down (Figure 4. 10). Similar results were seen in two 
breast cell lines, HB4a and MCF7, by expression of shRNA constructs targeting FBXL17 
expression (Figure 4. 11). These data indicate an overall increase in the levels of O-
GlcNAcylated proteins upon Fbxl17 knockdown in breast cancer cells. This is a surprising 
result since direct measurement of the Uap1 substrate UDP-GlcNAc indicates that Fbxl17 
promotes Uap1 activity. An increase in global O-GlcNAc following Fbxl17 knockdown hints at 









Figure 4. 10 - Knockdown of Fbxl17 increases global O-GlcNAcylation.  
U2OS cells treated with Fbxl17 siRNA3 or control siRNA for 48h followed by PugNAc treatment; an 
inhibitor of O-GlcNAc-β-N-acetylglucosaminidase (OGA), the enzyme responsible for removing O-
GlcNAc from proteins, 50µM 3h. Whole cell lysates immunoblotted with the indicated antibodies, n=2. 




Figure 4. 11 - Knockdown of Fbxl17 increases O-GlcNAcylation in breast cancer cells 
(A) FBXL17 mRNA knockdown by shRNA in HB4a immortalised normal breast (bottom panel). 
Expression normalised to GAPDH and plotted relative to miR30-infected control cells. Mean ± SEM of 
at least three independent experiments. O-GlcNAcylation monitored by immunoblotting with anti-O-
GlcNAc antibodies (top panel). (B) FBXL17 mRNA knockdown by shRNA in MCF7 breast cancer cells 
(bottom panel). Expression normalised to scRNA-infected cells. Mean ± SEM of at least three 
independent experiments. Total O-GlcNAcylation monitored by immunoblotting with anti-O-GlcNAc 
antibodies. + and ++, 25 or 50 mg of protein lysate (top panel). Experiments performed by Dr 
Susanne Flach, reproduced here with permission. 
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4.8 Fbxl17 knockdown results in decreased OGA expression 
O-GlcNAcylation is tightly regulated in order to maintain O-GlcNAcylation homeostasis.  The 
surprising results showing increased O-GlcNAcylation following Fbxl17 knockdown, despite a 
significant decrease in UDP-GlcNAc levels, can therefore only be explained if the expression 
or activity of the enzymes responsible for adding or removing O-GlcNAc is also altered in 
these cells. I therefore tested whether the expression of OGT and its mechanistic partner 
OGA; both of which act downstream of Uap1 and UDP-GlcNAc and are responsible for 
adding and removing O-GlcNAc modifications to proteins respectively, were altered 
following Fbxl17 knockdown. I identified a decrease in OGA levels following Fbxl17 siRNA 
treatment of U2OS cells, but no change in OGT expression, which strongly suggests the 
increase in O-GlcNAcylated proteins, is the result of decreased OGA expression. In support of 
this, mass spectrometry analysis of GlcNAc levels, the intermediate produced following 
hydrolytic cleavage of O-GlcNAc modifications from proteins by OGA, were decreased in 
Fbxl17 knockdown cells indicating decreased OGA activity, although this was not found to be 
statistically significant.  
 
Figure 4. 12 - Knockdown of Fbxl17 results in decreased OGA expression and activity  
(A) U2OS cells treated with Fbxl17 siRNA3 or control siRNA for 48h. Whole cell lysates immunoblotted 
with the indicated antibodies. Band intensities quantified by densitometry and normalised to GAPDH 
expression (values below blots), n=3. (B) LC-MS analysis of total GlcNAc levels in U2OS cells treated 
with Fbxl17 siRNA3 or control siRNA for 48h. Values are averages from five independent biological 
repeats ± SEM. 




To investigate the functional consequences of FBXL17 rearrangements, we screened for 
proteins interacting with the LRRs of Fbxl17. Our Y2H screen identified 37 novel interacting 
partners of Fbxl17. A previous survey of Fbxl17 binding proteins performed by Tan, et al. 
[249] shows partial overlap with the Y2H results. Among their large list of candidates, 7/37 of 
the proteins identified in the Y2H were also detected. Both screens identified the Kelch-like 
proteins Klhl7 and Klhl12, which were later verified as Fbxl17 substrates [251], confirming 
that the Y2H approach can identify true Fbxl17 interacting partners. However, Uap1, the 
most frequently recovered cDNA in the Y2H, was not found in either case. One possible 
explanation for this is that we used a normalised human cDNA library, which screens 
proteins from all cell types, while Tan, et al. [249] immunoprecipitated Fbxl17 from HEK293 
and HCT116 and so required endogenous proteins to bind at a detectable level. Conversely, 
the Y2H assay requires proteins to form productive interactions for transcription of the 
reporter gene, and so transient or weak interactions may be lost. Neither approach is likely 
to capture all interactions and argues for the use of a variety of experimental approaches to 
discover the regulatory networks of FBPs. 
In this chapter I set out to determine if Uap1 is a substrate of Fbxl17. We were able to verify 
that Fbxl17 and Uap1 interact directly and have shown that Uap1 binding is disrupted only 
when ten LRRs of Fbxl17 are truncated. This suggests Uap1 can bind to LRR2-8 and as such 
led to a model whereby, the number of LRRs in Fbxl17, as dictated by the position of a 
rearrangement within FBXL17, would influence its interaction with its repertoire of proteins. 
As highlighted in Chapter 3, even if binding to LRR-truncated Fbxl17 mutants is still possible, 
we predict the ubiquitination of these proteins to be diminished.  
There is not yet enough data on rearrangement of FBXL17 in cancers to conclusively identify 
Fbxl17 inactivation as a driver mutation in cancer.  Nonetheless, we were able to show a 
striking effect of reducing Fbxl17 expression on at least one important cancer relevant 
pathway, suggesting that inactivation of Fbxl17 would have a major effect on the cancer cell. 
This was through its regulation of Uap1, which is expressed in many breast cancers and 
other cancer types [58, 276]. Surprisingly, we did not find Uap1 to be ubiquitinated by 
Fbxl17, but instead our results showed that increased Fbxl17 expression prevented the 
phosphorylation of Uap1. In addition, this inhibition of Uap1 phosphorylation was 
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dependent on the Skp1-binding domain of Fbxl17, suggesting that SCFFbxl17 ligase activity or 
complex formation is essential. Fbxl17Δ3LRR was also able to inhibit the phosphorylation of 
Uap1 but Fbxl17Δ10LRR was not, highlighting LRRs 2-8 are also required. This suggests a 
need for direct binding to Uap1 given that deletion of ten LRRs abolished binding to Uap1. 
We also note that the phosphorylated form of Uap1 is only observed when we over-express 
ubiquitin. It is possible that the kinase responsible for phosphorylating Uap1 is activated by 
ubiquitination or indeed Uap1 is primed for phosphorylation by ubiquitination. The latter 
would require the Uap1 modification to be subsequently removed, given we could not 
detect any ubiquitination of Uap1. It is possible the inhibition of Uap1 phosphorylation by 
Fbxl17 overexpression is due to its ability to sequester the ubiquitin in the cell, which 
prevents it promoting Uap1 phosphorylation. If this holds true, over-expression of any E3 
ligase, regardless of Uap1-binding capability, should yield a similar result. We could test this 
hypothesis by repeating the in vivo ubiquitination assay in the presence of an alternative E3 
Figure 4. 13 - Model of interaction between Fbxl17 and Uap1.   
We propose a model whereby the presence of Fbxl17 (left panel) inhibits the phosphorylation of 
Uap1, either by inhibiting a yet unknown kinase or blocking the phosphorylation site by directly 
binding Uap1. The inhibition of Uap1 phosphorylation requires the F-box domain of Fbxl17. In the 
absence of Fbxl17 (right panel), phosphorylation of Uap1 inhibits the activity of Uap1 and therefore 
the production of UDP-GlcNAc. This is counteracted by a decrease in OGA expression and therefore 
activity, which results in a global increase in O-GlcNAcylation. 
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ligase. This would also help determine whether, the ligase activity, the binding to Uap1, or 
indeed both characteristics, are required for Fbxl17 to inhibit the phosphorylation of Uap1.  
In contrast to OGT and OGA [40], little is known about the regulation of Uap1, and my data 
suggest Fbxl17 positively regulates its activity (Figure 4. 13). UDP-GlcNAc levels are 
significantly decreased when Fbxl17 is knocked down, indicating reduced Uap1 activity. This 
is consistent with previous studies showing Uap1 expression is important for UDP-GlcNAc 
levels [34]. Importantly, this affect was observed in the absence of exogenous ubiquitin 
expression. Although we have not identified the kinase responsible for phosphorylating 
Uap1, one possibility is that Fbxl17 ubiquitinates this kinase to inhibit its phosphorylation of 
Uap1 and promote Uap1 activity. Alternatively, Fbxl17 could shield Uap1 from this kinase, 
via a direct interaction between Fbxl17 and Uap1 (Figure 4. 13).  
We have shown that Fbxl17 regulates the O-GlcNAcylation pathway since reducing Fbxl17 
expression in three cell lines increased global levels of O-GlcNAc-modified proteins. We did 
not assess glycosylation in the ER or Golgi, so cannot rule out a specific role for Fbxl17 there. 
However, the increase in global O-GlcNAcylation may be the result of greater utilisation of 
UDP-GlcNAc by OGT, which would explain the lower UDP-GlcNAc levels and higher O-
GlcNAcylation we observed in Fbxl17 knockdown cells. Although OGT expression levels were 
unchanged, we cannot eliminate the possibility its activity is increased when Fbxl17 levels 
are reduced.  A more likely reason for the higher levels of O-GlcNAc, is due to the observed 
decrease in OGA expression. It has been proposed that there is an optimal level of global O-
GlcNAcylation levels for cells to function and this is maintained by mutual regulation and 
balance of OGT/OGA expression and activity [59, 67]. The decrease in OGA expression may 
represent a compensatory mechanism adopted by the cell to counteract the decrease in 
Uap1 activity and UDP-GlcNAc levels. O-GlcNAcylation is an important post translational 
modification on many intracellular proteins—including p53, RNA polymerase II, the 
polycomb complex and Phosphofructokinase 1 (Pfk1), the main regulator of glycolysis—and 
is essential for viability of several mammalian cell types [64, 70].  Moreover, there is already 
considerable evidence that GlcNAcylation is altered in breast cancer and other cancers [81, 
82, 277, 278].  Caldwell et al. [77] found that breast cancer cells had increased O-
GlcNAcylation and elevated OGT.  Knocking down OGT inhibited tumour growth, decreased 
cell cycle progression, increased expression of the cell cycle inhibitor p27Kip1, and decreased 
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invasiveness [77]. High nuclear and cytoplasmic O-GlcNAc was also observed in breast cancer 
patients with increased relapse rates, increased sites of distant metastases and poor 
outcome [78]. In breast cancer, low OGA levels are linked to higher grade tumours and 
metastasis [80]. We have shown that the regulation of Uap1 by Fbxl17 and an unidentified 
kinase, are factors in determining the levels of the O-GlcNAcylated proteome. 
In summary, by screening for Fbxl17 interacting proteins we have identified Uap1 as a 
binding partner, rather than a substrate, of Fbxl17. I have established that Fbxl17, as a 
positive regulator of Uap1, controls global O-linked GlcNAcylation and as such, loss-of-
function mutations in FBXL17, caused by structural rearrangements in breast cancers, would 
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CHAPTER 5 - Role of Fbxl17 in DNA damage repair 
5. Introduction 
In the previous chapter, Uap1 was identified as a binding partner, but not a substrate, of 
Fbxl17 using a Y2H approach. The results of this assay, and other Fbxl17 substrate screens, 
highlight the importance of using a variety of experimental approaches to discover the 
regulatory networks of FBPs. Identifying potential interacting proteins through multiple 
approaches increases confidence in the interaction and verifies the approach. As such, I next 
carried out a mass spectrometry analysis of SCFFbxl17 E3 ubiquitin ligases (WT, ΔFbox and 
Δ10LRR) to try and identify the regulatory networks controlled by Fbxl17, the results of 
which are discussed in this chapter. 
Over 830 proteins were identified as potential interacting partners of Fbxl17. All published 
substrates of Fbxl17, except RRM2, were identified in the mass spectrometry screen, 
verifying the approach for substrate identification. Interestingly, we also noticed that several 
proteins involved in the DNA damage response (DDR), were identified as potential 
interacting partners of Fbxl17. The DDR is frequently dysregulated in breast cancers, and as 
such represents a cancer-relevant pathway that may be regulated by Fbxl17. As discussed in 
Chapter 3, FBXL17 is often rearranged in breast cancers leading to loss of SCFFbxl17 activity, 
which may therefore contribute to aberrant DDR in breast cancers.  
The DNA in our cells continually suffers damage from environmental and endogenous stimuli 
which can generate a variety of DNA lesions including DNA double-stand breaks (DSBs). DSBs 
are among the most harmful lesions and failure to accurately repair just one of these breaks 
can trigger permanent growth arrest and cell death and induce gross chromosomal 
rearrangements [106]. To cope with the continuous threat to genome integrity posed by 
DSBs, eukaryotic cells have evolved a complex DDR, which coordinates several DNA repair 
pathways with cell-cycle checkpoint activation. The two major DNA damage repair pathways, 
homologous recombination (HR) and non-homologous end-joining (NHEJ), are both tightly 
regulated by intricate control mechanisms that require the action of many proteins.  
In this chapter, I set out to test if Fbxl17 plays a role in the DDR and more specifically, 
whether Fbxl17 plays a role in HR or NHEJ. Several E3 ubiquitin ligases are already known to 
be involved in the DDR, such as RNF8, RNF168 and BRCA1 [279]. Through further 
investigation, I have identified the DNA-damage binding protein 53BP1 as a novel substrate 
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of SCFFbxl17. SCFFbxl17 can specifically ubiquitinate the BRCT domain of 53BP1 which I propose 
targets 53BP1 for degradation. 53BP1 is a well-known tumour suppressor involved in the 
inhibition of DNA end resectioning at DSBs and a key promoter of NHEJ.  
Given that the breast cancer-associated rearrangements in FBXL17 result in loss of SCFFbxl17 
activity (see Chapter 3), I also tested the effect of loss of Fbxl17 on the cellular response to 
DNA damage-inducing agents. Further understanding the role of Fbxl17 in the DDR will 
hopefully shed light on how Fbxl17, or indeed the lack thereof, may contribute to breast 
cancer pathogenesis. This may then identify potential therapeutic vulnerabilities of breast 
cancers containing FBXL17 mutations, which can be exploited for a subset of breast cancers. 
  




5.1 Identifying Fbxl17 interacting partners by mass spectrometry 
To identify interacting partners of Fbxl17, SCFFbxl17 E3 ubiquitin ligases were subjected to 
mass spectrometry analysis. HEK293T cells were transfected with the SCF subunits Cul1, 
Skp1 and Rbx1, and then co-transfected with either Fbxl17 WT, Fbxl17ΔFbox or 
Fbxl17Δ10LRR. Cells transfected with FLAG empty vector were used as a negative control. 
Fbxl17 was then immunoprecipitated from cells using α-FLAG agarose beads and eluted with 
FLAG peptide. Purified SCF ligases were then sent for mass spectrometry analysis.  
Mass spectrometry generated a list of 838 proteins, representing potential interacting 
partners of Fbxl17 and non-specific binding to the EV. The total spectrum counts for Fbxl17 
and the SCF subunits Cul1, Skp1 and Rbx1 are shown in Figure 5. 1. The total spectrum count 
represents the total number of spectra (peaks), within a sample, associated with a single 
protein/ protein group, including those shared with other proteins. The total spectrum 
counts for Fbxl17 were highest in the SCFFbxl17Δ10LRR sample (Figure 5. 1), which may reflect 
the increased expression of Fbxl17Δ10LRR we have observed previously (see Chapter 3, 
Figure 3. 4A). As expected SCFFbxl17ΔFbox had lower spectrum counts for Cul1 and Skp1 
Figure 5. 1 - Total spectrum count of SCF subunits and published Fbxl17 substrates 
Total spectrum count represents the total number of spectra associated to a single protein/protein 
group including those shared with other proteins. Colour scale (Green, high; yellow, medium; red, 
low) applied to total spectrum count for visualisation.  
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compared to SCFFbxl17 and SCFFbxl17Δ10LRR, and no spectra for Rbx1 (Figure 5. 1). However, the 
spectrum counts for Cul1 in the SCFFbxl17ΔFbox sample and for Fbxl17 and Cul1 in the EV 
sample were higher than expected, indicating background in the analysis. The samples were 
run on a highly sensitive Orbitrap Fusion™ Mass Spectrometer, which can detect peptides 
that are carried over between sample runs. However, the EV sample was run first to avoid 
this problem and so is unlikely to be the cause of the background counts in this case. 
Another possibility is that the EV sample was contaminated with another SCFFbxl17 ligase 
sample and overexpression of the SCF subunits may have led to off-target binding. 
SCFFbxl17ΔFbox may be able to homodimerise with WT Fbxl17 which would explain the slight 
increase in spectrum counts for Cul1 in the SCFFbxl17ΔFbox sample compared to the EV sample. 
Despite the background binding, there is a clear difference in total spectrum counts between 
the EV and SCFFbxl17 (WT, ΔFbox and Δ10LRR) ligase samples. 
The mass spectrometry analysis was carried out to identify novel substrates of Fbxl17. To 
verify this approach could identify Fbxl17 binding partners, I searched the list of hits for 
known Fbxl17 substrates and compared the total spectrum counts. The first thing I noted 
was the spectrum counts for known substrates were much lower than for the SCF subunits. 
This is as expected, given any co-immunoprecipitated proteins are expressed at endogenous 
levels in HEK293T cells prior to immunoprecipitation of Fbxl17, whereas Fbxl17 (WT, ΔFbox 
and Δ10LRR) and the SCF subunits were overexpressed. Manual inspection of the hits 
showed that the published substrates Sufu and PRMT1 co-immunoprecipitated with all three 
SCFFbxl17 ligases. This suggests that binding to these substrates does not require LRRs 2-11. 
The total spectrum count for PRMT1 was the same for EV and SCFFbxl17 samples, which 
further highlights background in the assay, and makes it difficult to distinguish true hits from 
background. In contrast, BACH1 and the KLHL proteins 7, 9, 12, 13, 20, 21, 25 and 26 co-
immunoprecipitated with SCFFbxl17ΔFbox only (Figure 5. 1). It may be that the deletion of the 
FBD stabilises binding to some substrates, as they cannot be subsequently ubiquitinated and 
targeted for degradation, and so remain bound to the FBP. Fbxl17ΔFbox still contains all 11 
LRRs and so we do not expect its ability to bind substrates to differ from WT Fbxl17. 
However, we do not know what effect loss of the FBD has on the 3D structure of 
Fbxl17ΔFbox. Uap1, the Fbxl17 interacting partner identified in the previous chapter, was 
not isolated in the mass spectrometry analysis, but interestingly, we isolated the HBP protein 
OGT which had the highest total spectrum count with SCFFbxl17ΔFbox (Figure 5. 1). 
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5.1.1 Mass spectrometry analysis with DAVID 
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) is a 
comprehensive online bioinformatic tool that serves to extract biological meaning from large 
lists of genes/proteins, such as those generated by mass spectrometry. DAVID provides a 
comprehensive set of functional annotation tools that utilise an integrated biological 
knowledgebase to cluster genes into functionally-related gene groups and pathways [280, 
281].  
In order to determine which pathways are targeted by Fbxl17, the 838 proteins that co-
immunoprecipitated with EV or SCFFbxl17 E3 ubiquitin ligases (WT, ΔFbox or Δ10LRR), as 
identified by mass spectrometry, were uploaded to the DAVID Bioinformatics Resources v6.8 
website (https://david.ncifcrf.gov/tools.jsp). The Functional Annotation tool was used to 
perform gene-enrichment analysis, pathway mapping and a gene/term similarity search 
using DAVID default annotations. The ‘Functional Annotation Clustering’ function clusters 
functionally similar terms associated with a gene list into groups. The top five enriched 
annotation clusters for the 838 proteins identified by mass spectrometry are shown in Figure 
5. 2. The ribosome/ribosomal proteins comprised the most enriched cluster with an 
enrichment score of 67.47 (groups with scores ≥1.3 are considered enriched). The group 
enrichment score represents the geometric mean of members’ p-values in a corresponding 
cluster. The top ranked groups are predicted to have consistently lower p-values for their 
associated members. Ribosomal proteins are amongst the most abundant proteins in the 
cell, so may also have a greater chance of being isolated by mass spectrometry. It is 
therefore unsurprising that the ribosome was the highest ranked cluster. 
To focus the DAVID analysis on potential pathways regulated by Fbxl17 I next looked at the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis annotation. The KEGG 
pathway reference database is a collection of pathway maps for major biological processes 
and highlights the proteins involved in these networks. Of the proteins in my list, 56% were 
assigned to one or more of 25 different enriched KEGG pathways. The most significantly 
enriched pathway was the Ribosome with 88 proteins, followed by the Proteasome, another 
highly abundant protein complex, and Spliceosome, with 30 and 38 proteins respectively 
(Figure 5. 3). Interestingly, several breast cancer-relevant pathways were identified, 
including the cell cycle, DNA replication and non-homologous end-joining, all of which are
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 mis-regulated in cancer.  DNA damage repair is often aberrant in breast cancers and leads to 
the high levels of genomic instability associated with this cancer type [282]. Thus, the 
involvement of Fbxl17 in NHEJ and in DDR represented an interesting avenue to investigate 
further.   
 
Figure 5. 2 - Functional Annotation Clustering Chart 
Chart report of annotation terms for all selected annotation categories of the 838 proteins identified 
by mass spectrometry, grouped into clusters. Top five annotation clusters shown (5/144), 
classification stringency set to medium. The enrichment score ranks the annotation clusters, using the 
geometric mean of all the enrichment p-values of each annotation term in the group, the higher, the 
more enriched. P-value is the significance of the gene-term enrichment calculated with a modified 
Fisher Exact’s test (cutoff 0.1). Count represents the number of genes involved in that term.   






Figure 5. 3 - KEGG Pathway functional annotation chart 
Annotation-term based view of the enriched KEGG pathways associated with the proteins identified in 
the mass spectrometry analysis for SCFFbxl17 E3 ubiquitin ligases. Count represents the number of 
genes from the mass spectrometry list associated with each pathway, minimum count threshold set 
to 2. Percentage (involved genes/total genes in query list). P-value is the significance of the gene-term 
enrichment calculated with a modified Fisher Exact’s test (cutoff 0.1).   
 
 
5.1.2 Co-immunoprecipitates of SCFFbxl17 ligases are enriched for DNA damage/repair 
proteins 
By surveying the functional annotation clustering, described previously (5.1.1), I found that 
of the mass spectrometry hits, DNA damage and DNA repair associated-proteins comprised 
the 19th most enriched cluster with an enrichment score of 5.16 (Figure 5. 4). This was 
ranked higher than the cluster containing BTB domain-containing proteins (cluster 24, 
enrichment score 4.24), which are known Fbxl17 substrates (Figure 5. 4).  




Figure 5. 4 - Fbxl17 co-immunoprecipitates are enriched for DNA damage/repair proteins 
Chart report of annotation terms for all selected annotation categories for the 838 proteins identified 
by mass spectrometry grouped into clusters. DNA damage/repair proteins are the 19th most enriched 
functional annotation cluster, comprising 43 unique proteins. P-value is the significance of the gene-
term enrichment calculated with a modified Fisher Exact’s test (cutoff 0.1). Count represents the 
number of genes involved in that term.   
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In total 43 proteins associated with DNA damage and/or DNA repair were co-
immunoprecipitated with Fbxl17 SCF ligases (WT, ΔFbox or Δ10LRR) or EV. Among the 
identified proteins were the NHEJ -associated proteins DNA-PKcs, Ku70 and Ku80 as well the 
HR and end resection-associated protein Mre11 (Figure 5. 5). Interestingly, the published 
Fbxl17 substrate BACH1 was also included in this list, suggesting the turnover of BACH1 by 
Fbxl17 may also have implications in the DDR.  
 
Figure 5. 5 - Total spectrum counts of DNA damage/repair proteins 
Total spectrum counts for Annotation Cluster 19 proteins. Counts represent the total number of 
spectra associated to a single protein/protein group, including those shared with other proteins. 
Colour scale (Green; high, yellow; medium, red; low) applied to total spectrum count for visualisation. 
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Similarly, to the known Fbxl17 substrates, SCFFbxl17ΔFbox had the highest total spectrum count 
for most of the DNA damage/repair proteins (35/43) (Figure 5. 5). Over half (24/43) were not 
detected in the EV sample suggesting they are true interacting partners of the Fbxl17 SCF E3 
ubiquitin ligases. The highest spectrum count, across all 43 proteins, was for DNA-PKcs in the 
SCFFbxl17Δ10LRR sample (Figure 5. 5).  
STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) analysis was also carried 
out for the 43 DNA damage/repair proteins. STRING is a biological database of known and 
predicted protein-protein interactions derived from five main sources: genomic context 
predictions, high-throughput experiments, co-expression, automated text mining and 
previous knowledge in databases. The DNA damage/repair proteins identified by mass 
spectrometry were uploaded to the STRING online search tool (https://string-db.org/) and a 
network of protein interactions was generated (Figure 5. 6). A clear cluster of protein-
protein interactions can be seen centred around Ku70 (XRCC6) and includes the NHEJ 
proteins Ku80 (XRCC5) and DNA-PKcs (PRKDC). Several HR-associated proteins are also 
within this cluster, including RPA and MRE11 which are both involved in DNA end resection. 
Together these data implicate Fbxl17 is affecting DNA damage and/or DNA repair proteins. I 
therefore set out to determine whether Fbxl17 plays a role in a specific DDR pathway. 




Figure 5. 6 - STRING analysis of DNA damage/ repair proteins identified by DAVID 
Network of known and predicted protein-protein interactions for the 43 DNA damage/repair proteins 
identified by mass spectrometry as potential interacting partners of SCFFbxl17. Line thickness indicates 
the strength of data support, set to medium confidence. Interactions devised from text-mining, high-
throughput experiments and co-expression data.    
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5.2 Fbxl17 knockdown results in a decrease in cell colony size  
To test whether the presence or absence of Fbxl17 affects the ability of cells to repair and 
recover from IR-induced DNA damage I performed a colony formation assay. Colony 
formation or clonogenic assays test the ability of single cells to grow into a colony in vitro 
following insult. U2OS cells were treated with control siRNA or Fbxl17 siRNA3 for 48 hours 
before plating to 6 well dishes at low density. Cells were then subjected to IR at 1,2,3 and 4 
Gy, to induce low levels of DNA damage, and unirradiated cells included as a control. Cells 
were cultured for ~10 days to allow colonies to form. After crystal violet staining, colonies 
(>50 cells) were counted and normalised to the unirradiated controls (Figure 5. 7A and B). 
Increasing the dose of IR consistently decreased cell survival and proliferation, as 
demonstrated by a reduction in colony formation (Figure 5. 7A and B). Overall, knockdown 
of Fbxl17 had little effect on colony formation number following IR. siRNA3 treated cells 
showed the same survival percentages as the control across all IR dosages, except for 2Gy, 
where siRNA3 cells have a slightly reduced survival (~5%). The experiment would need to be 
repeated to test if this decrease is significant.  
As I identified no difference in total colony number between control and knockdown cells, I 
next looked to see if there was a difference in colony size. Stained colonies were imaged, 
magnified 2X and then differentiated into small (<1mm diameter) and large (>1mm) 
colonies. The number of small colonies was similar, when comparing the controls with 
Fbxl17 siRNA3 knockdown cells. However, my data shows that there are fewer large colonies 
in the Fbxl17 knockdown cells, compared to control, after exposure to 1Gy and 2Gy of IR 
(Figure 5. 7C). One possible explanation for this, is that Fbxl17 knockdown cells take longer 
to repair the IR-induced damage and so do not form as many large colonies compared to the 
control cells. Alternatively, knockdown of Fbxl17 may slow the proliferation rate of the cells 
but have no effect on DNA damage repair. As before, the experiment would need to be 
repeated to test if the difference in colony size is significant. This suggests that knockdown 
of Fbxl17 impairs or slows the cells ability to repair and recover from IR-induced DNA 
damage. 




Figure 5. 7 - Fbxl17 knockdown does not affect clonogenic ability of U2OS cells 
(A) Representative scanned images (top panel), and corresponding black and white images (bottom 
panel), of fixed colonies from a clonogenic assay. U2OS cells treated with Fbxl17 siRNA3 or control 
siRNA and irradiated at the indicated doses (Note: 1Gy and 3Gy images not shown). Colonies formed 
over 10 days fixed and stained with crystal violet staining solution. (B) Graph depicting the survival 
percentage of plated cells at the indicated IR dosages. Values represent the average number of 
colonies from 3 biological replicates, relative to unirradiated (0 Gy) cells. (C) Graphs representing 
small and large colonies formed after IR. Values represent mean of three biological replicates, 
relative to unirradiated cells.  
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5.3 Cell cycle analysis 
The clonogenic assay suggested that knockdown of Fbxl17 slows cell recovery from IR-
induced DNA damage. This suggests that Fbxl17 knockdown cells may be less efficient at 
DNA damage repair. HR and NHEJ operate at different phases of the cell cycle, and so we 
wanted to test whether this defect could be linked to a certain cell cycle phase, and 
therefore a certain damage repair pathway. To test this, I performed a cell cycle analysis of 
Fbxl17 knockdown cells following IR-induced DNA damage. In order to stably knockdown 
Fbxl17 protein expression, I first designed and constructed three FBXL17 targeting shRNA 
plasmids to inhibit Fbxl17 mRNA expression (see section 2.1.6). Fbxl17 shRNA3, which 
targets the 3’ untranslated region (UTR) of FBXL17, resulted in an ~80% knockdown of Fbxl17 
steady state protein levels in MCF7 (Figure 5. 8) and U2OS cells but had no effect in HEK293T 
cells (data not shown).  
 
Figure 5. 8 - shRNA knockdown of Fbxl17 expression in MCF7 cells 
MCF7 cells infected with Fbxl17 targeting shRNA constructs or empty vector. Whole cell lysates 
immunoblotted for indicated antibodies. 
 
U2OS cells stably expressing Fbxl17 shRNA3 or mir30 control were irradiated (2Gy) to induce 
low levels of DNA damage. Cells were then harvested and fixed at 4, 8, 16, 24 and 48h post-
irradiation, un-irradiated cells were collected at 4h and 48h as controls. Cells were 
subsequently stained with propidium iodide (PI), a fluorescent DNA intercalating agent, for 
flow cytometry analysis. PI stains cells in proportion to the amount of DNA in the cells. Most 
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cells within a population reside in G1 phase of the cell cycle, as they enter S and G2 phases 
their DNA content increases, so the DNA stains proportionally more with PI, and therefore 
the cells fluoresce more brightly (Figure 5. 9A). Both U2OS cells expressing Fbxl17 shRNA3, 
and those expressing mir30 control, arrested after IR, illustrated by an accumulation of cells 
in G2/M at 8h and 16h post-irradiation (Figure 5. 9B and C). This suggests that knockdown of 
Fbxl17 does not affect DNA damage sensing or activation of cell cycle checkpoints. For the 
most part, the two cell lines behaved the same in response to damage. At 8h and 16h the 
Fbxl17 knockdown cells have a greater population of cells in G1 than the controls, 
accompanied by a subtle decrease in cells in S phase. This perhaps suggests the knockdown 
cells are cycling quicker and proceeding without first repairing damaged DNA or that the 
cells have arrested in G1 and are unable to recover from the DNA damage as fast. Both cell 
lines had recovered from IR-induced damage by 24h, with the largest percentage of cells 
once again in G1.  
This preliminary data shows that Fbxl17 knockdown does not have a clear effect on the 
ability of cells to repair IR-induced DNA damage. The experiment needs to be repeated to 
determine if the subtle changes observed are significant. It is worth noting that over time, 
the cell lines expressing Fbxl17 shRNA3 lost their knockdown of Fbxl17 protein expression. 
This suggests that either the cells with low expression of Fbxl17 are being selected against, 
or the cells are silencing the shRNA construct to overcome its inhibitory effects. Transient 
knockdown of Fbxl17 using siRNA would overcome this issue and may also be a better 
approach given the clonogenic assay results were observed with siRNA-mediated 
knockdown of Fbxl17 expression. Synchronising the cells at the same cell cycle stage prior to 
IR may also help to enhance the subtle differences we have observed. DSBs induced by IR 
can be repaired by both HR and NHEJ and therefore inducing DNA damage by other 
methods, such as treatment with DNA damaging drugs e.g. Camptothecin, which generates 
DSBs that can only be repaired by HR, may be a more informative approach.  




Figure 5. 9 - Cell cycle analysis of Fbxl17 knockdown cells in response to IR 
(A) Schematic showing a typical flow cytometry plot for DNA content after PI staining. Labels indicate 
the cell cycle stages associated with each part of the curve. (B) Cell cycle analysis of U2OS cells stably 
expressing Fbxl17 shRNA3 or mir30 control. Histograms generated by flow cytometry analysis of PI 
stained cells, fixed at the indicated time points, following IR-induced DNA damage, NT, no treatment/ 
unirradiated control. (C) Quantification of (C) showing the percentage of cells in each stage of the cell 
cycle at the indicated time points, NT, no treatment/ unirradiated control. 
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5.4 Loss of Fbxl17 sensitises cells to Camptothecin treatment 
The mass spectrometry analysis suggested that Fbxl17 may interact with both HR and NHEJ-
associated proteins. To test if either pathway is impaired following Fbxl17 knockdown I 
treated Fbxl17 knockdown cells with two DNA damaging inducing agents; Camptothecin 
(CPT), a topoisomerase I inhibitor that induces single-ended DSBs during replication, which 
requires HR for accurate repair, and etoposide (ETO), a topoisomerase II inhibitor that 
induces DSBs predominantly repaired by NHEJ. U2OS cells were treated with Fbxl17 siRNA3 
or control siRNA for 48h before treatment with 10µM CPT or ETO. After 24h of treatment 
cells were stained with the apoptotic cell marker Annexin V and PI. Flow cytometry analysis 
was used to determine the percentage of double positive cells as a readout of apoptotic cells 
(Figure 5. 10 B). Unexpectedly, ETO had no effect on either cell line (data not shown), 
suggesting the drug concentration was incorrect or the cell line used is resistant to ETO. CPT 
treatment on the other hand, induced apoptosis in both the control and Fbxl17 knockdown 
lines, observed as an increase in Annexin V/PI double positive cells. Knockdown of Fbxl17 
resulted in a decrease in double Annexin V/PI double positive cells compared to the control, 
suggesting Fbxl17 affects the cellular response to CPT (Figure 5. 10B). 
To test this further, I titrated the concentration of CPT from 0.0625µM to 10µM and treated 
the cells as above (Figure 5. 11). As observed previously, at 10µM, knockdown of Fbxl17 
resulted in a decrease in Annexin V/PI double positive cells. However, at low concentrations 
of CPT, up to and including 2.5µM, knockdown of Fbxl17 expression increased the 
percentage of apoptotic cells, suggesting cells lacking Fbxl17 are more sensitive to CPT. At 
5µM the percentage of apoptotic cells was the same between the control and siRNA3 
treated cells. Collectively this data suggests that Fbxl17 may be important for DSB repair by 
HR due to the altered response to CPT in Fbxl17 knockdown cells.  
 




Figure 5. 10 - Knockdown of Fbxl17 protects cells from Camptothecin-induced apoptosis. 
(A) A representative Annexin V-Alexa Fluor 647/ propidium iodide staining and flow cytometric 
analysis of U2OS cells treated with Fbxl17 siRNA3 or control siRNA, undergoing apoptosis following 
treatment with 10µM Camptothecin for 24h, n=2. (B) Graphical representation of Annexin V-Alexa 
Fluor 647/ propidium iodide double positive cells following flow cytometric analysis of U2OS cells 
treated with Fbxl17 siRNA3 or control siRNA, treated with 10µM Camptothecin for 24h, data 
represents two biological repeats for each condition, both shown side by side.   
 




Figure 5. 11 - Fbxl17 knockdown sensitises cells to low concentrations of Camptothecin 
Graphical representation of Annexin V-Alexa Fluor 647/propidium iodide double positive cells 
following cytometric analysis of U2OS cells treated with Fbxl17 siRNA3 or control siRNA, subjected to 
increasing concentrations (0.625, 1.25, 2.5, 5 and 10μM) of Camptothecin for 24h, n=1.  
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5.5 Fbxl17 is recruited to DNA damage sites 
DNA damage repair proteins are rapidly recruited to DSBs to ensure rapid and precise repair. 
Laser micro-irradiation in combination with live cell microscopy can be used to visualise this 
highly dynamic process in real-time. In short, cells are pre-sensitised with the 
photosensitiser BrdU which is incorporated into DNA. Upon laser micro-irradiation BrdU 
forms radicals, which induce DNA breaks specifically in the region of interest that was 
irradiated. To determine if Fbxl17 is recruited to DNA damage sites, U2OS cells stably 
expressing 53BP1 fused to RFP were transfected with Fbxl17 fused to the fluorescent tag 
Venus at its C-terminus. 53BP1 is a known DNA damage repair protein that has been shown 
to accumulate at laser-induced DSBs and so acted as a positive control in this experiment 
[283]. 53BP1 accumulates rapidly at break sites where it inhibits DNA end resection to 
promote repair by NHEJ. DNA double-strand breaks (DSBs) were induced in the transfected 
Figure 5. 12 - Fbxl17-Venus is not recruited to laser-induced DNA breaks. 
Confocal images of live U2OS cells, at indicated time points, after laser micro-irradiation to induce 
DNA damage. A 405nm laser beam was focused on BrdU-sensitised cells and Venus-tagged Fbxl17 
(green) was monitored for accumulation. RFP-53BP1 was used as a positive control. 
CHAPTER 5                                                                                Role of Fbxl17 in DNA damage repair 
140 
 
U2OS cells by laser micro-irradiation in lines across the nucleus. Cells were imaged at 
approximately 10 minutes and 30 minutes post DNA damage induction (Figure 5. 12). RFP-
53BP1 showed clear accumulation at the laser induced DSB lines which was maintained 
throughout, but Fbxl17-Venus showed no accumulation in any cell across the observed time-
frame (Figure 5. 12).   
During the initial laser lines experiment, we noted that the Fbxl17-Venus construct appeared 
to show exclusively cytoplasmic localisation which contrasted to what I had previously 
observed for endogenous Fbxl17 (see section 3.2.3). We proposed that the C-terminal fusion 
of Venus to Fbxl17 may be interfering with its subcellular localisation. To overcome this, I 
cloned Fbxl17 into a pEGFP-C1 vector to produce an Fbxl17 construct with GFP fused at the 
N-terminus of Fbxl17. Confocal microscopy confirmed the C-terminal Fbxl17 fusion protein 
localised mainly to the nucleus consistent with that of endogenous Fbxl17 (Figure 5. 13).  
Figure 5. 13 - Localisation of N-terminally GFP-tagged Fbxl17. 
(A) Subcellular localisation of endogenous Fbxl17 using immunostaining with FBXL17 antibodies and 
Alexa Fluor 488. (B) Live imaging of a U2OS cell expressing an N-terminally tagged GFP-Fbxl17 
construct. Scale bar is 15μm. 
The laser micro-irradiation experiments were repeated using GFP-Fbxl17 in U2OS cells 
expressing RFP-53BP1. We found that Fbxl17 is recruited to the sites of DNA damage, albeit 
to a lesser extent than the positive control 53BP1. Fbxl17 accumulation could be observed 
from 2-minutes post-irradiation, coincident with 53BP1, and remained at the DNA damage 
site for the entire observed time-frame (7 minutes post-irradiation) (Figure 5. 14). Cells 
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expressing RFP-53BP1 alone were also irradiated to confirm the signal observed in the GFP 
channel was not bleed-through from the RFP channel; no signal was detected in the GFP 
channel in this instance (data not shown). 
Figure 5. 14 - Fbxl17 is recruited to DNA damage sites 
Laser micro-irradiation of U2OS cells stably expressing RFP-53BP1 transfected with GFP-Fbxl17 to 
determine recruitment of Fbxl17 to double-strand breaks (bottom panel). RFP-53BP1 (top panel) used 
as a positive control. A 405nm laser beam was focused on BrdU-sensitised cells and live-cell images 
taken at the indicated time points by confocal microscopy. White triangles indicate site of micro-
irradiation across nucleus, images taken at 1 min intervals, scale bar represents 15µm.  
CHAPTER 5                                                                                Role of Fbxl17 in DNA damage repair 
142 
 
5.6 Fbxl17 overexpression decreases 53BP1 expression  
After transfecting U2OS cells expressing RFP-53BP1 with GFP-Fbxl17, we were surprised to 
see, by confocal microscopy, that cells very rarely expressed both proteins at once, inferred 
by the absence of RFP signal in GFP positive cells. To investigate this further, U2OS cells or 
U2OS cells stably expressing RFP-53BP1 were transfected with GFP-Fbxl17 or GFP EV control 
and the steady state levels of 53BP1 were monitored by immunoblotting. Overexpression of 
Fbxl17 in both cases resulted in decreased 53BP1 protein expression (Figure 5. 15, 
comparing lane 2 to 3, and 5 to 6). Transfection of GFP-EV unexpectedly increased 53BP1 
expression (Figure 5. 15, comparing lane 4 to 5). This may be a cellular response to 
transfection which is inherently stressful on cells. These data suggest Fbxl17 is targeting 




Figure 5. 15 - Fbxl17 overexpression decreases 53BP1 steady state levels. 
(A) U2OS or U2OS stably expressing RFP-53BP1 transfected with GFP-Fbxl17 WT or GFP empty vector 
(EV) for 48h, whole cell lysates immunoblotted with the indicated antibodies, (-) indicates 
untransfected cells, n=1. (B) Quantification of the first three lanes in (A) showing endogenous 53BP1 
expression in U2OS cells transfected with GFP-Fbxl17 or GFP EV. 53BP1 expression normalised to 
GAPDH, n=1. 
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5.7 Fbxl17 ubiquitinates the BRCT domain of 53BP1 
Fbxl17 ubiquitinates substrates to target them for degradation. We therefore proposed that 
the decrease in 53BP1 steady state levels is due to ubiquitination by Fbxl17. 53BP1 is a large 
protein >200kDa and when resolved by SDS-PAGE runs at over 250kDa, therefore observing 
size shifts in 53BP1 as a result of ubiquitination is difficult to visualise by immunoblotting 
techniques. Indeed, we did not observe a size shift with 53BP1 fused to RFP which is ~27 
kDa, compared to a single ubiquitin molecule which is only 8 kDa.  To overcome this, I 
acquired full-length 53BP1 and five 53BP1 truncated constructs described in [284], from the 
Jackson lab at the Gurdon Institute, that map the entire length of the protein: full-length 
53BP1 (1-1972aa), 53BP1ΔBRCT (1-1798aa, deletion of tandem BRCT domain), NLS_53BP1_N 
(1-1052aa with NLS fused to N-terminus), 53BP1_C (1052-1972aa, C-terminal fragment), 
53BP1_BRCT (1708-1972aa, NLS and BRCT domain only) and 53BP1_CΔBRCT (1052-1709aa, 
C-terminus fragment with deletion of BRCT domain) (Figure 5. 16A). To ensure the 
constructs could be expressed in mammalian cells, HEK293T cells were transfected with all 
six constructs. 48h after transfection cells were lysed and resolved on a 4-20% Tris-Glycine 
gradient gel by SDS-PAGE. All constructs were well expressed, and we noted that higher 
molecular weight smears characteristic of post-translational modification by ubiquitin were 
present in two of the lanes, 53BP1_C and 53BP1_BRCT (Figure 5. 16B, lanes 4 and 5). This 
suggested that the C-terminus of 53BP1 is the acceptor site for this modification. Moreover, 
given that the higher molecular weight smear was abolished in cells expressing the 53BP1 
construct lacking the tandem BRCT domain (Figure 5. 16B, lane 6) we hypothesised that this 
domain of 53BP1 is ubiquitinated.  
  




Figure 5. 16 - Schematic of 53BP1 domains and truncated constructs. 
(A) Full-length 53BP1 contains a C-terminal nuclear localisation signal (NLS, black line) and tandem 
BRCT domain (dark blue boxes). All constructs are HA-tagged at the N-terminus. In NLS 53BP1-N the 
NLS of 53BP1 was fused to the N-terminus of an N-terminal 53BP1 fragment. (B) Protein lysates from 
HEK293T cells transfected with the indicated 53BP1 constructs resolved on a gradient gel by SDS-
PAGE and immunoblotted with anti-HA antibody, * indicates band representing 53BP1 fragment, n=2. 
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To test whether SCFFbxl17 could ubiquitinate the tandem BRCT domain of 53BP1, we 
conducted an in vitro ubiquitination assay. HA-53BP1_BRCT was purified from HEK293T cells 
by immunoprecipitation and eluted from agarose beads with HA-peptide. HA-Sufu was 
included as a positive control. Higher molecular weight smears can be seen after the 
addition of SCFFbxl17 (Figure 5. 17, lane 5). SCFFbxl17ΔFbox shows reduced ubiquitination activity 
against 53BP1_BRCT compared to SCFFbxl17 (Figure 5. 17, lane 6) suggesting Fbxl17 is capable 
of ubiquitinating 53BP1_BRCT dependent on its F-box domain. HA-Sufu showed a similar 













Figure 5. 17 - WT Fbxl17 ubiquitinates the BRCT domain of 53BP1 
In vitro ubiquitination assay of SCFFbxl17 and SCFFbxl17ΔFbox ligase complexes in combination with HA-
tagged 53BP1_BRCT or HA-tagged Sufu in the presence of a ubiquitin mix (ubiquitin buffer, UBE1, 
UbcH5a and ATP). Proteins resolved by SDS-PAGE and membrane probed with anti-HA antibody, n=5. 
Arrow indicates position of band representing 53BP1_BRCT (resolves at ~70 kDa). Experiment done 
by Gus Rottenberg, reproduced here with permission. 
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Despite the increased ubiquitination observed after addition of SCFFbxl17, the assay contained 
a lot of background ubiquitination. Higher molecular weight smears were observed for 
53BP1_BRCT even in the absence of Fbxl17 SCF ligases (Figure 5. 17, lanes 1 and 2). This was 
not due to auto-ubiquitination of SCFFbxl17 and SCFFbxl17ΔFbox as the ligases incubated with Ub 
mix alone did not result in smears (Figure 5. 17, lanes 3 and 4). We hypothesised that the 
53BP1_BRCT, which is isolated from HEK293T cells, may already be ubiquitinated before it is 
used in this assay or that an E3 ubiquitin ligase was being co-immunoprecipitated with 
53BP1_BRCT and would therefore be present in 53BP1_BRCT eluates. As SCFFbxl17 was shown 
to increase the ubiquitination of 53BP1_BRCT, we proposed that endogenous Fbxl17 may be 
present in 53BP1_BRCT eluates. To test this, we immunoblotted the 53BP1_BRCT protein 
purified from HEK293T cells, following lysis with two different lysis buffers, for the presence 
of Fbxl17. Endogenous Fbxl17 was identified in both samples suggesting 53BP1 and Fbxl17 





Figure 5. 18 - Endogenous Fbxl17 co-immunoprecipitates with HA-53BP1 BRCT. 
Immunoprecipitates; using anti-HA beads and elution with HA peptide, of HEK293T cells expressing 
HA-53BP1 BRCT lysed in KCl or RIPA buffer and probed for endogenous Fbxl17. Experiment done by 
Gus Rottenberg, reproduced here with permission. 
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Since the data in Figure 5. 18 suggest that Fbxl17 is co-immunoprecipitating with 53BP1 
isolated from cells, this might explain the high background seen in the ubiquitination assays. 
To determine if this was the case and to try to overcome this, 53BP1_BRCT was purified from 
U2OS cells treated with Fbxl17 siRNA3 to knockdown Fbxl17 expression. This batch of 
purified 53BP1_BRCT was subsequently used in an in vitro ubiquitination assay and 
53BP1_BRCT ubiquitination detected by immunoblotting. Remarkably, the high background 
observed previously was completely abolished (Figure 5. 19, lanes 1 and 2). A higher 
molecular weight smear was present after the addition of SCFFbxl17 but SCFFbxl17ΔFbox showed 
no ubiquitination activity towards 53BP1_BRCT (Figure 5. 19, lanes 5 and 6 respectively). 
SCFSkp2, another LRR-containing FBP, also showed no ubiquitination activity (Figure 5. 19, 
lane 7), further highlighting that the ubiquitination of 53BP1_BRCT is specific to the ligase 
activity of Fbxl17.  
Figure 5. 19 - WT Fbxl17 ubiquitinates the BRCT domain of 53BP1. 
In vitro ubiquitination assay of SCFFbxl17 and SCFFbxl17ΔFbox ligase complexes or the LRR-domain 
containing FBP Skp2 in combination with HA-tagged 53BP1_BRCT purified from U2OS cells treated 
with an siRNA targeting Fbxl17. Reaction performed in the presence of a ubiquitin mix (ubiquitin 
buffer, UBE1, UbcH5a and ATP). Proteins resolved by SDS-PAGE and membrane probed with anti-HA 
antibody, n=3. 
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5.8 Loss of Fbxl17 LRRs abolishes ubiquitination of 53BP1 
Finally, I tested whether Fbxl17 truncation mutants could ubiquitinate 53BP1_BRCT. I 
performed an in vitro ubiquitination assay with HA-53BP1_BRCT purified from Fbxl17 siRNA-
treated U2OS cells, in the presence of SCFFbxl17, SCFFbxl17ΔFbox, SCFFbxl17Δ3LRR or SCFFbxl17Δ10LRR. 
Samples were resolved by SDS-PAGE and immunoblotted for the HA-tag on 53BP1_BRCT. As 
observed previously, a higher molecular weight smear indicative of polyubiquitination was 
present after the addition of SCFFbxl17 but abolished with SCFFbxl17ΔFbox (Figure 5. 20, lanes 2 
and 3 respectively). Both LRR truncation mutants showed no ubiquitination activity towards 
53BP1_BRCT, comparable to SCFFbxl17ΔFbox (Figure 5. 20, lanes 4 and 5), suggesting the 
















Figure 5. 20 - Loss of Fbxl17 LRRs impairs ubiquitination of 53BP1_BRCT. 
In vitro ubiquitination assay of SCFFbxl17 and mutant ligase complexes in combination with HA-tagged 
53BP1_BRCT purified from U2OS cells treated with an siRNA targeting Fbxl17, in the presence of a 
ubiquitin mix (ubiquitin buffer, UBE1, UbcH5a and ATP). Proteins resolved by SDS-PAGE and 
membrane probed with anti-HA antibody, n=1. 
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5.9 Fbxl17 interacts with DNA damage response proteins  
We serendipitously identified 53BP1 as a substrate of Fbxl17 but note that it was not 
identified in the Y2H or the mass spectrometry screen. The mass spectrometry results 
suggested Fbxl17 interacts with other DNA damage response proteins. However, due to high 
levels of background in the assay it was difficult to identify true interacting partners of 
Fbxl17. Mammalian expression constructs of three proteins from this list, Ku70, Ku80 and 
DDB1, were kindly provided by the Jackson and Khoronenkova laboratories. I performed a 
co-immunoprecipitation assay in mammalian cells to test independently if these were 
interacting partners of WT Fbxl17. Immunoprecipitates from HEK293T cells expressing either 
Ku70, Ku80, DDB1, or FLAG EV control, were co-transfected with HA-tagged Fbxl17 (1-
701aa). Lysates were immunoprecipitated with anti-FLAG agarose beads and immunoblotted 
for HA (Fbxl17). Cells were lysed and immunoprecipitated in the presence of the 
endonuclease benzonase to degrade contaminating DNA/RNA that might potentially bridge, 
non-specifically, proteins which metabolise DNA. Ku70 and Ku80 were expressed well in 
HEK293T cells (Figure 5. 21, input) but only weak expression of DDB1 was detected. Fbxl17 
expression was low in the Ku70 and Ku80 samples, suggesting an issue with transfection for 
these samples, as Fbxl17 was detected in the DDB1 and EV lanes (Figure 5. 21, input). 
Alternatively, overexpression of the Ku proteins may promote Fbxl17 degradation. Western 
blotting revealed that Fbxl17 co-immunoprecipitates with all three DNA damage/repair 
proteins (Figure 5. 21). Concurrent with the total spectrum counts (Figure 5. 5), binding of 
Fbxl17 was strongest with DDB1. However, this most likely reflects the difference in Fbxl17 
input, not the binding capacity of Fbxl17.  This data verifies that three of the proteins 
identified by mass spectrometry analysis can co-immunoprecipitate with Fbxl17, suggesting 












Figure 5. 21 - Co-immunoprecipitation of Fbxl17 with DDR proteins 
Immunoprecipitates, using anti-FLAG beads, of HEK293T cells expressing the FLAG-tagged DNA 
damage/repair proteins Ku70, Ku80 or DDB1, or empty-vector control, co-transfected with HA-tagged 
Fbxl17, immunoblotted with the indicated antibodies. Right panel represents a longer exposure of the 
adjacent anti-FLAG blot, n=1. 
  




To identify further substrates of Fbxl17, I performed a mass spectrometry analysis of purified 
Fbxl17 SCF E3 ubiquitin ligases. Over 830 proteins were identified as potential interacting 
partners of Fbxl17. Among these proteins were the known Fbxl17 substrates BACH1, Sufu, 
PRMT1 and several Klhl proteins, verifying the mass spectrometry approach for substrate 
discovery. In addition, no spectra associated with these proteins were isolated in the EV 
sample, except for PRMT1, for which only 2 counts were recorded in the EV sample. 
However, many of the known substrates of Fbxl17 were only isolated in the SCFFbxl17ΔFbox 
sample. It may be that the deletion of the FBD stabilises binding to some substrates, as they 
cannot be subsequently ubiquitinated and targeted for degradation, and so remain bound to 
the FBP. As a result, the purification conditions for the ligases sent for mass spectrometry 
analysis may need to be optimised further. It is possible that the wash steps during ligase 
purification are too stringent and are abolishing the interactions between SCFFbxl17 and its 
substrates. Due to the background observed in the EV sample and the lack of binding of 
known substrates to SCFFbxl17 I did not exclude any proteins for DAVID analysis. A more 
sophisticated approach is most likely needed to identify potential interacting partners of 
Fbxl17 with some degree of confidence and to test the difference in binding between Fbxl17 
and the breast cancer-associated truncation mutants.  
DAVID analysis of the full list of interacting proteins showed that DNA damage- and DNA 
repair-associated proteins were enriched, suggesting a role for Fbxl17 in the DDR. It is worth 
noting that the samples prepared for mass spectrometry were not treated with an 
endonuclease to degrade DNA and RNA in the samples. Therefore, it is possible that 
contaminating DNA or RNA could have bound non-specifically to the anti-FLAG agarose and 
resulted in the co-immunoprecipitation of DNA binding proteins. However, this is unlikely to 
be the case, given over half (24/43) of the DNA damage/repair associated proteins were not 
detected in the EV sample, and a further 14 recorded total spectrum counts of 4 or less. 
Furthermore, I verified that Fbxl17 can bind to three of the DDR proteins identified by mass 
spectrometry, Ku70, Ku80 and DDB1, even after benzonase treatment. Fbxl17 may be 
required for the removal of Ku heterodimers from DNA ends, to promote DNA end resection 
and HR. 
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The 43 DNA damage/repair proteins identified by mass spectrometry are involved in several 
repair pathways including HR and NHEJ. In this chapter I set out to determine if Fbxl17 is 
required for DNA damage repair and whether Fbxl17 plays a role in a specific repair 
pathway. My preliminary clonogenic assay data suggests that Fbxl17 is required for the 
repair of and recovery from IR-induced DNA damage, as knockdown of Fbxl17 resulted in 
decreased colony size. This defect did not seem to be associated with a specific cell cycle 
stage. However, I have shown that knockdown of Fbxl17 expression changes the response of 
cells to the DNA damaging agent Camptothecin. Knockdown of Fbxl17 expression sensitised 
cells to low concentrations of CPT and induced apoptosis. FBXL17 is frequently rearranged in 
breast cancers resulting in loss of Fbxl17 activity. As such, CPT treatment may be a useful 
therapeutic approach for treating tumours with FBXL17 rearrangements. It would be 
important to study the relationship between Fbxl17 knockdown and CPT sensitivity in a 
breast cell line to rule out cell-specific effects.  
CPT induces DSBs as a result of replication fork collision during S phase, which can only be 
repaired efficiently by HR. Therefore, my data suggests Fbxl17 is required for HR. The Traffic 
light reporter (TLR) assay, which employs a dual fluorescent readout to monitor the 
efficiency of DNA damage repair by HR and NHEJ simultaneously, could be used to further 
test this [285]. Although there is not yet enough data to conclusively show Fbxl17 is 
important for HR, I have been able to show that Fbxl17 is recruited to DNA damage sites. 
Fbxl17 is recruited to DNA damage sites within 2 minutes of damage induction and is 
maintained at these sites. It is still unclear how Fbxl17 is recruited to the DNA damage sites 
and indeed the role it plays there. Fbxl17 may localise independently of other factors or may 
be brought to break sites via interactions with other DNA damage proteins such as 53BP1. 
Loss of LRRs reduces Fbxl17 E3 ligase activity and its ability to bind substrates, it would 
therefore be interesting to test if the Fbxl17 truncation mutants are still recruited to sites of 
damage and if Fbxl17 can still be recruited in the absence of 53BP1. 
Within this chapter I have identified the well-known DNA damage protein, 53BP1, as a novel 
substrate of Fbxl17. I have shown in vitro, that Fbxl17 can ubiquitinate the tandem BRCT 
domain of 53BP1 and loss of Fbxl17 LRRs abolished this modification. Furthermore, 
endogenous Fbxl17 co-immunoprecipitates with 53BP1_BRCT. This interaction may be 
important for the recruitment of Fbxl17 to sites of DNA damage. The tandem BRCT domain 
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of 53BP1 is an important protein-protein binding domain that facilitates the interaction of 
53BP1 with the known tumour suppressor p53 [155]. The chromatin modulator EXPAND1 
also binds to the BRCT domain of 53BP1, and relies on this interaction for its accumulation at 
DSB sites [286]. The ubiquitination of the BRCT domain of 53BP1 by Fbxl17, may facilitate 
53BP1 binding to other proteins. Indeed, it has already been shown that the DDR protein 
MDC1 requires ubiquitination of its tandem BRCT domain to facilitate binding to RAP80, a 
damage response protein that recruits BRCA1 to sites of damage [287].  
A more likely consequence of 53BP1 ubiquitination by Fbxl17, is that it targets 53BP1 for 
proteasomal degradation. I found that overexpression of Fbxl17 leads to a decrease in 53BP1 
steady state protein levels and 53BP1 levels have already been shown to be regulated by 
ubiquitination. Pozo et al. showed that, under normal growth conditions, 53BP1 exists in 
three forms; chromatin-bound, lamin A/C-bound and free forms. The free form undergoes 
UbcH7-dependent proteasomal degradation which maintains a 53BP1 equilibrium [288]. 
Deletion of UbcH7 stabilised 53BP1 leading to an imbalance in DNA repair pathway choice. 
Cells favoured NHEJ and, in agreement with what I have observed for Fbxl17 depletion, 
knockdown of UbcH7 sensitised cells to CPT treatment [288, 289].   
53BP1 was not identified as a potential interacting partner of Fbxl17 by mass spectrometry. 
However, other BRCT domain containing proteins were isolated, including replication factor 
C subunit 1 (RFC1) and the DNA damage protein PARP1. Mena, et al. have already shown 
that Fbxl17 can target proteins with shared domains, via its capacity to target BTB domain-
containing proteins for degradation [251]. BRCT domain-containing proteins may therefore 
represent a second group of proteins regulated by Fbxl17. In addition, I have verified that 
Fbxl17 can co-immunoprecipitate with other DDR proteins that were identified by mass 
spectrometry, namely Ku70, Ku80 and DDB1. This suggests multiple DDR proteins may be 
substrates for Fbxl17.  
Combining my data, regarding Fbxl17 and 53BP1, I propose a model whereby Fbxl17 
regulates the expression of 53BP1 to control DNA damage repair pathway choice. In the 
presence of Fbxl17, 53BP1 expression is maintained at an equilibrium by the ubiquitination 
and subsequent degradation of excess/free 53BP1 (Figure 5. 22, left panel), potentially 
through an interaction with the E2 ubiquitin ligase UbcH7. In the absence of Fbxl17, free 
53BP1 accumulates leading to hyper-inhibition of BRCA1 and HR. This leads to the promotion 
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of NHEJ and a reduced capacity for repair by HR (Figure 5. 22, right panel). This would 
explain the increased sensitivity to CPT we have observed. Therefore, by identifying the DNA 
repair pathway regulated by Fbxl17, we can exploit the vulnerabilities caused by Fbxl17 





Figure 5. 22 - Proposed model of interaction between Fbxl17 and 53BP1 
I propose a model whereby, Fbxl17 ubiquitinates free 53BP1 to target it for proteasomal degradation, to 
control 53BP1 expression levels. In the absence of Fbxl17, 53BP1 accumulates and hyper-inhibits BRCA1 
and therefore HR, leading to the promotion of DNA repair by NHEJ. 
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CHAPTER 6 - General Discussion 
Breast cancer remains the most common cancer in women globally and is characterised by 
vast genomic instability and tumour heterogeneity. Increasingly, somatic rearrangements 
are found to be prevalent in breast cancer and importantly, are proving to be therapeutically 
significant. By surveying the METABRIC array-CGH copy number data, it was previously 
shown that the F-box protein encoded by FBXL17 is rearranged in ~7% of breast cancer cases 
[255]. In agreement with this, I have observed further examples of FBXL17 rearrangements 
in paired-end whole-genome DNA and RNA sequencing data from 250 primary breast 
tumours, of which ~2% contained rearrangements in FBXL17.  
What is most striking about FBXL17 rearrangements, is the consistency with which they 
target the region of the gene that encodes the substrate-binding leucine rich repeat (LRR) 
domain of Fbxl17. The rearrangements I observed in primary breast tumours often truncate 
Fbxl17, removing some or all the LRRs and sometimes also the FBD. The non-synonymous 
point mutations identified by surveying publicly available TCGA data, also cluster at the FBD 
and LRRs of FBXL17. Truncation rate has previously been utilised as a method to distinguish 
if a protein is an oncogene (OG) or a tumour suppressor gene (TSG) [290]. By studying the 
mutational pattern of proteins, it has been shown that TSGs are often enriched in truncation 
events, suggesting Fbxl17 may therefore be a tumour suppressor. Interestingly, the non-
synonymous mutations of the FBP Fbxw7, a well-known tumour suppressor, also occur most 
frequently within the WD40 domains, the protein-protein interaction domains akin to LRRs 
in Fbxl17 (Figure 6. 1, middle panel) [291]. In contrast Skp2, an LRR domain-containing 
protein and known oncogene is mutated across the entire length of the protein (Figure 6. 1, 
bottom panel) [292]. This data suggests the mutational pattern of FBPs may be useful for 
determining whether they have oncogenic or tumour suppressive properties in cancer. 
TSGs are associated with loss of function (LOF) mutations; therefore, we would expect the 
loss of Fbxl17 LRRs to be deleterious to its function. Indeed, I have shown that truncating 
Fbxl17 LRRs impaired its association with the other SCF holoenzyme subunits Skp1, Cul1 and 
Rbx1, and decreased its ubiquitination activity, despite mutant constructs still containing the 
characteristic FBD. Loss of the LRRs also affected Fbxl17 binding to its targets, which we 
propose is due to a change in the 3D structure of Fbxl17. Thus, genomic rearrangements in 
FBXL17 have the potential to disrupt SCFFbxl17-regulated networks in cancer cells.  




Figure 6. 1 - Mutational patterns of the FBPs Fbxl17, Fbxw7 and Skp2 
Non-synonymous somatic mutations mapped to Fbxl17, the known tumours suppressor 
Fbxw7 and the known oncogene Skp2, as reported by The Cancer Genome Atlas (TCGA), 
visualised using GDC Data Portal. Pink rectangle below graphs represent the location of the 
F-box domain, blue rectangles represent WD40 repeats. 
 
To investigate the functional effect of these rearrangements, we performed a yeast two-
hybrid screen to identify Fbxl17-interacting proteins. Among the 37 binding partners Uap1, 
an enzyme involved in O-GlcNAcylation of proteins was identified most frequently. I have 
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demonstrated that Fbxl17 binds to UAP1 directly and this requires LRRs 2-8. The data 
published so far for Fbxl17 has exclusively identified typical substrates of SCFFbxl17. SCFFbxl17 
shows a strong preference for K48-linked ubiquitin chains, the linkage type often mediated 
by SCF-type ubiquitin ligases, and as such the ubiquitination activity of SCFFbxl17 has been 
shown to target substrates for proteasomal degradation. However, I have identified Uap1 as 
a binding partner, rather than a substrate, of Fbxl17. The interaction of Uap1 with Fbxl17 
does not lead to its ubiquitination and subsequent degradation by the proteasome. Instead, 
Fbxl17 inhibits the phosphorylation of Uap1, which we propose regulates its activity. This 
suggests a novel role for Fbxl17 in ‘running interference’, whereby Fbxl17 can bind to 
proteins, but instead of ubiquitinating them, regulates their modification by post-
translational modifications (PTMs) other than ubiquitin. It has already been shown that FBPs 
can have SCF-independent roles [198]. However, the inhibition of Uap1 phosphorylation 
requires the FBD and LRRs of Fbxl17, and so is likely to be an SCF-dependent function of 
Fbxl17. These data show that not all proteins that bind to the protein-binding domains of 
FBPs are substrates for ubiquitination. Furthermore, these data highlight an important 
crosstalk that exists between PTMs. The crosstalk between phosphorylation and 
ubiquitination is well established [293, 294] but should be considered more frequently in 
studies of this kind. Loss of Fbxl17 activity will not only affect the ubiquinome of the cell, but 
will also undoubtedly have consequences for other PTMs, such as phosphorylation, and as I 
have shown in this dissertation O-GlcNAcylation.  
As discussed previously, the breast cancer-associated rearrangements in Fbxl17 result in loss 
of SCFFbxl17 activity. We were able to show a striking effect of reducing Fbxl17 expression on 
at least one important cancer-relevant pathway, in a relevant cell type. This was through its 
regulation of Uap1 and the HBP. Knockdown of Fbxl17 resulted in a decrease in UDP-GlcNAc, 
the intermediate produced by Uap1. Surprisingly, this resulted in elevated O-GlcNAcylation, 
an important PTM for a number of intracellular proteins, arguing for a functional role for 
Fbxl17 in this pathway. The increase in O-GlcNAc modified proteins is most likely due to a 
compensatory decrease in OGA levels, which I observed following Fbxl17 knockdown. 
Increased protein O-GlcNAcylation and changes in OGT and/or OGA expression have already 
been reported in breast cancer, where increased global O-GlcNAcylation and low OGA levels 
are linked to higher grade tumours and metastasis [80]. In agreement with this, the majority 
of primary breast tumours we identified with FBXL17 rearrangements were basal-like, and 
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half clustered to IntClust 10, both of which are considered aggressive and high-risk subtypes. 
Breast tumours containing FBXL17 mutations may therefore represent a clinically important 
subset of cancer, that can be targeted therapeutically. 
To identify further interacting partners of Fbxl17, we performed a mass spectrometry 
analysis of purified Fbxl17 SCF E3 ubiquitin ligases. Co-immunoprecipitates were enriched for 
DNA damage/DNA repair proteins suggesting a novel role for Fbxl17 in the DNA damage 
response (DDR). In support of this, I have demonstrated that Fbxl17 is rapidly recruited to 
DNA damage sites upon double-stand break (DSB) induction and loss of Fbxl17 impairs the 
ability of cells to repair and recover from IR-induced DNA damage.  
Unlike the role of Fbxl17 in the HBP, Fbxl17 plays a more classical role in the DDR. I have 
shown that Fbxl17 can ubiquitinate the tandem BRCT domain of the well-known DDR protein 
53BP1, which we propose targets 53BP1 for proteasomal degradation. Studies have already 
shown that the levels of 53BP1 are controlled by proteasomal degradation, with the E2 
ubiquitin-conjugating enzyme UbcH7 implicated in modifying and degrading free forms of 
53BP1 under normal growth conditions [288, 289]. This ensures an equilibrium of 53BP1 
expression is maintained. Loss of UbcH7 stabilises 53BP1 creating an imbalance in DSB repair 
pathway choice, forcing cells to adopt NHEJ instead of HR [288, 289]. The E3 ubiquitin ligase 
responsible for bringing together 53BP1 and UbcH7 remains undiscovered and as such I 
propose that Fbxl17 is the E3 ligase responsible for dictating the ubiquitination of 53BP1. 
Auto-ubiquitination assays for Fbxl17 have shown that it is active with several E2 enzymes 
and therefore could form an active SCF complex with UbcH7. However, perhaps the most 
compelling evidence that Fbxl17 controls 53BP1 levels is the increased sensitivity to CPT 
observed following siRNA knockdown of Fbxl17 expression. Han et al. observed increased 
sensitivity to CPT in UbcH7-depleted cells which they proposed was due to the inability of 
these cells to promote HR for the repair of CPT-induced DSBs. Therefore, whilst only 
preliminary, my data suggests that Fbxl17 and its regulation of 53BP1 may also be required 
for efficient HR. By understanding the vulnerabilities of Fbxl17 deficient tumours we can 
design suitable therapeutic strategies to effectively treat this subset of breast cancers. 
In conclusion, by surveying structural rearrangements in cancer databases, we discovered 
rearrangements commonly occur in FBXL17 which affect its ability to bind substrates and 
assemble as part of a functional SCF ubiquitin ligase complex. By screening for Fbxl17 
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interacting proteins, we have identified two regulatory networks of Fbxl17 which provide an 
insight into the role of Fbxl17 in breast cancer pathogenesis. We first discovered Uap1 as a 
binding partner of Fbxl17 and established that Fbxl17 is a regulator of global O-linked 
GlcNAcylation. I then identified a novel role for Fbxl17 in the DDR, through its ability to 
ubiquitinate 53BP1, and propose Fbxl17 is important for HR-mediated DSB repair. These 
pathways may be amenable to therapeutic targeting in the future for the treatment of 
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Abstract
In cancer, many genes are mutated by genome rearrangement, but our understanding of the functional consequences of this 
remains rudimentary. Here we report the F-box protein encoded by FBXL17 is disrupted in the region of the gene that encodes 
its substrate-binding leucine rich repeat (LRR) domain. Truncating Fbxl17 LRRs impaired its association with the other 
SCF holoenzyme subunits Skp1, Cul1 and Rbx1, and decreased ubiquitination activity. Loss of the LRRs also differentially 
affected Fbxl17 binding to its targets. Thus, genomic rearrangements in FBXL17 are likely to disrupt  SCFFbxl17-regulated 
networks in cancer cells. To investigate the functional effect of these rearrangements, we performed a yeast two-hybrid screen 
to identify Fbxl17-interacting proteins. Among the 37 binding partners Uap1, an enzyme involved in O-GlcNAcylation of 
proteins was identified most frequently. We demonstrate that Fbxl17 binds to UAP1 directly and inhibits its phosphorylation, 
which we propose regulates UAP1 activity. Knockdown of Fbxl17 expression elevated O-GlcNAcylation in breast cancer 
cells, arguing for a functional role for Fbxl17 in this metabolic pathway.
Keywords FBXL17 · Genome rearrangements · O-GlcNAcylation · O-GlcNAc · UAP1 · Ubiquitin · Phosphorylation · 
Breast cancer
Introduction
The genomes of most common epithelial cancers, such as 
breast cancer, are highly rearranged, but our knowledge of 
the rearrangements and the genes they target remains rudi-
mentary [1]. A few common, large-scale rearrangements 
have been known for some time, such as loss of the distal 
arm of 8p, 17p and 18q and the amplification of ERBB2 
in breast cancer, but many more less-frequently occurring 
aberrations remain to be characterised and may be diagnosti-
cally or therapeutically important. For example, the EML4-
ALK fusion occurs in only approximately 5% of non-small 
cell lung cancers and is a target for therapy [2]. Genome 
sequencing has focused on point mutations in exomes, with 
only a few results for structural mutations reported so far, 
for limited sets of tumours [3–8]. Array-CGH detects larger 
scale unbalanced rearrangements and is available for large 
panels of tumours [9]. If such breaks fall within genes, they 
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must at least inactivate that copy of the gene, and in some 
cases they will create truncated proteins or gene fusions. 
Some gene fusion data are also available, from genomic 
[3–8] or transcript sequencing [10]. From surveying these 
datasets, we determined that FBXL17 is among the more fre-
quently rearranged genes in a number of epithelial cancers, 
including breast, prostate and oesophageal cancers.
FBXL17 encodes a little-studied member of the F-box 
family of proteins (FBPs). They are components of the ubiq-
uitin conjugation pathway, which, by directing the ubiquit-
ination of target proteins, regulate major cellular processes 
that require rapid alterations in protein levels, activity and 
localisation, such as cell cycle progression, cell signalling, 
and receptor recycling [11]. Ubiquitination of proteins 
requires an enzymatic cascade involving an E1 ubiquitin-
activating enzyme, an E2 ubiquitin-conjugating enzyme, and 
an E3 ubiquitin ligase [12]. FBPs are subunits of the SCF 
(Skp1-Cul1-F-box protein)-type E3 ubiquitin ligases, which 
utilise protein–protein interaction domains, like leucine-rich 
or WD40 repeats, to recruit substrates to the ligase. FBPs 
bind an adaptor protein Skp1 through their F-box domains 
(FBD), and the FBP:Skp1 dimer is a switchable unit that 
docks with a cullin scaffold and Rbx1 (Ring finger domain 
containing protein), which in turn recruits a ubiquitin-
charged E2 ligase. The Cand1 protein actively dissociates 
the pool of FBP:Skp1 dimers from cullin, regulating the lev-
els of active E3 ligases in the cell [13, 14]. FBPs not engaged 
as part of active E3 ligases also have functions outside of the 
Ubiquitin Proteasome System (UPS) [15].
Several FBPs have oncogenic and/or tumour suppressive 
activities [16, 17]. Indeed, the first FBP described, Skp2 
(S-phase kinase-associated protein 2, Fbxl1) is activated 
by amplification in several cancers, including breast, lym-
phoma, non-small cell lung cancer and glioblastoma [18, 
19]. Skp2 is thought to have its main oncogenic activity by 
promoting the degradation of the cyclin-dependent kinase 
inhibitor, p27 [20–22]. However, loss of SKP2 also induces 
senescence in response to oncogenic stimuli, such as Ras 
expression or the loss of Pten [23]. Fbxw7 is a tumour sup-
pressor, inactivated in approximately 7% cancers [24], which 
targets the turnover of important oncogenes, such as Myc, 
cyclin E, and Notch [16]. β-TrCP (BTRC , Fbxw11) is also 
mutated in several cancers, including breast and colorectal 
cancer and melanoma, potentially stabilising its oncogenic 
substrate β-catenin [19]. The true extent of FBP dysregula-
tion in cancer, particularly through genomic rearrangements, 
is unknown. We found FBXL17 is rearranged in breast can-
cers, and these rearrangements often disrupt the LRRs of 
Fbxl17. Loss of LRRs leads to a differential loss of interac-
tion with Fbxl17 binding partners, and prevents its assembly 
into a functional SCF complex. We show that Fbxl17 inter-
acts with Uap1, UDP-N-acetylglucosamine pyrophosphory-
lase 1, to regulate the overall levels of N-acetylglucosamine 
modification (O-GlcNAcylation) of proteins in cells. Our 
data support a model whereby Fbxl17 has tumour suppressor 
activity in breast cancers.
Results
FBXL17 is rearranged in cancer
To identify genes that are rearranged in breast cancers, 
we scanned segmented array-CGH copy number data for 
1992 primary breast tumours [9]. 135 (7%) had at least one 
genomic break within FBXL17, detected as a copy number 
step, distributed in various ways (Fig. 1a). The majority of 
these copy number losses or gains occurred at the 3′ end 
of FBXL17. Given the LRRs of Fbxl17 are encoded from 
exon 3 onwards it is likely these protein–protein interacting 
domains are disrupted by such rearrangements.
In addition to breaks in tumours, array-CGH data showed 
breaks in FBXL17 in four cancer cell lines, the breast car-
cinoma cell lines, BT-474, HCC38, and HCC1395, and the 
oesophageal/gastric cardia adenocarcinoma line OE-19 
[25]. The breaks were verified by FISH (Figs. 1b and S1). 
In BT-474, one of three copies of FBXL17 was broken, 
with retention of the 3′ end, exons 7–9 (Figs. 1b and S1B). 
Both HCC38 and OE-19 had an extra copy of the 5′ end of 
FBXL17, up to intron 1 and intron 7, respectively (Figs. 1b 
and S1B). In HCC38, this break was confirmed to be the 
FBXL17-PJA2 fusion transcript reported in [10] (Fig. S1C, 
S1F and S1G). In HCC1395, both array-CGH (Fig. S1H) 
and paired-end sequencing showed an internal homozygous 
deletion in FBXL17 between exons 6 and 9 [5, 25] verified 
by RT-PCR and FISH (Fig. S1D, S1E and S1I) which would 
truncate Fbxl17 near its C-terminus and encode a mutant 
protein lacking approximately three LRRs (Fig. 1b).
Because the cell line examples may not be typical, we 
looked for examples of FBXL17 rearrangements in breast 
cancers, in paired-end whole-genome DNA sequencing 
Fig. 1  Breaks in FBXL17 and the proteins encoded. a Breaks in 
135/1992 breast tumours [9], detected as copy number steps by 
array-CGH. X-axis is genomic sequence of FBXL17, reversed 
since FBXL17 is a negative strand gene. Each horizontal line repre-
sents a tumour, with breaks indicated by colour change. Blue, copy 
number loss; white, no change; red, gain. b FBXL17 exons from 
Ensembl transcript ENST00000542267.5 (Refseq NM_001163315.2, 
NP_001156787.2), chr5:107,859,045-108,382,098 in GRCh38/hg38. 
Triangles indicate breakpoints in FBXL17 identified in cell lines (as 
labelled) or primary breast tumours (unlabelled), Asterisk indicates 
known fusion. Bottom, protein domains of Fbxl17 scaled to protein 
sequence. L, leucine-rich repeat. c Non-synonymous somatic muta-
tions mapped to Fbxl17 as reported by The Cancer Genome Atlas 
(TCGA), arrows indicate breast cancer associated mutations. Sche-
matic underneath represents Fbxl17 domains, green, N-terminus, pur-
ple, F-box domain, red, leucine-rich repeats
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data from 250 primary breast tumours of the Cambridge 
Personalised Breast Cancer Programme. Rearrangements 
(‘Structural variants’) in FBXL17 were identified in five of 
the tumours. Manual inspection of RNA sequences from 
these five tumours confirmed that two of the rearrange-
ments were transcribed as predicted: a translocation joining 
exon 6 to an undocumented exon on chromosome 7 and a 
duplication of exon 6, respectively (Fig. 1b; Supplementary 
Table 1). A third case with a breakpoint in intron 6 showed 
unspliced transcription from exon 6 into intron 7; however, 
we cannot rule out that this was normal unspliced RNA. 
Serendipitously, a further RNA sample, inspected because 
it had a rearrangement which did not pass filtering, showed 
splicing from exon 6 into exon 4. This suggested the pres-
ence of a rearrangement which was not detected by DNA 
sequencing in an additional tumour. The partial agreement 
we find between RNA and DNA sequencing is expected as 
both methods lack sensitivity to identify all rearrangements 
[26]. Thus, consistent with the cell line rearrangements, the 
breakpoints in the tumours fell within introns that would dis-
rupt the expression of LRRs, with the majority (4/6) occur-
ring in intron 6 (Fig. 1b, Supplementary Table 1). There 
was no clear relationship between FBXL17 rearrangement 
and any molecular classification [27] of the tumours and cell 
lines, although five of the six tumours and the breast cell 
lines were TP53 mutant (Supplementary Table 1). Of the 
tumours, three were oestrogen receptor (ER) positive, and 
three were ER-negative. One tumour and one cell line were 
ERBB2/HER2 positive. We also classified these tumours 
into the 11 IntClust sets [27], and they fell into three sets: 
clusters 4, 7 and 10. In addition, classifying these six cases 
using PAM50 breast cancer subtyping, gave four basal and 
two luminal A cases. Although the number of cases is small, 
these data suggest Fbxl17 is not rearranged in a particular 
cancer subtype.
Rearrangements of FBXL17 have also been detected in 
other epithelial cancers (Supplementary Table 2) including 
prostate [8] and oesophageal adenocarcinoma [7]. Many of 
these rearrangements are also predicted to truncate Fbxl17, 
resulting in loss of LRRs. TCGA (Cancer Genome Atlas 
project) data was mined for genomic alterations affecting 
FBXL17 using cBioPortal (http://cbiop ortal .org) [28]. Per-
haps most striking was the TCGA mapping of non-synon-
ymous somatic FBXL17 mutations. Mutations in FBXL17 
almost exclusively (68/70) target its C-terminus containing 
the FBD and LRRs (Fig. 1c).
In summary, FBXL17 is broken in approximately 7% of 
breast cancers, and additionally rearranged or mutated in 
other epithelial cancers. At least some of the breaks truncate 
Fbxl17, removing some or all of the LRRs and sometimes 
also the FBD. Examples of truncation are present in three 
cancer cell lines, and rearrangements have been confirmed in 
primary breast tumours. These genomic alterations suggest 
the ability of Fbxl17 to recruit substrates for ubiquitination 
or to form part of an SCF complex may be compromised.
Deletion of LRRs in Fbxl17 compromises 
ubiquitination activity due to impaired recruitment 
of SCF subunits
As most of the genomic rearrangements in FBXL17 are 
predicted to target its LRRs, we wanted to investigate the 
effect of their loss on Fbxl17 ligase activity. We used co-
immunoprecipitation assays to check the incorporation 
of Fbxl17 into an SCF E3 ligase. HEK293T cells were 
co-transfected with the subunits of SCF ligases, Skp1, 
Cullin1, Rbx1, and various N-terminally FLAG-tagged 
Fbxl17 constructs (full-length Fbxl17 (1-701aa), an inter-
nal FBD deletion, Fbxl17ΔFbox (Δ324-358aa) and two 
LRR-truncation constructs Fbxl17∆3LRR (1-586aa), and 
Fbxl17∆10LRR (1-384aa) (Fig. 2a). 48 h post transfec-
tion, cells were lysed, immunoprecipitated with FLAG 
antibodies, and blotted for the associated SCF subunits 
(Figs. 2b and S2B). While Skp1, Rbx1 and Cullin1 co-
immunoprecipitated efficiently with WT Fbxl17, these 
components were reduced in the immunoprecipitates of 
the truncation mutants. For example, Cullin1 binding to 
Fbxl17Δ3LRR was reduced by 81% (p = 4.12E−04; n = 4) 
and Fbxl17Δ10LRR by 82% (p = 1.28E−06; n = 4) relative 
to WT Fbxl17, while Skp1 binding to Fbxl17Δ3LRR was 
reduced by 77% (p = 5.52E−05; n = 5) and Fbxl17Δ10LRR 
by 67% (p = 2.74E−05; n = 4) relative to WT Fbxl17, despite 
these truncations having intact FBDs (Figs. 2b and S2B). As 
expected, when the FBD was deleted in Fbxl17ΔFbox, none 
of the subunits were co-immunoprecipitated. These data 
indicate that in addition to the FBD, the LRRs of Fbxl17 
facilitate the assembly of the  SCFFbxl17 ligase.
Fig. 2  Loss of Fbxl17 LRRs impairs recruitment of  SCFFbxl17 subu-
nits and  SCFFbxl17 ligase activity. a Schematic showing Fbxl17 con-
structs used to make SCF ligases, all contain an N-terminal FLAG 
tag (not shown). L, leucine-rich repeat. b A representative immunob-
lot for SCF holoenzyme components that co-immunoprecipitate with 
FLAG-Fbxl17 and mutant Fbxl17 constructs FLAG-Fbxl17ΔFbox, 
FLAG-Fbxl17Δ3LRR and Fbxl17Δ10LRR, n = 4. c Titration of the 
auto-ubiquitination activity of purified  SCFFbxl17 ligase complexes. A 
concentration gradient (12.5  nM, 25  nM, 50  nM, 100  nM) of puri-
fied  SCFFbxl17 or mutant complexes  SCFFbxl17ΔFbox,  SCFFbxl17Δ3LRR 
or  SCFFbxl17Δ10LRR was used in an in  vitro ubiquitination assay in 
the presence of a ubiquitin mix (ubiquitin buffer, UBE1, UbcH5a 
and ATP). Following SDS-PAGE membranes were probed with 
anti-FLAG antibody to detect  SCFFbxl17 ligases, n = 2. d As (C) but 
probed with anti-ubiquitin antibody, n = 2. e In  vitro ubiquitination 
assay of  SCFFbxl17 and mutant ligase complexes in combination with 
HA-tagged substrate Sufu in the presence of a ubiquitin mix as in c. 
Proteins resolved by SDS-PAGE and membrane probed with anti-HA 
antibody, n = 3
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Since the Cullin1 and Rbx1 subunit allow E2 recruitment, 
these data suggest that the mutant  SCFFbxl17 ligases will have 
reduced activity. We tested this by performing in vitro ubiq-
uitination assays of purified SCF complexes, assembled with 
either WT or LRR-truncated Fbxl17 proteins, in the pres-
ence of an E1 and E2 enzyme. We first tested the ability of 
the mutant Fbxl17 proteins to promote auto-ubiquitination as 
part of an SCF E3 ligase (Figs. 2c, d and S2A). We observed 
higher molecular weight bands using an antibody raised 
against Fbxl17 using 25 nM of  SCFFbxl17 in in vitro ubiqui-
tination reactions, and the signal intensified with increasing 
concentrations of the WT ligase. In parallel assays, 50 nM of 
mutant  SCFFbxl17∆3LRR ligase showed residual activity which 
increased at 100 nM, but it was considerably less than WT 
 SCFFbxl17 ligase.  SCFFbxl17Δ10LRR ligase showed the greatest 
reduction in activity (Fig. 2c), comparable to the inactive 
 SCFFbxl17ΔFbox mutant. The difference in activity of the SCF 
complexes was even more apparent when the membranes 
were probed for ubiquitin (Fig. 2d).  SCFFbxl17ΔFbox had no 
ligase activity, while E3 ubiquitin ligases made with the 
LRR-truncated Fbxl17 mutants had reduced ligase activity 
compared to WT Fbxl17.
To test whether the ligases made by WT or mutant ver-
sions of Fbxl17 could ubiquitinate a heterologous substrate, 
we performed in vitro ubiquitination assays using Sufu 
(Fig. 2e) [29]. HA-Sufu was purified from HEK293T cells 
by immunoprecipitation. High molecular weight smears can 
be seen after the addition of  SCFFbxl17 (Fig. 2e, lane 4) and to 
a much lesser extent  SCFFbxl17Δ3LRR (Fig. 2e, lane 6). Both 
 SCFFbxl17ΔFbox and  SCFFbxl17Δ10LRR show greatly reduced 
ubiquitination activity. Together these data indicate that the 
LRRs in Fbxl17 contribute to assembly of the SCF E3 ligase 
and its ligase activity.
Fbxl17 interacting proteins identified by yeast‑two 
hybrid screening
Our data suggest that if Fbxl17 is mutated in the LRR-
encoding region, the proteins interacting with them will be 
mis-regulated as a result of aberrant SCF assembly and its 
effects on ligase activity. We performed a yeast two-hybrid 
screen to identify Fbxl17 interacting partners. To focus 
the screen on LRR-binding partners, we engineered the 
bait plasmid to contain the FBD and LRRs (321-701aa) of 
Fbxl17 but omitted its N-terminus. 37 unique prey, cloned 
in-frame to the Gal4 activation domain (GAD), were identi-
fied as candidate partners for Fbxl17 (Table 1; Fig. S3A). 
More than a third (13/37) of the prey were isolated inde-
pendently at least twice. The most common prey plasmids 
isolated encoded GAD fusions to UDP-N-acetylglucosamine 
pyrophosphorylase 1 (Uap1) and to ubiquitin-fold modifier 
conjugating enzyme 1 (Ufc1), which were isolated 26 and 13 
times, respectively. Moreover, since multiple, non-identical 
plasmids were isolated, a minimal common region defined 
a likely interacting domain within it, e.g. aa 357-505 at the 
C-terminus of Uap1 (Table 1). Additionally, Klhl12 and 
Klhl7, two members of the Kelch-like family of proteins, 
casein kinase 2b (Csnk2B), rearranged L-Myc fusion (Rlf), 
and C21orf91 were repeatedly isolated. To test whether the 
interaction between Fbxl17 and its prey was dependent on 
its LRRs, three LRRs (Δ3LRR) were deleted from the bait 
plasmid. Although this truncation did not affect Fbxl17 
expression (Fig. S3B), none of the yeast co-transformed with 
the Δ3LRR bait plasmid and the various prey grew under 
the selective conditions requiring a bait-prey interaction. 
These results indicated Fbxl17 interaction with its prey was 
dependent on its three C-terminal LRRs (Fig. S3A).
Fbxl17 interacts with Uap1, Ufc1, Klhl12 and Csnk2B 
in human cells in vivo
To validate the yeast two-hybrid results, we tested Uap1, 
Ufc1, Csnk2B and Klhl12 for their interaction with Fbxl17 
in human cells, using co-immunoprecipitation assays. All 
four proteins tested were detected in immunoprecipitates 
of FLAG-tagged Fbxl17 (Fig. 3a–d). We noted truncation 
of LRRs resulted in increased expression of mutant Fbxl17 
(Fig. 2b–d). Despite their enhanced expression, Klhl12 did 
not interact with either the ∆3LRR or ∆10LRR mutants, 
indicating its interaction with Fbxl17 was dependent on the 
LRRs (Fig. 3a). Uap1 and Ufc1 both co-immunoprecipitated 
with WT and ∆3LRR Fbxl17, but truncation of 10 LRRs 
ablated their interaction (Fig. 3b, c). Uap1 was also present 
in immunoprecipitates of the mutant FLAG-Fbxl17∆Fbox 
indicating that Uap1 binding is dependent on LRR2-8 in 
Fbxl17 (Fig. S3C). In contrast to the other partner proteins, 
HA-Csnk2B co-immunoprecipitated roughly equivalently 
with WT, ∆3LRR, and ∆10LRR constructs, suggesting 
that their interaction does not rely on the LRRs and thus 
may interact via the FBD or N-terminus of Fbxl17 in human 
cells (Fig. 3d).
The diminished interactions of truncated Fbxl17 with 
some of its binding partners could be caused by a change 
in its subcellular distribution. Cellular fractionation and 
immunofluorescence assays were conducted in parallel to 
determine the distribution of the WT and mutant proteins in 
cells. Endogenous Fbxl17 was present in both cytoplasmic 
and nuclear fractions (Figs. S3D, S4A). Immunofluores-
cence showed all transfected Fbxl17 constructs showed a 
predominantly nuclear localisation and also weaker cyto-
plasmic staining (Fig. S4A). This argues against an altered 
localisation preventing the mutant forms from interacting 
with its binding partners.
In sum, these data validate results from the yeast two-
hybrid screen since the binding partners identified also 
interact in human cells with the full length Fbxl17 protein. 
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Furthermore, the association of Klhl12, Ufc1, and Uap1 
with Fbxl17 was dependent on its LRRs, as truncation of 
this region weakened or ablated their interaction.
To test the directness of the interaction between Fbxl17 
and one of its interacting proteins, we performed a GST 
pull-down assay using Uap1. We tested GST-Fbxl17(321-
701aa), GST-Fbxl17Δ10LRR(321-383aa), and GST-Skp2, 
another LRR-containing FBP, and GST only were used 
as controls. GST-FBP proteins were co-expressed with 
an IRES-Skp1 to facilitate expression in bacteria, with 
the exception of Fbxl17Δ10LRR, which was robustly 
expressed. GST-FBPs were immobilised on a GST col-
umn and incubated with in vitro transcribed and translated 
Uap1. Following binding assays, samples were resolved 
by SDS-PAGE, and membranes probed with antibodies 
Table 1  Fbxl17 interacting proteins
Minimal region denotes the amino acids present in all interacting cDNA clones; full-length size is the predicted size of the protein. Ub denotes 
protein is ubiquitinated in [39]
Gene symbol Full name isolates Minimal region (aa) Full-length 
size (aa)
Modified
UAP1 UDP-N-acetylglucosamine pyrophosphorylase 1 26 357–505 505 Ub
UFC1 Ubiquitin-fold modifier conjugating enzyme 1 13 12–95 167 Ub
CSNK2B Casein kinase 2, beta polypeptide 4 1–123 215 Ub
KLHL12 Kelch-like 12 (Drosophila) 4 1–162 568
RLF Rearranged l-myc fusion 4 1670–1914 1914
C21orf91 EURL/Chromosome 21 open reading frame 91 4 1–178 296
ACSBG2 Acyl-CoA synthetase bubblegum family member 2 3 528–666 666
ETFA Electron-transfer-flavoprotein, alpha polypeptide 3 103–284 333 Ub
METAP2 Methionyl aminopeptidase 2 3 323–342 478 Ub
AKD1 Adenylate kinase domain containing 1 2 415–624 1911
SCG5 Secretogranin V (7B2 protein) 2 1–188 212
TASP1 Taspase, threonine aspartase, 1 2 135–318 420
KLHL7 Kelch-like 7 (Drosophila) 2 37–240 586 Ub
PHF7 PHD finger protein 7 1 50–236 381
ZMYM2 Zinc finger, MYM-type 2 1 141–390 1377
IDO1 Indoleamine 2,3-dioxygenase 1 1 14–128 403
PSME4 Proteasome (prosome, macropain) activator subunit 4 1 367–420 1843 Ub
PPP3CB Protein phosphatase 3, catalytic subunit, beta isozyme 1 381–496 524 Ub
ZNF350 Zinc finger protein 350 1 310–532 532
TGFBI Transforming growth factor, beta-induced, 68 kDa 1 115–326 683
SCPEP1 Serine carboxypeptidase 1 1 273–452 452 Ub
FILIP1L Filamin A interacting protein 1-like 1 508–705 1135
ACPL2 Acid phosphatase-like 2 1 266–464 480
TPP2 Tripeptidyl peptidase II 1 879–1141 1249 Ub
OLR1 Oxidized low density lipoprotein (lectin-like) receptor 1 1 124–273 273
USP25 Ubiquitin specific peptidase 25 1 323–450 1055 Ub
FAM190A Family with sequence similarity 190, member A 1 555–726 900
PCCB Propionyl CoA carboxylase, beta polypeptide 1 172–468 539
TMOD1 Tropomodulin 1 1 66–334 359
IFT46 Intraflagellar transport 46 homolog (Chlamydomonas) 1 1–216 304
SRBD1 S1 RNA binding domain 1 1 260–491 995
MED14 Mediator complex subunit 14 1 1053–1282 1454 Ub
CCDC147 Coiled-coil domain containing 147 1 478–684 872
HADH Hydroxyacyl-CoA dehydrogenase 1 112–261 261 Ub
CLPX ClpX caseinolytic peptidase × homolog (E. coli) 1 42–341 633
COG2 Component of oligomeric golgi complex 2 1 457–534 738 Ub
TMEM126A Transmembrane protein 126A 1 89–195 195 Ub
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to Uap1. We observed Uap1 binding specifically to GST-
Fbxl17(321-701aa), but not to GST only or to GST-Skp2. 
Moreover, deletion of 10 LRRs abolished Uap1 binding to 
Fbxl17 (Fig. 4a). These results indicate Fbxl17 interacts 
directly with Uap1, and this occurs via its LRRs.
Fbxl17 inhibits the phosphorylation of Uap1
To test the functional significance of Fbxl17 interaction 
with Uap1, we over-expressed Fbxl17 and monitored the 
steady state levels of Uap1 by immunoblotting. We found 
Uap1 levels were unchanged in the presence of MG132 or 
with increased levels of Fbxl17 (Fig. 4b), which suggests it 
does not promote the proteasomal degradation of Uap1. We 
next tested whether Uap1 was a substrate of  SCFFbxl17 ligase 
in vivo, by co-transfecting cells with HA-Uap1, Myc-ubiqui-
tin, and FLAG-Fbxl17 (WT or ∆F-box domain) constructs. 
However, we found no evidence of laddering or smearing 
of Uap1, indicative of its poly-ubiquitination. Instead, we 
detected a discrete, higher molecular weight species of Uap1 
upon transfection of Myc-ubiquitin (Fig. 4c, lane 2). More-
over, levels of this modified form of Uap1 were reduced 
when Fbxl17 was overexpressed (Fig. 4c, lane 5), indicat-
ing Fbxl17 opposed this modification of Uap1. Interestingly, 
this reduction of Uap1 modification was not observed when 
Fbxl17ΔFbox was overexpressed, (Fig. 4c, lane 6) suggest-
ing this effect was dependent on Skp1 binding and/or the 
ligase activity of Fbxl17.
To determine the type of modification this higher molecu-
lar weight species of Uap1 represented, we immunoblotted 
with antibodies to ubiquitin and to Myc-epitope tag (Myc-
ubiquitin). Surprisingly, these antibodies did not yield any 
signal in Uap1 immunoprecipitates, despite the overexpres-
sion of ubiquitin (S2C and S2D). These results indicated 
that the post-translational modification present on Uap1 was 
not ubiquitination. Based on the PhosphoSitePlus database, 
A
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Fig. 3  Deletion of the LRRs of Fbxl17 affects its binding to differ-
ent proteins to different extents. a Immunoprecipitates; using anti-
FLAG beads, of HEK293T cells expressing FLAG-Fbxl17, FLAG-
Fbxl17∆3LRR or FLAG-Fbxl17∆10LRR, probed for endogenous 
Klhl12. b–d As (a), but with co-expression of exogenous HA-tagged 
Uap1 (b), Ufc1 (c), or Csnk2B (d) and probed with anti-HA antibody
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Fig. 4  Fbxl17 inhibits the phosphorylation of UAP1. a In vitro GST 
pull-down assay using bacterially expressed and purified Fbxl17 con-
structs or Skp2/GST as controls immobilised on a GST column incu-
bated with rabbit reticulocyte lysate (left panel). Fbxl17(321-701aa) 
and Skp2 constructs contained an IRES_Skp1 to aid expression. Input 
for rabbit reticulocyte lysate = 20%. Coomassie staining of GST pro-
teins, volume of sample loaded indicated below lanes (right panel) * 
indicates bands relating to expressed proteins, arrow represents Uap1, 
n = 2. b HEK293T cells transfected with Fbxl17WT, ΔFbox or empty 
vector (EV) for 48 h then treated with 10 µM MG132 or DMSO for 
4 h. Whole cell lysates immunoblotted with the indicated antibodies, 
n = 3. c In vivo ubiquitination assay for UAP1. HA-UAP1 immuno-
precipitated from HEK293T cells transfected with ubiquitin and indi-
cated Fbxl17 constructs. Membranes probed with anti-UAP1 anti-
body, arrow indicates modified Uap1, n = 3. d In vivo ubiquitination 
assay for UAP1 as in c in the presence of β-glycerophosphate (lane 3) 
and alkaline phosphatase (CIP) (lane 4), n = 2. e LC–MS analysis of 
total UDP-GlcNAc levels in U2OS cells treated with Fbxl17 siRNA3 
or control siRNA for 48 h. Mean ± SEM for five biological replicates, 
*p < 0.05
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where multiple studies report Uap1 to be a phosphorylated 
protein, we tested whether this modified form of Uap1 rep-
resented a phosphorylated form. We conducted the in vivo 
ubiquitination assay in the presence of the phosphatase 
inhibitor β-glycerophosphate and alkaline phosphatase 
(CIP). Strikingly, the levels of modified Uap1 were almost 
completely absent following CIP treatment, suggesting the 
higher molecular weight species represented a phospho-
rylated form of Uap1 (Fig. 4d, lane 4). In sum, these data 
show that the overexpression of ubiquitin increases Uap1 
phosphorylation, and Fbxl17 overexpression prevents this 
modification, and this function is dependent on its FBD.
FBXL17 knockdown results in increased levels 
of O‑GlcNAcylation
Since Fbxl17 overexpression reduced the abundance of a 
phosphorylated Uap1, but not Uap1 steady state levels, we 
reasoned Fbxl17 might regulate Uap1 activity. Uap1 cataly-
ses the formation of UDP-N-acetylglucosamine (UDP-Glc-
NAc), which is used by the glycosyltransferase O-GlcNAc 
Transferase (OGT) to add N-acetylglucosamine in O-glyco-
sidic linkages to nuclear and cytosolic proteins. UAP1 is the 
main enzyme synthesizing UDP-GlcNAc [30–34]. Since our 
results indicate Fbxl17 opposes Uap1 phosphorylation, we 
tested whether reducing Fbxl17 expression would affect the 
amount of UDP-GlcNAc in the cell. U2OS cells were trans-
fected with an siRNA targeting Fbxl17 (Fig. S4B), metabo-
lites were extracted from these cells and UDP-GlcNAc lev-
els were determined by mass spectrometry. We observed a 
36% decrease (p = 0.013; n = 5) in total UDP-GlcNAc levels 
in Fbxl17 knockdown cells (Fig. 4e), which suggests that 
Fbxl17 promotes Uap1 activity.
To determine the downstream effects of Fbxl17 on 
this pathway, we next tested the effect of reduced Fbxl17 
expression on the levels of O-GlcNAc modified cellular 
proteins. U2OS cells were treated with Fbxl17 siRNA as 
above, and cell lysates were immunoblotted for O-GlcNAc. 
Although UDP-GlcNAc levels were reduced in Fbxl17 KD 
cells (Fig. 4e), we observed increased levels of O-GlcNAc-
modified proteins in Fbxl17 knockdown cells (Fig. 5a). This 
was also shown in two breast cell lines, HB4a and MCF7, by 
expression of shRNA constructs targeting FBXL17 expres-
sion (Figs. 5b, c; S4C). This increase in O-GlcNAc modified 
proteins, despite reduced levels of UDP-GlcNAc, may be a 
result of changes in the expression or activity of the enzymes 
responsible for adding or removing O-GlcNAc, namely Ogt 
and Oga, which act downstream of Uap1 and UDP-GlcNAc. 
We therefore determined whether Ogt and Oga were changed 
following knockdown of Fbxl17. Although Ogt levels were 
unchanged, Oga levels were reduced which suggests the 
increased O-GlcNAcylated proteins is due to decreased 
Oga levels (Fig. 5d). Consistent with reduced Oga levels, 
mass spectrometry analysis of levels of GlcNAc, the product 
of Oga-mediated cleavage of O-GlcNAc modifications from 
proteins, were reduced by 18%, although this was not signifi-
cant, in cells treated with Fbxl17 siRNA (Fig. 5e). Finally, 
we surveyed the expression of Fbxl17 and Uap1 expression 
in breast cancer datasets using the R2 platform (http://www.
r2.amc.nl). Kaplan–Meier analysis for these genes revealed 
that breast tumours with either low Fbxl17 expression, or 
high Uap1 expression were associated with poorer survival 
in patients (Fig. S5).
Discussion
Our results collectively indicate that FBXL17 is frequently 
mutated in epithelial cancers in the genomic regions encod-
ing its LRRs. We found FBXL17 was rearranged in around 
7% of breast cancers according to array-CGH, and also in 
cancer cell lines. Independently, analysis of sequence-level 
mutation data also suggested that FBXL17 behaves like a 
tumour suppressor gene [35]. Many point mutations and 
breaks in FBXL17 occurred in regions encoding its LRRs. 
These motifs are proposed to be the substrate docking sites 
within FBXL proteins, and are predicted to cause a failure 
to recruit substrates. Indeed, we find that progressive dele-
tion of its LRRs caused decreased auto-ubiquitination and 
ubiquitination of a substrate, Sufu, by  SCFFbxl17. However, 
we also discovered that deleting LRRs impaired the assem-
bly of the E3 ubiquitin-ligase complex. Both of the Fbxl17 
LRR truncation mutants, ∆3LRR and ∆10LRR, bound Skp1 
less well compared to WT, despite them containing the Skp1 
binding motif. Reduced interactions with Cul1 and Rbx1 are 
likely due to less Skp1 binding, since FBPs do not interact 
directly with Cul1 or Rbx1 [36]. The C-terminus of an FBP 
has been shown in specific cases to contact Skp1 to stabilise 
the ligase [36], and our data show that truncating the LRRs 
of Fbxl17 also destabilises the SCF ligase. We predict that 
even if a truncated Fbxl17 were able to recruit some of its 
substrates, it would be less efficient in ubiquitinating them. 
Thus in the context of breast cancer, the rearrangements that 
target the LRRs of FBXL17 would likely diminish ubiquit-
ination of the network of  SCFFbxl17 substrates.
To investigate functional consequences of these rear-
rangements, we screened for proteins interacting with the 
LRR of Fbxl17. Our yeast two-hybrid screen identified 
37 novel interactions, which was found to only minimally 
overlap with previous studies reporting Fbxl17 interact-
ing proteins [37, 38]. Only eight proteins, Klhl12, Klhl7, 
Zmym2, Hadh, Clpx, Ppp3cb, Pccb, Srbd1 also appeared in 
these other studies. However, Uap1 and Ufc1, the most fre-
quently recovered cDNAs in our screen, were not identified 
by either. The varied findings by different screening meth-
odologies, indicates they identify distinct partner proteins 
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and argues for a variety of experimental approaches to dis-
covering protein interaction networks. Screens for interact-
ing partners may identify substrates or regulators of FBPs. 
When validating four of the most repeatedly isolated prey 
cDNAs in mammalian cells, we noted differential binding 
(Csnk2B > Uap1 > Ufc1 > Klhl12) depending on the deletion 
of 3 or 10 LRRs. Notably, the Casein Kinase 2 subunit, 
Csnk2B, remained bound to Fbxl17 after deletion of 10 
LRRs, suggesting that it binds to another region of Fbxl17, 
or other E3 ubiquitin ligase components, and may be a reg-
ulator of the ligase. Among the other interactors, Fbxl17 
binding to Klhl12 or Ufc1 was decreased when the last three 
Fig. 5  Knockdown of Fbxl17 
increases total O-GlcNAcyla-
tion. a U2OS cells treated with 
Fbxl17 siRNA3 or control 
siRNA for 48 h followed by 
PugNAc treatment, 50 µM 3 h. 
Whole cell lysates immunoblot-
ted with the indicated antibod-
ies, n = 2. b FBXL17 mRNA 
knockdown by shRNA in HB4a 
immortalised normal breast 
cells (bottom panel). Expression 
normalised to GAPDH and plot-
ted relative to miR30-infected 
control cells. Mean ± SEM 
of at least three independent 
experiments. O-GlcNAcylation 
monitored by immunoblotting 
with anti-O-GlcNAc antibodies 
(top panel). c FBXL17 mRNA 
knockdown by shRNA in MCF7 
breast cancer cells (bottom 
panel). Expression normal-
ised to scRNA-infected cells. 
Mean ± SEM of at least three 
independent experiments. Total 
O-GlcNAcylation monitored 
by immunoblotting with anti-
O-GlcNAc antibodies. + and 
++, 25 or 50 μg of protein 
lysate (top panel). d U2OS cells 
treated with Fbxl17 siRNA3 or 
control siRNA for 48 h. Whole 
cell lysates immunoblotted 
with the indicated antibodies. 
Band intensities quantified by 
densitometry and normalised 
to GAPDH expression (values 
below blots), n = 3. e LC–MS 
analysis of total GlcNAc levels 
in U2OS cells treated with 
Fbxl17 siRNA3 or control 
siRNA for 48 h. Mean ± SEM 
for five biological replicates. f 
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LRRs were truncated. However, Uap1 binding was disrupted 
only when ten LRRs were truncated suggesting Uap1 can 
bind to LRR2-8. These data led us to a model whereby the 
number of LRRs in Fbxl17, as dictated by the position of a 
rearrangement within FBXL17, would influence its interac-
tion with its repertoire of partners. However, due to inef-
ficient ligase assembly by LRR-truncated Fbxl17 mutants, 
we predict the ubiquitination of these proteins would be 
diminished. We note that 15 of the 37 proteins identified 
in the yeast two-hybrid screen are listed as being ubiquit-
inated proteins in a whole proteomic analysis of HEK293 
cells (Table 1) [39].
There are not yet enough data on rearrangement of 
FBXL17 in cancers to conclusively identify FBXL17 inacti-
vation as a driver mutation in cancer. Nonetheless, we were 
able to show a striking effect of reducing Fbxl17 expression 
on at least one important cancer-relevant pathway, in a rel-
evant cell type, suggesting that inactivation of Fbxl17 would 
have a major effect on the cancer cell. This was through 
its regulation of Uap1, which is expressed in many breast 
cancers (Figs. S4D, S5D) and other cancer types [34, 40]. 
Surprisingly, we did not find Uap1 to be ubiquitinated by 
Fbxl17, but instead our results showed that increased Fbxl17 
expression prevented the phosphorylation of Uap1. In addi-
tion, this inhibition of Uap1 phosphorylation was depend-
ent on the Skp1-binding domain of Fbxl17, suggesting that 
 SCFFbxl17 ligase activity is essential. In contrast to Ogt and 
Oga [41], little is known about the regulation of Uap1, and 
our data suggest Fbxl17 positively regulates its activity 
(Fig. 5f). UDP-GlcNAc levels are significantly decreased 
when Fbxl17 is knocked down suggesting reduced Uap1 
activity which is consistent with previous studies showing 
Uap1 expression is important for UDP-GlcNAc levels [34]. 
Although we have not identified the kinase responsible for 
phosphorylating Uap1, one possibility is that Fbxl17 ubiqui-
tinates this kinase to inhibit its phosphorylation of Uap1 and 
promote Uap1 activity. Alternatively, Fbxl17 could shield 
Uap1 from this kinase, via a direct interaction between 
Fbxl17 and Uap1 (Figs. 4a, 5f).
We have shown that Fbxl17 regulates the O-GlcNAcyla-
tion pathway since reducing FBXL17 expression in three 
cell lines increased global levels of O-GlcNAc-modified pro-
teins. We did not assess glycosylation in the ER or Golgi, 
so cannot rule out a specific role for Fbxl17 there. How-
ever, the increase in global O-GlcNAcylation may be the 
result of greater utilisation of UDP-GlcNAc by Ogt, which 
would explain the lower UDP-GlcNAc levels and higher 
O-GlcNAcylation we observed in Fbxl17 knockdown cells. 
Although Ogt expression levels were unchanged, we cannot 
rule out that its activity is increased when Fbxl17 levels are 
reduced. However, the higher levels of O-GlcNAc modi-
fied proteins are likely due to the observed decrease in Oga 
expression. It has been proposed that there is an optimal 
level of global O-GlcNAcylation levels for cells to func-
tion and this is maintained by mutual regulation and balance 
of Ogt/Oga expression and activity [41, 42]. The decrease 
in Oga expression may represent a compensatory mecha-
nism adopted by the cell to counteract the decrease in Uap1 
activity and UDP-GlcNAc levels. O-GlcNAcylation is an 
important post-translational modification on many intra-
cellular proteins—including p53, RNA polymerase II, the 
polycomb complex and Phosphofructokinase 1 (Pfk1), the 
main regulator of glycolysis—and is essential for viability 
of several mammalian cell types [43, 44]. Moreover, there 
is already considerable evidence that GlcNAcylation is 
altered in breast cancer and other cancers [45–48]. Cald-
well et al. [49] found that breast cancer cells had increased 
O-GlcNAcylation and elevated OGT. Knocking down OGT 
inhibited tumour growth, decreased cell cycle progression, 
increased expression of the cell cycle inhibitor p27Kip1, and 
decreased invasiveness [49]. High nuclear and cytoplasmic 
O-GlcNAc was also observed in breast cancer patients with 
increased relapse rates, increased sites of distant metastases 
and poor outcome [50]. In breast cancer, low OGA levels 
are linked to higher grade tumours and metastasis [51]. We 
have shown that the regulation of Uap1 by Fbxl17 and an 
unidentified kinase, are factors in determining the levels of 
the O-GlcNAcylated proteome.
In conclusion, by surveying structural rearrangements in 
cancer databases, we discovered rearrangements commonly 
occur in FBXL17 which affect its ability to bind substrates 
and also assemble as part of a functional SCF ubiquitin 
ligase complex. By screening for Fbxl17 interacting pro-
teins, we discovered Uap1 as a binding partner, but not a 
substrate of Fbxl17, and established that Fbxl17 is a negative 
regulator of global O-linked GlcNAcylation. The loss-of-
function mutations in FBXL17 caused by structural rear-
rangements could have additional effects on the cell, since 




The matchmaker gold yeast two-hybrid system (Clontech) 
was used to screen a human cDNA library (Mate & Plate™ 
Library—Normalized, Universal Human (Clontech)). 
Fbxl17 aa 321 to 701 was PCR amplified and subcloned 
into pGBKT7 (Clontech). aa 321 to 586 was amplified from 
pGBKT7-FBXL17 plasmid and subcloned into pGBKT7 to 
create the (∆3LRR) bait construct.
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Purification of  SCFFbxl17 complexes
HEK293T cells were transfected with SCF components 
(Skp1, Cul1, Myc-Rbx1) and FLAG-Fbxl17 constructs. 
After 48 h, cells were resuspended in lysis buffer (LB) 
(25 mM Tris–HCl, pH 7.5, 225 mM KCl, 1% NP-40) with a 
protease inhibitor cocktail (Sigma-Aldrich) and phosphatase 
inhibitors (10 mM NaF, 1 mM PMSF, 1 mM  Na3VO4). 
Lysates were incubated with Anti-FLAG® M2 Affinity 
Gel (Sigma-Aldrich) for 5 h at 4 °C with rotation. Beads 
were washed in LB and eluted in 300 µg/mL FLAG peptide 
(Sigma-Aldrich) in elution buffer (10 mM HEPES, pH 7.9, 
225 mM KCl, 1.5 mM  MgCl2, 0.1% NP-40) for 1 h at 4 °C 
with rotation. Purified SCF complexes were stored in 15% 
glycerol.
In vitro ubiquitination assays
A screen of 10 different E2 enzymes determined that E2 
UbcH5a enabled the most specific  SCFFbxl17 activity and 
was used in subsequent experiments. Purified SCF com-
plexes at 12.5, 25, 50 and 100 nM were tested in the pres-
ence of a ubiquitin-mix (ubiquitin buffer, ubiquitin (20 µM) 
E1 (UBE1, 100 nM), E2 (UbcH5a, 500 nM) and Mg-ATP 
(2 mM) (Boston Biochem)) incubated at 30 °C for 90 min 
to determine ligase activity by auto ubiquitination. 50 nM 
of the SCF was sufficient for ligase activity and used in sub-
sequent experiments. To test substrate ubiquitination sub-
strates were transfected into HEK293T cells and immuno-
precipitated using their indicated epitope tags conjugated to 
agarose beads. The purified substrate was then eluted from 
the beads and added as a component of the ubiquitin-mix. 
HA-Sufu was kindly provided by Vincenzo D’Angiolella 
(CRUK/MRC Oxford Institute for Radiation Oncology, 
Oxford, UK). Ubiquitination was detected by probing for 
the substrate or HA tag.
In vivo ubiquitination assays
HEK293T cells were transfected with expression constructs 
of interest, including myc-ubiquitin, and treated with 10 µM 
MG132 (Sigma-Aldrich) 5 h prior to lysis. UAP1 was then 
immunoprecipitated with Monoclonal Anti-HA-Agarose 
antibody (Sigma-Aldrich). Modified UAP1 was detected 
with an endogenous UAP1 antibody. To test for phospho-
rylation 10 mM β-glycerophosphate or alkaline phosphatase 
(CIP) was added to the LB where indicated. LB containing 
CIP did not contain phosphatase inhibitors (NaF,  Na3VO4).
DNA constructs
Coordinates and exon numbers for the FBXL17 gene are 
from Ensembl transcript ENST00000542267.5 (Fig. 1). 
Human FBXL17 cDNA (GenScript) was subcloned into 
pcDNA3 and pcDNA3-FLAG. Truncation (∆3LRR) 
and (∆10LRR) and deletion constructs (ΔFbox) were 
constructed by amplification or two-step PCR mutagen-
esis. Human Ufc1 and Uap1 cDNAs were obtained from 
GeneArt. pcDNA3.1-FLAG-hKLHL12 was kindly provided 
by S. Angers (University of Toronto, Canada). pCK2_
V2N1_Venus2-HA-CSNK2B_N1 was kindly provided by 
A. Beck-Sickinger (Leipzig University, Germany).
Antibodies
The following antibodies were purchased anti-β-actin 
(Abcam, ab8227), anti-Cul1 (Santa Cruz, sc-11384), anti-
Fbxl17 (Genetex, GTX119211), anti-FLAG® M2 (Sigma-
Aldrich, F3165), anti-Gal4 DBD (Santa Cruz, sc-510), 
anti-GAPDH (Sigma, G9545), anti-HA (Abcam, ab9110), 
anti-HA (C29F4) (Cell Signalling, 3724S), anti-Histone 
H1 (Santa Cruz, sc-8030), anti-Klhl12 (Abcam, ab14233), 
anti-myc tag (Cell Signalling, 2272), anti-O-GlcNAc (Cov-
ance, MMS-248R), anti-p19 (Skp1) (BD Biosciences, 
610530), anti-UAP1 (Abcam, ab95949), anti-Ub (Santa 
Cruz, sc-8017), HRP-conjugated antibodies to mouse or 
rabbit IgG (Santa Cruz Biotechnology, sc-2055, sc-2313) 
or chicken IgY (Abcam, ab97135), Donkey anti-Rabbit and 
anti-Mouse IgG conjugated to Alexa Fluor 488 (Invitro-
gen). Signal detection was by enhanced chemiluminescence 
(ECL) (GE Healthcare).
Cell culture, plasmids and transfection
HB4a is an immortalised normal breast epithelial cell 
line from M.J. O’Hare [52]. Cell lines were maintained 
in DMEM supplemented with 10% foetal bovine serum 
(ThermoFisher), 2 mM glutamine, 100 U/mL penicillin and 
streptomycin at 37 °C in a humidified 5%  CO2 atmosphere. 
Where indicated, cells were treated with (50 µM) PugNAc, 
an inhibitor of O-GlcNAc-β-N-acetylglucosaminidase (Oga), 
for 3 h prior to cell lysis.
Immunoblotting and immunoprecipitation analysis
Cells were lysed in protein extraction buffer (20  mM 
Tris–HCl pH 7.4, 1% IGEPAL, 1% Triton X-100, 50 mM 
NaCl, 2 mM EDTA pH 8, 30 mM  NaP2O7 and protease 
inhibitor cocktail (Roche)). For the analysis of O-Glc-
NAcylated proteins, cells were lysed in RIPA buffer plus 
protease inhibitors.
For immunoprecipitation (IP) experiments, cells were 
lysed in hypotonic lysis buffer (10 mM Tris–HCl pH 7.5, 
10 mM NaCl, 2 mM EDTA, 0.5% Triton X-100 and protease 
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inhibitors) and immunoprecipitated with agarose-anti-HA 
(Sigma) or agarose-anti-FLAG (Anti-FLAG® M2 Affin-
ity Gel, Sigma-Aldrich) for 3.5 h. Beads were pelleted 
and washed four times in 1 × NET2 wash buffer (50 mM 
Tris–HCl pH7.5, 150 mM NaCl, 0.05% Triton X-100). 
Bound proteins were eluted by addition of 40 µL 2 × Lae-
mmli sample buffer and incubation at 60 °C for 3 min.
siRNA and shRNA expression
siRNAs were purchased from Eurofins genomics and 
transfected at a final concentration of ~ 60 nM using Lipo-
fectamine™ RNAiMAX (ThermoFisher). Sequences for the 
siRNAs were as follows:
siRNA2: GCA GAG AAC TCA AAG ATA T
siRNA3: GGA CAA ACT CAC TGA TGA A
4 × 106 ψNx cells were calcium phosphate transfected 
with shRNA or scRNA retroviral expression constructs with 
25 μM chloroquine (Sigma-Aldrich). 2 days post-transfec-
tion, 2 × 106 of target cells were infected with retroviruses 
in the presence of polybrene (Sigma-Aldrich).
Sequences for the shRNAs were as follows:
shRNA 1: GGA CAA ACT CAC TGA TGA AGG (targets 
exon 3 of FBXL17);
shRNA 2: GCT TGG ACC TAC GTC ATA TCA (targets 
exon 6 of FBXL17);
shRNA 3: AGG CAT GAT CGT CAT AGC TAA (targets 
exon 4 of FBXL17).
The following day, cells were selected using 1.7 μg/mL 
of puromycin. After selection, RNA was extracted, reverse 
transcribed and quantified by qPCR. Expression level was 
normalised to GAPDH expression and was plotted rela-
tive to the expression of FBXL17 in the relevant control. 
Values represent mean ± SEM of at least three independent 
experiments.
Metabolites extraction and LC–MS analysis
Cells were washed three times with PBS prior the extraction 
and 1 ml of extraction buffer (50% LC–MS grade methanol 
and 30% acetonitrile, 20% ultrapure water) was added per 
1 × 106 cells. Cell were then incubated on dry ice for 15 min, 
collected, kept under vigorous shaking for 15 min at 4 °C, 
and left for 1 h incubation at 20 °C. Samples were centri-
fuged at 13,000 rpm and supernatants were transferred to 
autosampler vials for LC–MS analysis. To avoid bias due 
to machine drift and processed blindly, samples were rand-
omized. Q Exactive mass spectrometer (Thermo Fisher Sci-
entific) coupled to a Dionex U3000 UHPLC (Thermo Fisher 
Scientific) system was used to perform the LC–MS analysis. 
Sequant ZIC-pHILIC column (150mm 3 2.1 mm) and guard 
column (20 mm 3 2.1 mm) (Merck Millipore) were utilized 
for the chromatographic separation and the column oven 
temperature was maintained at 40 °C. The mobile phase 
was composed of 20 mM ammonium carbonate and 0.1% 
ammonium hydroxide in water (solvent A), and acetonitrile 
(solvent B). The flow rate was set at 200 mL/min with the 
gradient was programmed as follows: initially stayed at 20% 
of A and 80% of B for 2 min, then subjected to a linear 
increase to 80% of A and decrease to 20% of B in 15 min. 
Both solvents were then brought back to initial condition and 
staid for 8 min. The mass spectrometer was operated in full 
MS and tSIM (targeted Single Ion Monitoring), in positive 
and negative mode. XCalibur Qual Browser and XCalibur 
Quan Browser software (Thermo Fisher Scientific) were 
used to acquire the spectra and analyse the data.
Quantitative PCR
All qPCR reactions were performed in triplicates using 
 LightCycler® 480 SYBR Green Master Mix (Roche) accord-
ing to manufacturer’s instructions. The relative expression 
ratio of a target gene in comparison to a reference gene in a 
cDNA panel was quantified [53]. GAPDH was used as an 
endogenous housekeeping transcript. The relative expres-
sion level was based on the difference in Ct values between 
a control cell line such as HB4a and a sample cell line in the 
cDNA panel.
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